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Abstract

This dissertation is concerned with determining the prevalence of metabolic syndrome
(MetS) in Emirati females aged 17–25 years and its relation to overweight and obesity.
It also aims to determine the glycemic index (GI) and glycemic load (GL) values for
traditional Emirati foods that have not been tested yet.
In a cross-sectional study design, anthropometric measurements, blood pressure and
biochemical measurements were collected from a total of 555 Emirati female college
students and the prevalence of MetS was concluded. Furthermore, at least fifteen
healthy subjects participated in the measurement of GI and GL values for each of the
twenty-three Emirati test foods.
This study showed a high prevalence of MetS among college female young adults aged
17–25 years (6.8%). Of the 555 participants enrolled, 23.1% were overweight and
10.4% were classified as obese. MetS was significantly associated with obesity, waisthip ratio, glycated hemoglobin and high sensitivity C-reactive protein. The current
study also provides a comprehensive food composition table including proximate data,
minerals, vitamins, lipids, and sugars contents, along with GI and GL values of twentythree locally consumed foods in the UAE which could be utilized in offering better
dietary recommendations for the Emirati population.
The results advocate the need for MetS identification and immediate intervention
programs to improve the future health of this youthful group.

Keywords: Metabolic syndrome, Emirati, Young adults, Glycemic index, Glycemic
load, Emirati foods, Diabetes, Obesity.
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)Title and Abstract (in Arabic

مؤشر نسبة سكر الدم لبعض األطعمة التقليدية اإلماراتية ،السمنة ومخاطر متالزمة األيض
عند الفتيات الشابات في اإلمارات

الملخص
تهدف هذه األطروحة لتحديد مدى انتشار متالزمة األيض لدى اإلناث اللواتي تتراوح أعمارهن بين 17و25
عاما ً في اإلمارات وعالقتها بزيادة الوزن والسمنة .كما أنها تُعنى بتحديد مؤشر نسبة سكر الدم لبعض األطعمة
التقليدية اإلماراتية التي لم يتم اختبارها بعد.
في دراسة مستعرضة ،تم جمع القياسات الجسمانية وقياس ضغط الدم والقياسات البيو كيميائية من  555طالبة
في جامعة اإلمارات العربية المتحدة ،واستخدمت البيانات لتحديد مدى انتشار متالزمة األيض لديهن .كما شارك
خمسة عشر شخصا ً أصحاء على األقل في قياس قيم مؤشر نسبة سكر الدم لكل من األطعمة اإلماراتية الثالثة
وعشرين التي تم اختيارها.
أظهرت هذه الدراسة ارتفاع معدل انتشار المتالزمة األيضية بين الشابات اللواتي تتراوح أعمارهن بين 17و25
عاما ً ( .)6.8٪كما تبين بأن  ٪23.1من الشابات المشاركات في الدراسة يعانون من زيادة الوزن و ٪10.4منهن
يعانون من السمنة المفرطة .إضافة إلى ذلك ،فقد كشفت الدراسة عن وجود ارتباط كبير بين المتالزمة األيضية
وك ٍل من السمنة ،ونسبة الخصر للورك ،والهيموجلوبين السكري وبروتين سي التفاعلي عالي الحساسية .كما
خلصت الدراسة إلى توفير جداول غذائية شاملة لثالث وعشرين من األطعمة التقليدية اإلماراتية .بما في ذلك
جداول عن نسب المركبات الغذائية والمعادن والفيتامينات والدهون ،والسكريات ،ومؤشر نسبة سكر الدم لهذه
األطعمة .وتعد هذه الجداول مرجعا ً هاما ً يمكن استخدامه لتقديم توصيات غذائية أفضل لسكان اإلمارات.
وعكست نتائج هذه الدراسة عن الحاجة الملحة للكشف المبكر عن المتالزمة األيضية وضرورة تطوير برامج
للتدخل الفوري سعيا ً لتحسين الصحة المستقبلية لهذه الفئة العمرية من الشباب.

مفاهيم البحث الرئيسية :مؤشر نسبة سكر الدم ،المتالزمة األيضية ،السمنة ،األطعمة التقليدية اإلماراتية.
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Chapter 1: Introduction

Non-Communicable Diseases (NCDs) are the leading cause of deaths worldwide,
with diabetes mellitus the fourth major cause of NCD deaths [1]. Diabetes is a chronic
disease characterized by abnormalities in the metabolism of carbohydrate, fat, and
protein, along with hyperglycemia. During the past three decades, the prevalence of
diabetes mellitus in the world has doubled, which has presented a great challenge to
public health in every country. The International Diabetes Federation (IDF) estimated
the global prevalence for diabetes mellitus to be 8.3% in 2014, however, it is estimated
that around 46% of people with diabetes remain undiagnosed [2]. Moreover, the IDF
expects 205 million new cases of diabetes mellitus by the year 2035.
The United Arab Emirates (UAE) has been ranked as having the fifth highest
prevalence in the Middle East and North Africa (MENA) region with 19%, coming
after other Gulf Cooperation Council (GCC) countries, like Qatar, Saudi Arabia and
Bahrain [2]. In 2010, a survey conducted in the UAE reported the prevalence of
undiagnosed diabetes mellitus and pre-diabetes to be 14.6% and 31% respectively [3].
This indicates the great number of people living with undiagnosed diabetes mellitus
and pre-diabetes in the country. The existence of pre-diabetes combined with
dyslipidemia, elevated blood pressure, and obesity leads to the diagnosis of Metabolic
Syndrome (MetS) [4]. The MetS has a major public health impact through high
disease prevalence, significant downstream pathophysiological effects, and enormous
financial responsibilities. Therefore, the diagnosis of the syndrome and its
components at an early stage would assistance in preventing the development of type
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2 diabetes mellitus (T2DM), hypertension, and cardiovascular disease (CVD), and
may help reduce the risk of morbidity and mortality.
The prevalence of MetS was reported to be 32.9% among Emirati men, 45.9%
among Emirati women, and the total prevalence was 40.5%, based on the IDF
definition for MetS [5]. This alarming prevalence is thought to be emerging from the
high prevalence of MetS among younger age groups (13% of Emirati adolescents
suffered from MetS) [6]. The observed increasing incidence of MetS and pre-diabetes
among children, adolescents, and younger adults caused an equal increase in the need
for understanding the etiology of the disease, along with developing better screening
practices, and improved prevention programs in the UAE. Anthropometric measures
have been reported in several studies to assess in the diagnosis of MetS and its
components [7-9]. Thus, identification of anthropometric measures of obesity that
best identify MetS among the Emirati population is essential to improve screening and
facilitate prevention.
The causes behind the epidemic of MetS and T2DM are part of a multifactorial
genetic and social system, controlling behavioral and environmental influences [10].
However, there are several key risk factors believed to be contributing to the
occurrence of the MetS. These include: weight gain and obesity[11]; sedentary
lifestyle with low physical activity [12, 13]; ethnicity [14]; family history of diabetes
and poor dietary habits [15]; while other factors could be cigarette smoking and
alcohol consumption [16]. Accordingly, dietary management could have a great
impact on the number of people affected by diabetes, or preventing it in those at high
risk of developing the disease [17]. The American Diabetes Association
recommended an effective ongoing support program targeting glycemic control,
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weight loss of seven per cent of body weight and increasing physical activity to at
least 150 min/week of moderate activity for people living with pre-diabetes [16].
Dietary management was found to be dependent on the quality and quantity of nutrient
intake. Studies suggested that the total amount of carbohydrates or fat in the diet does
not seem to be associated with T2DM risk, but specific forms of carbohydrates or fat
were found to be associated with the disease [18, 19]. For example; the ability of
carbohydrates to increase blood glucose and insulin levels after food ingestion differs,
and that is known as the glycemic index (GI) of foods [20]. This concept was
developed in 1981 as a tool for predicting the blood glucose response to various foods.
Since the amount of carbohydrate in a food varies, researchers have also introduced
the concept of glycemic load (GL), which is the amount of available carbohydrate in
a serving size of a food item multiplied by its glycemic index [21]. Prospective studies
investigating the relations between dietary carbohydrate intake and risk of T2DM
using glycemic index (GI) and glycemic load (GL) supported the protective role of
low GI and low GL diets against the development of T2DM [19]. However, a high GI
food would cause a higher increase in the levels of blood glucose after its ingestion,
it will in turn increase the demand of insulin. Regular consumption of high GI foods
would therefore contribute to β cell distraction due to the elevated insulin demand
and/or continuously raised blood glucose concentration [19].
A study in 2010 from the United Arab Emirates aimed to determine factors
associated with poor glycemic control among patients with T2DM, stated the main
factor behind poor glycemic control was not following a dietitian recommended eating
plan and the negative attitude towards diabetes [22]. Another study from the UAE
examining the differences in the prevalence of diabetes mellitus between different
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ethnic groups in the UAE, reported a higher prevalence among UAE citizens (25%)
compared to that of expatriates (13–19% depending upon country of origin) [23].
These results suggest the need for better counseling programs focusing on the UAE
citizens, which in turn requires more information about the dietary practices of the
UAE citizens, food composition tables of locally consumed foods, and the GI values
of these food to facilitate the role of dietitians in developing better programs targeting
glycemic control in people living with pre-diabetes.
This dissertation provides a series of studies aiming to investigate the prevalence
of the MetS and its components among young Emirati adults; to identify the
anthropometric measures of obesity that best identify MetS; and to develop a
comprehensive food composition table with GI and GL values for locally consumed
foods in the UAE. This was established in an effort to contribute to the understanding
of these diseases, and to provide objective tools for nutrition therapy planning and
dietary management in the UAE.
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Chapter 2: Review of Literature

2.1 Introduction to the Metabolic Syndrome
2.1.1 History of the Metabolic Syndrome
The metabolic syndrome (MetS) can be described as a clustering of several
risk factors, including central adiposity, impaired glucose tolerance, dyslipidemia, and
hypertension.
The metabolic syndrome concept was first introduced in 1988 by Gerald
Reaven. He called it the “Syndrome X” and defined it as a cluster of abnormalities
(dyslipidemia, high blood pressure, and diabetes) arising from the underlying events
of insulin resistance and hyperinsulinemia [24]. Ten years later, in 1998, the World
Health Organization (WHO) first recognized the metabolic syndrome and developed
diagnostic criteria that could officially be used for clinical diagnosis [25]. However,
during these ten years, many other names were used to describe the co-occurrence of
these abnormalities all together, such as: the Plurimetabolic Syndrome by Crepaldi
and Nosadini in 1988 [26]; the Deadly Quartet by Kaplan in 1989 [27]; the Insulin
Resistance Syndrome by DeFronzo and Ferrannini in 1991 [28]; and Diabesity by
Shafrir in 1993 [29]. Conversely, Sarafidis and Nilsson proposed that the recognition
of the metabolic syndrome has evolved over about 90 years [30], starting in World
War I, when Hitzenberger and Richter-Quittner identified a link between hypertension
and diabetes [30]. The history of the metabolic syndrome is briefly described in Table
2.1, as adopted from Blaha and Tota-Maharaj with modifications [31].

6
Table 2.1: Brief History of the Metabolic Syndrome
Event

Year

Recognition of the co-existing of hyperglycemia and hypertension
[30].

1920s

Describing fat distribution and emphasis on abdominal obesity [30].

1950s

Emphasis on hyperlipidemia/dyslipidemia as part of the cluster [30].

1960s

Metabolically-obese, normal weight phenotype defined.

1981

Gerald Reaven describes “Syndrome X”: clustering around insulin
resistance [24].

1988

Kaplan describes “deadly quarter”: abdominal obesity, diabetes,
hypertension, and high triglycerides [27].

1989

Metabolic syndrome first operationalized as clinical diagnosis, based
on the WHO definition [25].

1998

NCEP ATP III definition: emphasis on abdominal obesity as
surrogate for insulin resistance [32].

2001

American Academy of Clinical Endocrinologists defines “Insulin
Resistance Syndrome”.

2003

The International Diabetes Federation definition - more emphasis on
abdominal obesity [33].
AHA/NHLBI further refine the NCEP ATP III definition.

2005

American Diabetes Association denounces the concept of metabolic
syndrome.
ADA/Obesity Society/American Society for Nutrition question
advantage of abdominal obesity over BMI.

2007

IDF/AHA/NHLBI/IAS: “Harmonized Definition” [4].

2009

WHO: metabolic syndrome of little utility for clinical practice or
epidemiologic research.

2010

Source: Blaha and Tota-Maharaj, 2012 [31].
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2.1.2 Definition of the Metabolic Syndrome
Over the past decade, the definition of the metabolic syndrome has been
greatly argued. The argument lingers to doubt whether there is such a syndrome or
not [34].
The first definition for “Syndrome X” proposed by Reaven in 1988 [24], was
the clustering of dysglycemia, dyslipidemia, hypertension, and insulin resistance. The
WHO proposed the addition of central obesity to the definition of the metabolic
syndrome and established the first diagnostic criteria for it in 1998-1999 [25]. The
WHO diagnostic criteria included the direct or indirect measure of insulin resistance.
Insulin resistance measurement was also part of the diagnostic criteria proposed by
the European Group for the Study of Insulin Resistance in 1999 [35]. Aiming to make
the clinical diagnosis of the metabolic syndrome easier and more user friendly, the
National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III
report established new guidelines in 2001 that do not include the measurement of
insulin resistance [32]. The American Association of Clinical Endocrinologists then
proposed an even more flexible definition in 2003 [36]. Other definitions were
developed and used over the past period included the NCEP ATP definition in 2005
[37], and the International Diabetes Federation definition in 2006 [33]. The latest and
most accepted diagnostic criteria for the metabolic syndrome is the harmonized
definition of the International Diabetes Federation Task Force on Epidemiology and
Prevention (IDF); the National Heart, Lung, and Blood Institute (NHLBI) ; the
American Heart Association (AHA); the World Heart Federation (WHF); the
International Atherosclerosis Society (IAS); and the International Association for the
Study of Obesity [4], published in 2009.
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2.1.3 Diagnostic Criteria of the Metabolic Syndrome
The diagnostic criteria of the metabolic syndrome that was published by the
WHO 1998, and revised in 1999 [25], considered cardiovascular disease as the main
outcome of the syndrome, and highlighted the importance of detecting insulin
resistance along with the presence of at least two of the following criteria: elevated
triglycerides; elevated blood pressure; central obesity; or reduced HDL [25]. The
European Group for the study of Insulin Resistance (EGIR) in 1999, also required the
measurement of insulin resistance [35]. This made the definition not very practical for
use in epidemiological studies of large populations.
The NCEP ATP III diagnostic criteria proposed in 2001 [32] did not require
the measurement of insulin resistance. However, it required the occurrence of at least
three of the following five criteria: central obesity; reduced HDL; elevated
triglycerides; elevated blood pressure; or elevated fasting glucose. The incidence and
the number of these components was thought to contribute to increase the risk and
progression of the syndrome [32].
The American Academy of Clinical Endocrinologists (AACE) proposed in
2003 a criteria for the diagnosis of the “Insulin Resistance Syndrome” [36]. It focused
the discussion on insulin resistance and hyperinsulinemia as the underlying
pathophysiology of the syndrome. Therefore, this definition was considered very
broad as it included cardiovascular and non-cardiovascular consequences of insulin
resistance, such as hypertension, polycystic ovarian syndrome (PCO), fatty liver
disease, and acanthosis nigricans[36]. The purpose of this definition was to alert
physicians to the metabolic state of the patient rather than determining the level of
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cardiovascular risk. A summary of the four discussed criteria for the diagnosis of
metabolic syndrome is presented in Table 2.2.
Table 2.2: Summary of the Metabolic Syndrome’s Diagnostic Criteria according to
the WHO, the EGIR, the NCEP ATPIII, and the AACE
WHO [25]
(1998 - 1999)

EGIR [35]
(1999) for nondiabetics

NCEP ATPIII
[32]
(2001)

AACE [36]
(2003)

Insulin resistance:
-Type 2 diabetes
- Impaired fasting
glucose
- Impaired glucose
tolerance (euglycemic
clamp)
+ 2 of the following:

Insulin resistance
OR
Hyperinsulinemia

At least 3 of the
following:

Impaired glucose
tolerance:
2-hour postprandial
glucose test >140 mg/dl

+ 2 of the following:

Fasting glucose:
- ≥ 110 mg/dl

Hypertension:
- BP (≥140/90
mmHg)

Hypertension:
≥ 140/90 mmHg
OR
- Anti-hypertensive
medication.
Dyslipidemia:
- Triglyceride (≥180
mg/dl)
OR
- HDL (<39 mg/dl)
OR
- Dyslipidemia
medication
Central Obesity:
- WC (Men ≥ 94 cm,
women ≥80 cm)

Hypertension:
≥ 130/85 mmHg
OR
- Anti-hypertensive
medication.
Elevated
triglyceride:
- (≥150 mg/dl)

Fasting glucose:
- between 110 and 126
mg/dl
Hypertension:
≥ 130/85 mmHg

Central Obesity:
- WC (Men ≥ 102cm,
women ≥88 cm)

Overweight:
- BMI > 25 kg/m2

Impaired fasting
glucose:
- FPG ≥ 110 mg/dl

Reduced HDL:
- <40 mg/dl in men,
<50 mg/dl in
women)
OR
- HDL medication

Other related factors:
- Family history of
T2DM, HTN, or CVD.
- PCO.
- Ethnicity.
- Sedentary lifestyle.
- Fatty liver disease.
- Acanthosis nigricans.

Dyslipidemia:
- Triglyceride (≥150
mg/dl)
OR
- HDL (<35 mg/dl in
men, <39 mg/dl in
women)
Obesity:
- BMI > 30 kg/m2
OR
- WHR >0.9 in men,
>0.85 in women.
Microalbuminuria:
- Urinary albumin
excretion rate≥20
µg/min
OR
- Albumin: Creatinine
ratio ≥30 mg/g

Dyslipidemia:
- Triglyceride (≥150
mg/dl)
AND
- HDL (<40 mg/dl in
men, <50 mg/dl in
women)

WHO: World Health Organization; EGIR: European Group for the study of Insulin Resistance; NCEP
ATP: National Cholesterol Education Program Adult Treatment Panel; BP: blood pressure; AACE:
American Academy of Clinical Endocrinologists; HDL: high-density lipoprotein Cholesterol; BMI:
body mass index, WHR: waist-to-hip ratio; WC: waist circumference; FPG: Fasting Plasma Glucose;
T2DM: type 2 diabetes mellitus; CVD: cardiovascular disease; PCO: polycystic ovarian syndrome;
HTN: hypertension.
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In 2005, the International Diabetes Federation proposed a new diagnostic
criteria emphasizing abdominal obesity. The IDF removed the WHO requirement for
insulin resistance measurement, and made abdominal obesity required for the
diagnosis, combined with four other factors (elevated triglycerides, elevated blood
pressure, elevated FPG, and reduced HDL cholesterol) [33]. The central obesity was
defined as waist circumference (according to an ethnic-specific value), which is
considered a simple and easy screening tool; the rest of the criteria remained identical
to the 2001 NCEP ATP III criteria.
The AHA/NHLBI also attempted to further refine and update the NCEP ATP
III definition in 2005. They proposed changing impaired fasting plasma glucose to
FPG ≥ 100 mg/dl compared to the old FPG ≥110 mg/dl used by the ATP III [37]. The
AHA/NHLBI did not mandate central obesity for the diagnosis of the metabolic
syndrome, and did not use ethnic-specific values for WC when defining central
obesity. This lack of agreement on the definition of central obesity between the IDF
and the AHA has resulted in confusion in the definition of metabolic syndrome among
researchers and scientists.
In 2009, the International Diabetes Federation Task Force on Epidemiology
and Prevention (IDF); the National Heart, Lung, and Blood Institute (NHLBI); the
American Heart Association (AHA); the World Heart Federation (WHF); the
International Atherosclerosis Society (IAS); and the International Association for the
Study of Obesity have all agreed on a joint interim statement for a new harmonized
definition for the metabolic syndrome [4].The diagnostic criteria of the IDF (2005),
the AHA/NHLBI (2005) and the harmonized definition (2009) are summarized in
Table 2.3. The harmonized definition follows the ATP III definition, but central
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obesity is no longer obligatory. Modifications might happen in the future, however,
using single definition in the previous couple of years have allowed the ability for
better comparisons among epidemiological studies.
Table 2.3: Summary of the Metabolic Syndrome’s Diagnostic Criteria according to
the IDF, the AHA/NHLBI, and the harmonized definition IDF/AHA/NHLBI.
The harmonized
IDF [33]

AHA/NHLBI [37]

definition

(2005)

(2005)

IDF/AHA/NHLBI [4]
(2009)

At least 3 of the
following:
Central Obesity:
(population- and
country- specific
values)
Impaired fasting glucose:
Impaired fasting
Impaired fasting
- FPG ≥ 100 mg/dl
glucose:
glucose:
- FPG ≥ 100 mg/dl
- FPG ≥ 100 mg/dl
OR
- Medication for
OR
OR
hyperglycemia
- Medication for
- Medication for
hyperglycemia
hyperglycemia
Hypertension:
Hypertension:
Hypertension:
≥ 130/85 mmHg
≥ 130/85 mmHg
≥ 130/85 mmHg
OR
OR
OR
- Anti-hypertensive
- Anti-hypertensive
- Anti-hypertensive
medication.
medication.
medication.
Elevated triglyceride:
Elevated triglyceride: Elevated triglyceride:
- (≥150 mg/dl)
- (≥150 mg/dl)
- (≥150 mg/dl)
OR
OR
- Treatment of lipid
- Treatment of lipid
abnormality
abnormality
Reduced HDL cholesterol: Reduced HDL
Reduced HDL
- Men <40 mg/dl
cholesterol:
cholesterol:
- Women <50 mg/dl
- Men <40 mg/dl
- Men <40 mg/dl
- Women <50 mg/dl
- Women <50 mg/dl
OR
- HDL medication
OR
OR
- HDL medication
- HDL medication
IDF: International Diabetes Federation; AHA: American Heart Association; HHLBI:
National Heart, Lung, and Blood Institute; HDL: high-density lipoprotein
Cholesterol; WC: waist circumference; FPG: Fasting Plasma Glucose.
Central Obesity:
(ethnic-specific values)
+ 2 of the following:

At least 3 of the
following:
Central Obesity:
- WC (Men ≥ 102cm,
women ≥88 cm)
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2.2 Risk Factors of the Metabolic Syndrome
There are many underlying risk factors discussed in the literature that could be
related to the pathophysiology of the metabolic syndrome. Some are modifiable
factors and others are non-modifiable. It has been proposed that all factors, whether
they are lifestyle factors (excess nutrients and physical inactivity), hormonal factors,
macronutrient factors or even aging factors, they are interlinked together in a very
complicated manner. Some are simplified and summarized in Figure 2.1.

- Genetics
- Diet
- Gender
- Sedentary lifestyle
- Chronic stress
- Aging
- Ethnesity

- Abdominal Obesity
- Insulin resistance
- Proinflamatory state
- Elevated blood glucose
- Elevated blood pressure
- Atherogenic dyslipidemia

- Type 2 diabetes (T2DM)
- Cardiovascular disease
- Fatty liver
- Polycystic ovary syndrome
- Sleep apenea
- Sexual dysfunction
- Cholesterol gallstones

Figure 2.1: Schematic Presentatin of the Metabolic Syndrome Risk Factors and
Consequances
2.2.1 Genetics of the Metabolic Syndrome
Each component of the MetS could be explained by a complex set of
interactions between the genes and the environment. Limited data is available about
the genetic factors behind the prevalence of metabolic syndrome; however, the genetic
susceptibility to the MetS can be organized in two groups: genes leading to insulin
resistance, and genes related to obesity phenotypes. Several genes were identified to
play a role in the development of MetS, yet the mechanisms of acting remained poorly
understood. There is no doubt that the MetS is a polygenetic disease, along with a
great number of influences from the environment. Moreover, even if the genetic-based
risk was successfully assessed, it would be unlikely to play the main role in the MetS
clinical management.
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In 2001, the ATP III identified obesity as the main underlying risk factor of
the MetS. The hypothesis emphasized the role of obesity in the development of MetS,
explained by individuals having the genetic susceptibility of the syndrome but failing
to manifest it because they never developed obesity [32]. In 2003 the WHO and the
AACE identified insulin resistance as the main underlying risk factor of the MetS
[36]. They agreed that physical inactivity, obesity, and aging all play a role in the
development of the syndrome, but focused on insulin resistance as the key trigger.
The most accepted view on the origins of the metabolic syndrome suggests the
importance of obesity and insulin resistance to engender the metabolic syndrome
along with other environmental and genetic factors. This considers the independent
effect of obesity and insulin resistance on the syndrome, and the effect of each of them
on the other. This hypothesis is adopted from the Atlas of Atherosclerosis and
Metabolic Syndrome by Grunday [38] and demonstrated in Figure 2.2.

Obesity and adipose
tissue disorders

Insulin resistance

Genetic variation in risk factor regulation
Atherogenic
dyslipidemia

Elevated Blood
pressure

Elevated
glucose

Pro-thrombotic
state

Pro-inflammatory
state

Figure 2.2: The Origins of the Metabolic Syndrome
Source: Grunday, 2011 [39].
Studies focusing on the MetS genetics have discussed two main genes in an
attempt to explain the pathophysiology of the syndrome; these are the FTO (fat mass
and obesity associated) gene and the PPARG (Peroxisome Proliferator-Activated
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Receptor Gamma) gene [40, 41]. The FTO gene is thought to increase caloric
consumption by upregulating the starvation signals of the hypothalamus resulting in
increased BMI and overall adiposity [42, 43]. The PPARG gene transcripts the nuclear
receptor family of the PPARs isotypes (PPARα, PPARδ, and PPARγ) that are
involved in the regulation of carbohydrate and lipid metabolism. Of these, the PPARγ
appears to play a principle role in the assimilation of lipids, insulin signaling, glucose
metabolism, fatty acids storage, and inflammation in endothelial cells [40].

2.2.2 Insulin Resistance
The insulin resistance mechanism was used by many researchers to justify the
occurrence of the MetS as a cluster and its individual components. Insulin resistance
alone was not enough to provide an explanation for the 30% of individuals diagnosed
with the MetS, yet had normal insulin sensitivity. Insulin resistance was suggested to
result from ectopic fat deposition and lipotoxicity [44]. It is characterized by high
concentrations of plasma insulin (hyperinsulinemia) that fail to maintain plasma
glucose homeostasis resulting in hyperglycemia and other components of the MetS.
The contributing factors to insulin resistance are very complex. Many hypothesis were
developed trying to explain it, such as the adiponectin hypothesis [45], and the plasma
copeptin hypothesis [46]; however, the obesity-induced insulin resistance hypothesis
is the most accepted [47].
Insulin sensitivity could be measured in different ways at whole-body level.
Traditional approaches use the hyperinsulinemic euglycemic clamp technique, which
requires measuring the amount of glucose needed to match the rate of removal of
different insulin concentrations. It could also be indirectly measured by measuring
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fasting insulin value. An easier and faster way is to calculate the fasting insulin
concentration to fasting plasma glucose (FPG) ratio by a mathematical formula known
as HOMA-IR (homeostasis model assessment for insulin resistance) [48]. As the
presence of insulin resistance is linked to the presence of central obesity, it is now
proposed to use the “hypertriglyceridemic waist” as an easy and simple measure for
the screening of insulin resistance [49].

2.2.3 Abdominal Obesity
Not all people living with obesity suffer from the MetS; similarly, not all
normal weight people are healthy and free from all components of the syndrome.
Modern medicine is still debating over the interaction between obesity, insulin
resistance and the MetS. Obesity itself is a multifactorial condition, caused by a
complex group of genetics and behavioral factors. Ectopic fat is the accumulation of
fat in tissues other than the subcutaneous adipose tissue, such as the liver, epicardium
of the heart, and the abdominal viscera. This is thought to happen when the
subcutaneous adipose tissue becomes dysfunctional, insulin resistant, lipodystrophic
(rare condition characterized by adipose tissue deficiency) or simply saturated with
fat during excess nutrient intake [50]. This accumulation of fat in the liver leads to
atherogenic dysglycemia, and the accumulation of fat in the muscles leads to insulin
resistance [51]. Ectopic fat and visceral fat have shown greater correlations with the
MetS when compared to the BMI [50]. Moreover, the role of the subcutaneous adipose
tissue as an endocrine organ cannot be ignored. The adipose tissue can release a range
of hormones (TNF-alpha, leptin, and resistin) pro-inflammatory, pro-thrombotic
adipokines and cytokines that in turn induce a systemic pro-inflammatory state,
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causing an increase the risk of metabolic disorders, such as diabetes, hypertension and
CVDs [52]. The release of these cytokines into the blood circulation could also induce
an inflammatory response in the epithelial arterial wall, leading to a disturbance in the
atherosclerotic plaques, which triggers plaque rupture, generating acute coronary
syndromes [53].
Simple anthropometric measures are used for the assessment of obesity and
fat deposition, such as the body mass index (BMI), the waist-to-hip ratio (WHR), and
the waist circumference (WC) [54]. Moreover, modern accurate computed imaging
systems became available and allowed direct quantifying of body fat.

2.2.4 Glucose Intolerance
Glucose intolerance is caused by the effect of insulin resistance on different
body tissue. Insulin resistance causes impairment in the uptake of insulin by cells,
which effects the cascade of reactions induced by insulin, causing dysregulation of
gluconeogenesis and glycogenolysis in the liver resulting in hyperglycemia. Detecting
glucose intolerance (or prediabetes) can be done by oral glucose tolerance test
(OGTT) 2-h PG in the 75-g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0
mmol/L) (IGT), or impaired fasting glucose (IFG) FPG 100 mg/dL (5.6mmol/L) to
125 mg/dL (6.9 mmol/L), or elevated HbA1c 5.7–6.4% [16].

2.2.5 Elevated Blood Pressure
The association between the MetS and the elevation in blood pressure has been
identified, but the mechanisms have not been fully defined [4]. This elevation might
only be high-normal (SBP 130-140/DBP 85-95 mmHg), or in some cases it increased
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to the next category (>140/190 mmHg). Multiple factors were proposed to be
involved, some of these are:
-

Obesity  Oxidative stress  reduce bioavailability of nitric oxide 
vasodilation  elevate blood pressure [55].

-

Obesity  increase adipocytes tissue  adipocytes produce angiotensinogen
 elevate blood pressure [56].

-

Obesity  increase adipocytes tissue  adipocytes produce inflammatory
cytokines  pro-inflammatory state  endothelial dysfunction  elevate
blood pressure [56].

-

Obesity  compresses the kidney with fat tissues  induce renal dysfunction
 increase renin  elevate blood pressure [57].

-

Insulin resistance  enhances the sympathetic nervous system  elevate
blood pressure [58].

-

Insulin resistance  increase sodium reabsorption  sodium retention 
elevate blood pressure [58].

2.2.6 Atherogenic Dyslipidemia
Another underlying risk factor of the metabolic syndrome is atherogenic
dyslipidemia. This condition is characterized by increased fasting and post-prandial
triglycerides level, increased Apo-lipoprotein (Apo-B), increased very low-density
lipoprotein (VLDL) cholesterol, increased small dense low-density lipoprotein (LDL)
profile, low high-density lipoprotein (HDL) cholesterol and small HDL particles [59].
Atherogenic dyslipidemia is the core of the MetS, and it is defined according to the
harmonized definition of the metabolic syndrome (IDF/ NHLBI/ AHA) [4] and the
2012 European guidelines on cardiovascular disease prevention [60] as an HDL-C
level < 40 mg/dL in men and <50 mg/dL in women, with a triglyceride level ≥150
mg/dL. The underlying mechanisms for the development of atherogenic dyslipidemia
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have been identified in the literature [59]. Due to insulin resistance, and/or fatty liver,
and/or lipid overloading of the liver, the liver will overproduce Apo-B containing
VLDL and VLDL triglycerides. VLDL is metabolized in the circulation into
intermediate density lipoprotein (IDL) and LDL. The origins of the small dense LDL
is not fully understood; however, many mechanisms were proposed to explain it. It
could be the activity of cholesterol ester transfer protein (CETP), which catalyzes the
exchange of cholesterol esters for triglyceride between LDL and VLDL, resulting in
the depletion of cholesterol ester from the LDL, and the production of small LDL
particles [59].
Other investigators believe that the increased production of Apo B-VLDL
from the liver, would produce VLDLs that are already smaller in size, and when
hydrolyzed they will produce smaller, denser LDL particles [61]. Lastly, it could be
the higher activity of hepatic triglyceride lipase (HTGL) (existing in MetS patients),
that is degrading the normal LDL into smaller denser LDL particles [62]. These
mechanisms also account for the production of less overall HDL and smaller size HDL
particles, causing less efficient reverse cholesterol transport in the circulation.
Whereas, the small, dense LDL is more likely to get oxidized and has a great ability
to transport cholesterol for the vessel.

2.2.7 Inflammation
People with the MetS were found to have a low-grade of systemic
inflammation [47, 63]. Many biomarkers of inflammation were shown to have an
association with the MetS, such as: increased high sensitivity C-reactive protein (HsCRP), increased interleukin 6 (IL-6), increased tumor necrosis factor alpha (TNF-α),
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increased leptin, decreased adiponectin, and increased resistin [64]. Inflammation in
the MetS is developed by the effect of insulin resistance on the liver and the
dysregulation of the adipose tissue, along with the effect of insulin resistance on the
sympathetic nervous system, causing an activation of inflammation and chemotaxis
pathways. The pro-inflammatory state of the MetS is illustrated in Figure 2.3. Under
the effect of insulin resistance, the liver produces higher levels of C-reactive protein
(CRP), fibrinogen, and plasminogen activator inhibitor 1 (PAI-1). On the other hand,
the adipose tissue produces a number of pro-inflammatory cytokines such as IL-6 and
TNF-α, and reduce the production of adiponectin, which is considered an important
anti-inflammatory agent.

Insulin Resistance

Obesity

Liver

Adipose Tissue

↑ Hs-CRP

↑ IL-6

↑ Fibrinogen

↑ TNF-α

↑ PAI 1

↓ Adiponectin

Inflammation
Figure 2.3: Pro-inflammatory State of the Metabolic Syndrome
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Many inflammation markers were used through the years to predict
cardiovascular events [63, 65], and a great number of investigators reported an
association between pro-inflammatory state and MetS [65, 66]. Ridker and others
showed evidence that the MetS represents an inflammatory state that could be seen
by the progressive increase of Hs-CRP levels with the increased number of the MetS
components according to the ATP III criteria (Figure 2.4) [67]. Up to date, the only
well-standardized marker of inflammation and a predictor of the MetS and future
cardiovascular events, is the Hs-CRP [68]. However, the measurement of Hs-CRP is
not yet included in the diagnostic criteria of the MetS, although it has been
recommended by a large number of investigators [67-71]. Inflammation is usually
measured through the measurement of serum Hs-CRP, where a level above 3 mg/l is
considered high according to the recommendations of the CDC and the AHA for
cardiovascular disease (CVD) risk assessment [63]. Although levels of fibrinogen, IL6, and adiponectin are also highly correlating with the prevalence of MetS in clinical
research studies [38, 64], routine measurement of these inflammation markers is not
yet recommended.

Figure 2.4: Hs-CRP and the Metabolic Syndrome
Source: Ridker and others, 2003 [67].
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2.3 Consequences of the Metabolic Syndrome
The MetS is linked to the increased risk of a range of disease consequences
including CVD, diabetes, polycystic ovary syndrome, fatty liver, asthma, cholesterol
gallstones, sleep apnea, and sexual dysfunction, as shown earlier in Figure 2.1.
Moreover, people living with diabetes, CVD, hypertension, and coronary heart
disease were reported to have a much higher prevalence of the MetS when compared
to the general population.
The Syndrome X was proposed in 1988 by Gerald Reaven [24] to explain the
grouping of CVD risk factors in individuals with insulin resistance. However, the
current understanding of the MetS includes increased risk of atrial fibrillation,
coronary heart disease (CHD), ischemic stroke, myocardial infarction, aortic valve
disease, and cardiomyopathy [72, 73].
The first epidemiological study associating the MetS with CVD morbidity and
mortality was the Botnia study in 2001 [74]. It included 4,483 subjects, aged between
35 and 70 years in Finland and Sweden. The study used the WHO 1998 definition for
the MetS and reported a three-fold increase in the risk for CHD and stroke in subjects
with the MetS (P < 0.001).
A year later (2002), the Kuopio Ischemic Heart Disease Risk Factor Study was
published [75]. This prospective cohort study included 1,209 Finnish men, between
the age of 42 and 60 years, who were studied from 1984 till 1998. The study concluded
an increase in CVD and all-cause mortality in men with the MetS, even in the absence
of diabetes and CVD at the baseline.
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A meta-analysis and a systematic review published in 2010, investigated the
association between cardiovascular risk and the ATP III definitions of the MetS. It
reported data from 87 studies including 951,083 patients, and showed that the MetS
is associated with an increased risk of CVD mortality (RR: 2.40), CVD (RR: 2.35),
stroke (RR: 2.27), all-cause mortality (RR: 1.58), and myocardial infarction (RR:
1.99) [76]. Moreover, the prevalence of the MetS among people living with diabetes
from various ethnic groups and different populations was reported to be between 76%
- 92% [77-79].
It is important to highlight that the risk of the MetS occurs even when diabetes
is absent. In 2003, Alexander and others [80] showed that patients with the MetS but
without diabetes had a higher prevalence of CHD (13.9%) than patients with diabetes
but without the MetS (7.5%), as presented in Figure 2.5.

Figure 2.5: Prevalence of CHD Categorized by Presence of MetS and Diabetes
Source: Alexander and others, 2003 [80].
This does not propose that there is no relation between the MetS and diabetes.
In fact, the MetS is an important underlying risk factor for the development of
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diabetes. Additionally, the relative risk of diabetes was reported to be three-fold
higher among patients with the MetS compared to those without it [81].
The pathophysiology of T2DM is usually explained by a two-step hypothesis.
First, individuals develop insulin resistance partly caused by obesity as explained
earlier in Section 2.2.2. Second, pancreatic β-cells get damaged or/and their function
decline gradually with time, which might happen even before the clinical diagnosis of
hyperglycemia. Considering the MetS is a state of pre-diabetes and insulin resistance,
it should not be surprising that it has the ability to predict new cases of T2DM.
The San Antonio Heart Study was published in 2003 [82]. It included 1,734
participants, between the age of 25 and 64 years, who completed eight years of followup. The study concluded that the MetS predicts T2DM independent of impaired
fasting glucose. It also showed that the MetS was associated with a five-fold higher
risk of diabetes over the eight years follow-up even with normal fasting plasma
glucose. This finding would suggest the need for a measure of diabetes that could have
a greater prediction power for diabetes and the metabolic syndrome than fasting
plasma glucose.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial [83]
showed an association between higher HbA1c levels and increased risk of mortality
over a 3.4 years follow-up. Glycated hemoglobin (HbA1c) is a simple, practical
measure, and has the ability to reflect glucose levels in the blood from the previous
three months. As a matter of fact, the new recommendation by the ADA on the
Standards of Medical Care in Diabetes-2015 [16], have added HbA1c test for the
diagnostic criteria of diabetes (HbA1c > 6.5%) and pre-diabetes (HbA1c 5.7%-6.4%),
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and did not require the confirmation of the test with other tests like fasting plasma
glucose or glucose tolerance test if the HbA1c has been confirmed by replication.
In 2007, two studies were conducted to study the association of glycated
hemoglobin (HbA1c) and the MetS. The first is the Chennai Urban Rural
Epidemiology Study (CURES) [84], which included 1,644 Asian Indian participants
with normal glucose tolerance (FPG <100 mg/dl and 2-h post-prandial plasma glucose
<140 mg/dl). It used the ATP III guidelines for the diagnosis of MetS. The study
showed strong association between HbA1c and the MetS (OR: 2.9 (95% CI 2.08–
4.00); P < 0.001).
The second study was conducted among 22,465 middle aged non-diabetic
Korean participants [85]. The study concluded that the prediction of MetS could be
archived at 5.45% of HbA1c and it recommended the use of HbA1c as a predictive
measure of impaired fasting glucose and MetS among the Koreans.
To conclude the consequences of the MetS and show the relative risk factor
between the MetS and CVD morbidity, CVD mortality, diabetes, and all-cause
mortality, a summary of all systematic reviews and meta-analyses published to
describe these associations is presented in Table 2.4.

Table 2.4: Summary of Systematic Reviews and Meta-analyses on the association of the MetS with CVD morbidity, CVD mortality, Diabetes,
and All-Cause Mortality
Author and year of
publication
Ford, 2005 [86]
Galassi et al., 2006
[87]
Gami et al., 2007 [88]

Ford et al., 2008 [81]

Li et al., 2008 [89]
Hui et al., 2010 [90]
Mottillo et al., 2010
[76]

Selection criteria
Articles published between
1998 and August 2004
Articles describing
prospective studies published
between 1966 and April 2005
Articles describing
prospective studies published
between 1966 and March 2005
Articles published between
1998 and April 2008
describing population-based
cohort studies

Articles published up to July
2007
Articles published between
2001 and 2009
Articles published up to June
2009

Definition of the MetS
NCEP 2001
WHO 1999, NCEP
2001 and modifications
WHO 1999, NCEP
2001 and modifications
WHO 1999
EGIR 1999
NCEP 2001
NHLBI/AHA 2004
AHA/NHLBI 2005
IDF 2005
WHO 1999, NCEP
2001
WHO 1999, NCEP
2001 and modifications
NCEP 2001 and revised
NCEP 2004

Outcome and follow-up
All-cause mortality
Cardiovascular disease
All-cause mortality
Cardiovascular disease mortality
Incident cardiovascular disease
Cardiovascular events or death

No. of studies/
participants
23,247 participants
43,054 participants
21 studies

37 studies, 43 cohorts
and 172,573 participants

Relative risk
(95% CI)
1.27 (0.90–1.78)
1.65 (1.38–1.99)
1.35 (1.17–1.56)
1.74 (1.29–2.35)
1.53 (1.26–1.87)
1.78 (1.58–2.00)

Incident diabetes over 2.3–20 years

42,419 participants (total
– subgroups for different
definitions)

5.17 (3.99–6.69) 4.45
(2.41–8.22) 3.53 (2.84–
4.39) 5.16 (4.43–6.00)
5.12 (3.26–8.05) 4.42
(3.30–5.92)

Incident stroke

13 studies and 92,732
participants
21 studies and 372,411
participants
87 studies and 951,083
participants

1.6 (1.48–1.75)

All-cause mortality over mean 11.5year follow-up
Cardiovascular disease
Cardiovascular disease mortality
All-cause mortality
Myocardial infarction
Stroke

1.46 (1.35–1.57)
2.35 (2.02–2.73) 2.40
(1.87–3.08) 1.58 (1.39–
1.78) 1.99 (1.61–2.46)
2.27 (1.80–2.85)

Source: Wild and others, 2011 [91]
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2.4 Management of the Metabolic Syndrome
The management of the MetS is achieved by treating underlying risk factors of
the syndrome. Therefore, the first-line therapy usually targets lifestyle modifications
including weight reduction for people living with obesity and introduction to regular
workout for inactive individuals [4]. Therapeutic lifestyle changes such as introduction
of the Mediterranean diet and teaching patients about the low glycemic index diet
along with recommending a certain intensity and duration of physical activity (for
example 10,000 steps/day) will help in decreasing insulin resistance, which in turn will
facilitate the treatment of the syndrome.
Drugs were also used in certain conditions to treat or even prevent the MetS.
Some of these are used for the management of diabetes (Metformin), hypertension
(ACE-inhibitor), CVD (aspirin) [92] and atherogenic dyslipidemia (statin, fibrate, and
niacin). However, some drugs have adverse side effects that include raising insulin
resistance; which should be stopped (if possible) and replaced with agents that do not
increase insulin resistance. Bariatric surgery could also be a treatment option,
especially for those patients living with morbid obesity. It has shown to resolve all
components of the MetS by a single procedure, eliminating the necessity for daily
drugs consumption.
Many guidelines are available from different organizations to help in the
management and prevention of the MetS. However, most lack simplicity, or not
specific for MetS, or treat each component separately and are difficult to use in clinical
settings.
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2.4.1 AHA/NHLBI Guidelines
In 2005, the American Heart Association (AHA) and the National Heart, Lung,
and Blood Institute (NHLBI) published detailed guidelines for the diagnosis and
treatment of MetS [37]. These guidelines are a great tool for health care professionals
to use during clinical settings, or for research purposes.
According to the AHA/NHLBI guidelines, the primary goal of clinical
management in patients with MetS is to decrease the risk of atherosclerosis and to
delay progression of T2DM, hypertension and CVD. A summary of these guidelines
and recommendations is presented in Table 2.5.
Table 2.5: AHA/NHLBI Guidelines for Metabolic Syndrome Management
Metabolic risk factors
Atherogenic dyslipidemia

Elevated BP
Elevated glucose
Pro-thrombotic state
Pro-inflammatory state
Lifestyle risk factors
Abdominal obesity

Goals of Therapy
Primary target: reduce LDL-C
Secondary target: reduce non-HDL-C
Tertiary target: increase HDL-C
Reduce BP to <140/90 mm Hg
And to <130/80 mm Hg if diabetes present.
IFG  delay progression to T2DM
Diabetes  HbA1c < 7.0%
Reduce thrombotic and fibrinolytic risk factors
Lifestyle therapies

Reduce body weight by 7% to 10% during the first
year of therapy.
Continue weight loss till achieving desirable weight
(BMI <25 kg/m2)
Physical inactivity
Regular moderate-intensity physical activity (30
min/day 5 days/week (and preferably ≥60 min,
every day).
Atherogenic diet
Reduced intake of saturated fat (<7% of total
calories), trans fat, cholesterol (<200 mg/dL), and
total fat (25% to 35% of total calories).
Source: Grundy and others, 2005 [37].
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2.4.2 The ABCDE Approach
Five requirements were suggested for effective MetS management guidelines,
these include being simple, comprehensive, easy to remember, easy to update and
does not focus much on the details [31]. In 2008, Blaha and others [93] developed
the first practical and comprehensive approach tailored especially for patients with
MetS, that is known as the “ABCDE” approach. This approach was established at
Johns Hopkins Hospital and peer-reviewed in the literature. It was then updated in
2010 to take into consideration new, and novel, research in the field of prevention
and management of the MetS [94]. The ABCDE approach was derived, in large,
from the existing 2005 AHA/NHLBI guidelines. Using this approach allows health
care professionals to provide the same attention and care to all their patients in an
equal manner. The “ABCDE” letters are easy to memorize as they are the first five
letters of the alphabet, and each of them represents an aspect in the management of
the syndrome. This is presented in Figure. 2.6.

A
B
C
D
E

Assessment/
Aspirin

Increase intermediate risk
group (5-20%)

Blood Pressure

Target 125-135/80 mmHg

Cholesterol

Aim to reduce Non-HDL-C

Diabetes
prevention/ Diet

Intensive lifestyle therapy

Exercise

Aim for 1000 steps/day

Figure 2.6: Summary of the ABCDE Approach with Recommendations
Source: Blaha and others, 2012 [31].
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2.4.2.1 Assessment
Assessment is the most important step of any management program. If
assessment was accurately performed, then diagnosis would be easily determined,
intervention will be more effective, and evaluating the intervention can be effortless
and more beneficial. The Framingham Risk Score (FRS) [95] in the United States and
the Systematic Coronary Risk Evaluation (SCORE) project [96] in Europe are widely
used for the assessment and prediction of CVD risk. These scores could predict the
risk of developing CVD within a ten-year period through the Ten-Year Risk model.
The model is divided into three risk groups, low (0-10%), intermediate (10-20%) and
high risk group (>20%). However, evidence from the DECODE study [97], showed
that patients classified in the low-risk group and had the MetS, presented around threefold more fatal CVD events compared to those from the same low-risk group but
without the syndrome. These findings lead to a novel risk detection strategy by Blaha,
suggesting the expansion of the intermediate-risk group to 5-20% in the presence of
the MetS. That would allow health care providers to initiate earlier intervention
strategies.
In addition to assessment, aspirin therapy has been added to the management
approach because evidence form the JPAD trail showed that a low dose of aspirin (81100 mg) can lessen thrombotic complications linked to CVD [92].

2.4.2.2 Blood Pressure
Elevated blood pressure is a key underlying risk factor of the syndrome.
According to the 2011 guidelines of the National Institute of Health and Clinical
Excellence (NICE), a measure ≥ 140/90 mmHg is the cutoff point for the diagnosis of
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hypertension [98]. The target of the MetS management is to achieve < 125-135/80
mmHg based on the recommendations of the ACCORD trail [99], as the results of this
study found no difference between SBP of 134 mmHg and SBP of 119 mmHg in
decreasing CVD events after a 4.7 years follow-up. The targeted blood pressure level
could be achieved by several approaches from lifestyle therapies including diet and
physical activity to pharmacologic agents (if needed) such as ACE-inhibitor, betablockers, thiazide diuretics, and calcium channel blockers.

2.4.2.3 Cholesterol
The “C” letter refers to “Cholesterol” and could also stand for “Cigarettes”.
However, smoking cessation is not often highlighted in the management of the
syndrome, because smoking is a risk factor for atherosclerotic cardiovascular disease,
but not for the MetS.
Cholesterol is a key measure of atherogenic dyslipidemia, one of the main
underlying risk factors of the MetS (see section 2.2.6). Under cholesterol, the focus
should be on measuring non-HDL-C. Non-HDL-Cholesterol includes the
concentrations of Apo-B lipoproteins, LDL, VLDL, IDL, and chylomicron remnants.
It can predict CVD better than LDL-C, especially when the levels of triglycerides are
high [59]. It can be calculated by measuring total cholesterol and HDL-C during
routine lipid profile testing.
Lifestyle therapies are the first approach in the management of atherogenic
dyslipidemia. A meta-analysis published in 2008 [100] included 37 prospective cohort
studies on the association of glycemic index and chronic disease risk concluded that
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diets with high fiber content and low glycemic index were preferable because of their
favorable effects on serum glucose, serum triglycerides, and insulin levels.
Regular exercise is also recommended for the management of atherogenic
dyslipidemia. The HERITAGE Family Study showed that people with elevated
triglycerides levels and reduced HDL levels, acquired the greatest advantage from a
regular aerobic exercise training program [101].
If dyslipidemia was still existing even after therapeutic lifestyle changes were
implemented, then certain drugs could be used to assist patients in achieving their
target lipid profile. The use of statins, fibrates and niacin has been recommended by
the AHA [37], which is presented in Table 2.5 based on the risk group of the patient.
Table 2.6: AHA Guidelines for treating Atherogenic Dyslipidemia in the MetS

Low

LDL-C goal
(mg/dl)
160

Non-HDL-C
goal (mg/dl)
190

Intermediate

130

160

Intermediate high
High

(130-100)
(100-70)

(160-130)
(130-100)

Risk Group

Recommended treatment
Therapeutic lifestyle
changes
Therapeutic lifestyle
changes
Use statin to achieve goals.
To achieve LDL goal 
use statin.
To achieve non-HDL goal
 intensify statin, and if
the goal was not met, add
fibrate or niacin.

Source: Grundy and others, 2005 [37].

2.4.2.4 Diet/Diabetes Prevention
“D” refers to diet and diabetes prevention. However, many therapies are now
available for diabetes prevention, thus it is treated as a separate aspect in the
management approach. Diet is supposed to feature weight reduction goals and
recommended macronutrient profile of food.
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Weight reduction is the primary goal of treatment for patients with central
obesity. It was proven that a reduction of 7%-10% from the initial weight will improve
all MetS components through reducing underlying risk factors like insulin resistance,
inflammation and ectopic fat storage [102].
Many diets were suggested and used over the years to induce weight loss. Verylow-caloric diet (800 Kcal/day) was able to reduce 6.5% of weight during four weeks,
resulting in a significant reduction of blood pressure, serum triglyceride, serum
glucose, and serum cholesterol [103]. However, these kinds of diet are usually
deficient in many essential nutrient and have poor compliance on the long run. Over
the period of one year a hypocaloric high-carbohydrate, low-fat diet (HCLF) was
compared with a hypocaloric low-carbohydrate, high-fat (LCHF), or high-protein diet,
also known as the Atkins diet. The study found significant weight reduction,
improvement in insulin sensitivity, and reduction in blood pressure were associated
with both diets, and no significant difference was found between the two [104].
A randomized control trail studied the effectiveness of four different diets for
reducing weight and MetS risk factors. One hundred and sixty obese/overweight adult
participants (22-72 years old) with hypertension, impaired fasting glucose, or
dyslipidemia were equally divided into the four following groups, Atkins diet (lowcarbohydrate), Zone diet (macronutrient balance), Ornish diet (low-fat), and Weight
Watchers diet (calorie restriction) [105]. After a year of dietary intervention, all four
diets triggered a modest reduction in body weight and a significant reduction in the
LDL/HDL ratio. Greater dietary adherence rates were associated with greater weight
reduction and improved cardiac risk factors for all groups; however, all groups had
low adherence after one year.
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The Mediterranean diet characteristics matches that of the diet recommended
by the AHA in 2005 [37]. It is rich in omega-3 fatty acids, natural antioxidants and
fiber from fruits, vegetables, nuts and whole grains. A recent meta-analysis of 50
studies including 534,906 participants, investigated the association between the
Mediterranean diet and the MetS. Adherence to the diet revealed a protective role
against MetS components like waist circumference (-0.42 cm; 95%CI -0.82 to -0.02),
triglycerides (-6.14mg/dl; 95%CI -10.35 to -1.93), systolic BP (-2.35 mmHg; 95% CI
-3.51 to -1.18), and plasma glucose (-3.89mg/dl; 95%CI -5.84 to -1.95) [106]. These
findings are very important from a public health perspective, since this diet is easy to
follow and it is highly efficient for prevention of the MetS and its components.
The low glycemic index diet is another great dietary approach for the
management of the MetS and prevention of T2DM and CVD [107, 108]. It is easy to
adopt by various populations and cultures because cultural or traditional diets can be
tailored to follow it. It is simply about choosing low glycemic index foods and
avoiding those with high glycemic index, regardless of the cuisine. The aim of the diet
is to cause a slow increase in plasma glucose after food ingestion. This diet is
recommended by the ADA for the prevention and management of diabetes [16]. A
randomized control trial included 73 obese young adults compared the metabolic
benefits of a low glycemic index diet and a low-fat diet for a total of 18 months (six
months dietary intervention and 12 months follow-up). After the six months of
intervention, the low glycemic index group had a greater reduction in triglyceride
(P=0.02) and greater increase in HDL-C (P =0.002). At 18 months, the low glycemic
index diet group had significantly more reduction in weight (–5.8 vs –1.2 kg; P = .004)
than the low-fat diet [107]. These findings demonstrate how beneficial a low glycemic
index diet could be, especially for the patients with the MetS.
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All discussed diets had the ability to reduce weight; however, weight reduction
is not enough. Maintenance of weight reduction is the key to prevention of metabolic
risk factors. Before recommending a certain diet for a patient, the dietitian should think
about the possibility of adopting that diet for life. Short-term (maximum of two years)
dietary intervention studies are only available, and they all show partial weight regain
and poor compliance on the long run [105, 107, 109]. Therefore, long-term studies are
required to confirm the ability of patients to lose weight using dietary interventions
without regaining it.
Patients should also be advised about improving their sleeping patterns. Recent
meta-analyses and systematic reviews provided evidence that quality and quantity
(very-long or short) of sleep are highly associated with weight gain and increase
incidence of diabetes, they could also predict cardiovascular and metabolic outcomes
[110-112].
Diabetes prevention programs usually use lifestyle therapies to reduce the
incidence of diabetes by reducing weight and increasing physical activity levels [113].
Moreover, other approaches like pharmacologic therapies including metformin [114],
α-glucosidase inhibitors [115], and thiazolidinedione [116] were investigated for
prevention and management of diabetes. Even bariatric surgery is considered one of
the treatment options, especially for people living with morbid obesity and other
comorbidities.
A randomized control trail entitled “The Diabetes Prevention Program”
included 3,234 non-diabetic adults, with elevated fasting plasma glucose and/or
elevated two-hour post prandial plasma glucose concentrations. The study included
two intervention groups, an intensive lifestyle therapy group and a metformin (850mg
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twice/day) group, and one control group receiving placebo. The mean follow-up period
of the study was 2.8 years. The metformin group reduced the risk of diabetes
development by 31%, whereas the intensive lifestyle intervention group decrease it by
58%, in comparison with the placebo group [114].
The ADA’s recommendations in 2015 included the use of intensive lifestyle
modifications as a first line therapy for diabetes prevention and management that
embraces reducing the weight by 7% to 10% and increasing physical activity to 150
minutes per week (moderate-intensity). The use of metformin could be considered for
patients with higher risk of developing diabetes (HbA1c > 6%, metabolic syndrome,
or family history of diabetes). The use of other oral drugs has currently no specific
recommendations, and could be used as a tertiary line of therapy [16].

2.4.2.5 Exercise
Physical activity was shown to promote weight reduction, improve insulin
sensitivity, reduce ectopic adipose tissue, and decrease inflammatory markers. A
systematic review and meta-analysis compared the effectiveness of dietary
interventions versus dietary plus exercise interventions on the long-term (two years),
confirmed the significant effect of diet plus exercise interventions in reducing weight,
compared to the diet only interventions [117].
Many studies from around the world confirmed the beneficial effect of exercise
in preventing and delaying the onset of MetS [118-121]. In the USA, 8,570 adult men
participated in a cross-sectional fitness study. The study concluded high inverse
association between cardiorespiratory fitness, muscular strength and the prevalence of
MetS [122].
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In Mexico, 5,118 adult participants were enrolled in a cohort study
investigating the association of MetS risk factors and level of physical activity. The
cohort noted a great reduction in the risk of developing MetS among men (OR 0.72;
95%CI 0.57-0.95) and women (OR 0.72; 95% 0.57-0.95) who reported exercising for
more than or equal to 30 minutes per day during their leisure time [123].
Current recommendations of the IDF/AHA/NHLBI advocate working out for
a minimum of 30 minutes five times per week. However, it is preferred to do moderateintensity physical activity for ≥ 60 min/day, every day [4]. Patients should be advised
to aim for weight reduction and weight maintenance when choosing the type and
intensity of their work out. Pedometers and other activity tracker could be used for
motivation [120]. Cardiac rehabilitation is highly recommended for patients with a
high risk of CVD or who recently experienced coronary heart failure[124].

2.4.3 Bariatric Surgery
Treatment options for patients with obesity could also include bariatric surgery.
Bariatric surgery could be considered as a treatment option for patients with morbid
obesity (BMI >40 kg/m2) or those with obesity (BMI >35 kg/m2) plus serious obesity
related comorbidities [125]. A meta-analysis published in 2013 included 11 studies
and 796 participants (BMI mean 30-52), and compared non-surgical methods of
treating obesity with surgical methods. The study found significantly higher reduction
in weight induced by bariatric surgery [126]. A randomized control trail included 60
patients (30 and 60 years) with a BMI ≥ 35, a five-year history of diabetes, and an
HbA1c ≥ 7.0%, randomly divided into three groups. The first group received medical
therapy, the second and third groups underwent two different types of bariatric surgery,

37
gastric bypass or biliopancreatic diversion. After two years of follow-up, the study
found no reduction in diabetes in patients from the medical therapy group, a 75%
reduction in the gastric bypass group and a 95% reduction in the biliopancreatic
diversion group (P<0.001, Figure 2.7) [127]. The same results were obtained with
similar trails investigating other surgical techniques like Roux-en-Y gastric bypass and
Sleeve gastrectomy [128, 129].

Figure 2.7: Change in the percentage of HbA1c during two years intervention of
Medical Therapy, Gastric Bypass, or Biliopancreatic Diversion
Source: Mingrone and others, 2012 [127].
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2.5 Prevalence of the Metabolic Syndrome
Prevalence of the MetS differs between nations, genders, age groups, ethnic
groups, and also according to the definition used for diagnosing. Moreover, the
prevalence of the syndrome is increasing among many populations around the world,
this is mainly due to the decrease in physical activity, increase in rates of obesity and
overweight, along with other environmental factors [130]. The total prevalence of the
MetS among Emirati adults according to the IDF and ATPIII definitions was 40.5%
and 39.6%, respectively in 2008[5]. This is higher than all other Gulf Cooperation
Council (GCC) countries (Table 2.7, Figure 2.8), and amongst the highest worldwide
(Table 2.8).
Table 2.7: Prevalence of the MetS among adults in GCC Countries
Country

Prevalence

Sample Size

MetS
Definition

Reference

Men: 22.8%
El-Aty et al., 2014
3,137
Women: 24.4%
WHO
[131]
Oman
Total: 23.6%
Men: 20.7%
Bener et al., 2009
1,204
Women: 32.1%
ATPIII
[132]
Qatar
Total: 26.5%
Men: 29.6%
Bener et al., 2009
Women: 37.7%
1,204
IDF
[132]
Total: 33.7%
Men: 36.2%
Al Rashdan et al.,
2,280
IDF
2010 [133]
Kuwait Women: 36.1%
Total: 36.2%
Men: 35.1%
Malik et al., 2008
ATPIII
Women:
42.7%
4,097
[5]
UAE
Total: 39.6%
Men: 32.9%
Malik et al., 2008
Women: 45.9%
4,097
IDF
[5]
Total: 40.5%
Men: 36.6%
Al Daghri, et al.,
Women: 34.1%
2,850
ATPIII
2010 [134]
KSA
Total: 35.3%
WHO: World Health Organization; ATP: National Cholesterol Education Program
Adult Treatment Panel; IDF: International Diabetes Federation; UAE: United Arab
Emirates; KSA: Kingdom of Saudi Arabia.
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It was noted that the MetS is more prevalent among adult women. The
difference between men and women ranged from 0.1% in Kuwait to 13% in the UAE.
This could be explained by the lower physical activity levels reported among Emirati
females due to cultural and weather restrictions [135].
The prevalence of the syndrome was reported to be significantly associated
with older age, in the same population. For example, in Saudi Arabia the prevalence
was 12.8% in the 18-29 years old group, increased to 32% in those aged 30-39, 53.1%
among adults aged 40-49 and 67.1% among older people (50-55 years) [134]. A
greater association was also observed between obesity level and the prevalence of the
syndrome in both genders. In China, for example, the prevalence of MetS increased
from 9.8% in normal weight adult men to 26.9% in overweight adult men, and from
17.8% in normal weight adult females to 31.1% in overweight adult females [136].
The MetS prevalence is generally increasing significantly over time. For instance, the
Korean population witnessed a great increase from 24.9% in 1998 to 31.3% in 2007
[137]. The prevalence of the MetS in different countries around the world is presented
in Table 2.8.
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Figure 2.8: Prevalence of the MetS in GCC Countries
Source: From data presented in Table 2.7
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Table 2.8: Prevalence of the MetS in different countries

Australia

America

Asia

Europe

MENA

Region

Country

Prevalence of
MetS

Sample Size
(age/years)
4,259
(20-90)
1,121
(>25)
499
(18-65)
836
(>40)
10,368
(≥20)
1,436
(>18)
11,149
(>18)
578
(>18)
2,100
(>19)
3,264
(20-79)
1,123
(>20)

Turkey

33.9%

Jordan

36.3%

Lebanon

31.2%

Tunisia

45.5%

Iran

30.1%

Portugal

23.9%

Spain

22.7%

Canary
Islands

24.4%

Italy

17%

Japan

7.8%

India

31.6%

China

21.3%
18.2%
10.5%

15,540
(≥18)

ATPIII
IDF
CDS

Korea

31.3%

2,890
(≥20)

ATPIII

Russia

19.3%
17.6%
18.9 %

3,705
(18-90)

AHA
ATPIII
IDF

Brazil

21.6%

U.S.A

34%

Canada

19.1%
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This high prevalence of the syndrome was not only observed among adults,
many studies reported high numbers in adolescents as well. In the US, the prevalence
of the MetS among adolescents (12-19 years) was 4.2% [156]. Six point five percent
of Mexican children and adolescents (10-18 years) met the ATPIII definition of the
syndrome [157]. In Saudi Arabia, the prevalence among 10-18 years old boys and girls
was 9.4% [158]. In Kuwaiti female adolescents (10-19 year), 14.8% met the IDF
defining criteria of the MetS [159]. Moreover, 13% of Emirati adolescents were
reported to have the MetS [6]. These numbers are extremely high and action is urgently
needed at the national and global level to reduce the prevalence of MetS, and its
components, especially obesity. The obesity epidemic is usually blamed on physical
inactivity and poor dietary habits [160].
Studies from the UAE reported very low physical activity levels between adults
and adolescents, especially females [135, 161, 162]. In 2009, Belal reported that the
prevalence of physical inactivity is almost 37.9% among men and 56.7% among
women. Moreover, 38.4% of adolescent males and 42.6% of adolescent females spend
≥ 3 hours/day sitting [163]. In a qualitative study among Emirati female adults, the
first barrier to being physically active was stated to be the lack of social support from
friends and families [164]. Another study claimed that low physical activity levels
between Emirati female adolescents is mainly due to cultural and climate restrictions
[135]. As a matter of fact, there is a lack of national-level studies investigating the
level of physical activity in the country, barriers to being active, and transition of
physical activity trends overtime. This type of information is highly important as it is
the basis for developing future interventions, policy making decisions, and assessing
these actions in the long term.
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Dietary habits in the UAE are better documented in the literature. In 1998,
Musaiger and others reported very low consumption of vegetables, fruits and dairy
products (yogurt, cheese and milk) among Emirati adults [165]. In 2009, Bin Zaal and
others, indicated high consumption of fast food and high caloric snacks among Emirati
adolescents, and found a significant association between the consumption of
chocolates, sweets, fast foods, soft drinks, and rates of obesity in Emirati adolescent
girls [166]. In the same year, Bilal stated that 77.5% of men and 75.7% of women eat
less than five servings of fruits and vegetables per day [163].
Recently, a study was published about nutrition transition in the UAE. The
study presented data about the high prevalence of obesity and factors behind it.
Positive energy balance was seen among all age groups, with around 40% of boys and
girls (6-10 years) consuming more calories than their requirements. More than 20% of
calories consumed were coming from calorie-dense snacks and 14% from emptycalorie drinks [167]. Other than the low consumption of fruits and vegetables, many
studies blamed high rates of obesity on the replacement of traditional Emirati foods by
westernized high caloric fast foods, and the replacement of water with empty-calorie
soft drinks [165-168]. A very recent study investigated the nutritional knowledge about
Emirati traditional foods among Emirati adults. About 50% of females and 70% of
males stated that they consider traditional foods healthy; however, only 18.2% of
males and 14% of females reported daily consumption of traditional foods [169].
Conversely, other studies from the Gulf region reported considering traditional food
as an unhealthy option, and it might be the reason behind the epidemic of obesity and
T2DM. These studies build their conclusions on food composition data available in
their countries, showing high carbohydrates and fat content in traditional foods [160,
170-173].
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Unfortunately, very little information is available about the food composition
and glycemic index of Emirati traditional foods. Food composition databases offer
comprehensive information on the concentrations of nutrients in foods; this
information is considered the base of any quantitative study of nutrition. It is also
useful in clinical practice, food manufacturing, designing health promotions,
regulation of nutrition and health claims, epidemiological studies, and policy decision
making [174].
Recently, ten traditional dishes commonly consumed in the UAE were
chemically analyzed for proximate composition and mineral content [175]. However,
some information is still needed to make better nutritional recommendations. For
instant, lipid profile, such as monounsaturated fatty acids, polyunsaturated fatty acids,
saturated fatty acids and trans-fatty acids content is considered crucial for planning a
diet like the Mediterranean diet. Glycemic index and glycemic load are also very
necessary for meal planning, especially in a population with high prevalence of MetS,
diabetes and CVD. Planning low glycemic diets using traditional foods could be the
key for better glycemic management and might prevent the progression of the MetS
into T2DM and CVD as discussed earlier in Section 2.4.2.4.

44
2.6 Glycemic Index: History
The dietary fiber hypothesis developed in the 1970s by Trowell was the first
step into the establishment of the glycemic index concept [176]. Trowell observed that
the fiber part of carbohydrates was not absorbed in the gut, which influenced certain
actions within the lumen of the gastrointestinal tract. He linked this observation to the
risk of some diseases like diabetes and ischemic heart disease [177, 178].
In 1981, David Jenkins and his colleagues invented the term “glycemic index”
[20]. The concept was developed from observing the dramatic variation in blood
glucose response after the ingestion of carbohydrate rich foods. Ever since, many
studies started investigating the possible health benefits of low glycemic index diets.
The GI concept was first used for the prevention and management of diabetes [21].
Afterwards, studies also investigated other important implications of the GI for the
prevention and treatment of obesity and coronary heart disease [179, 180]. Recent
evidence indicates the role of low glycemic index diets in the treatment and prevention
of diabetes [181], hyperlipidemia and CVD [182]. Moreover, low GI diets were
associated with improved insulin sensitivity [183] and regulating appetite [184].
In 1995 the first International Tables of Glycemic Index were published. The
aim of these tables was to gather all published data on the GI from different studies
and produce a convenient tool to be used in research and clinical practice [185]. About
600 separate entries were included in the first edition of the GI tables. Furthermore, in
2002 [186] and in 2008 [187] an updated version of the GI tables was published and
included GL values as well. The 2008 International Table of Glycemic Index and
Glycemic Load Values includes more than 2,480 individual food items [187].
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The use of GI for the classification of carbohydrate-containing foods has been
validated by the Food and Agriculture Organization of the United Nations and the
World Health Organization in 1998 [188]. They recommended the use of GI of foods
along with food composition tables as a guide for food choices. The American
Diabetes Association also recommends the use of low GI diets for diabetes
management and prevention [16]. Since many studies reported a reduction in HbA1c
levels from around 3% to about 19% when low GI diet was implemented [181, 189,
190].

2.6.1 Definition of the Glycemic Index and Glycemic Load
The glycemic index is a measure of how fast a certain food could increase
blood glucose after ingestion compared to that of pure glucose. It is defined as “the
incremental area under the blood glucose response curve of a 50g carbohydrate portion
of a tested food expressed as a percent of the response to the same amount of
carbohydrate from a standard food taken by the same subject (either white bread or
glucose), on a different day” [188]. The area under the curve (AUC) of the blood
glucose response after consumption of pure glucose is given the value of 100. The
AUC of blood glucose curve after ingestion of a carbohydrate-containing food is
compared to that of pure glucose and classified as low (induces a slow raise of plasma
glucose), intermediate, or high (causes a quick and sharp increase of plasma glucose)
[20]. The categories of the GI values are presented in Table 2.9. Foods like legumes
and non-starchy vegetables tend to have low glycemic index, while foods like rice,
white bread, and honey cause larger post prandial elevation in plasma glucose
concentrations and therefore considered high in glycemic index [182].
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In 1997, the concept of “glycemic load” was introduced [21, 191]. Glycemic
load is a way to measure the glycemic index of foods depending on a standard portion
size. It is typically calculated as the glycemic index of the food multiplied by the
amount of available carbohydrate in standard serving, divided by 100 [21]. It is
regularly essential to consider the GL in conjunction with GI values, particularly when
the carbohydrate content of the test food is relatively small. For instance, broad beans
have a high GI but because of their low carbohydrates content, they are classified as a
low GL food [186] . The categories of the GL values are presented in Table 2.9.
Table 2.9: Categories of Glycemic Index and Glycemic Load Values
Category

Glycemic Index Value

Glycemic Load Value

Low

≤ 55

≤ 10

Medium

56-69

11-19

High

≥ 70

≥ 20

Source: Brand-Miller and others, 2005 [192], Salmeron and others, 1997 [191].

2.6.2 Methodology of the Glycemic Index
The first protocol of measuring GI with clinical utility and without
methodological controversy was described by Wolever and others in 1991 [193]. This
protocol was later adopted by the FAO/WHO in 1998 with minor modifications [188].
The sample size for testing glycemic index with sufficient statistical power
should be at least 10 test subjects [188]. Fifty grams of available carbohydrates is used
to calculate the portion size of test foods, which is equivalent to 50 g of standard food
(glucose). However, for low carbohydrate foods, 25 g could be used [194]. Tests
should be randomized in blocks and the duration of testing should not exceed four
months [194]. The standard food should be measured twice and once for each test food,
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with one day gap between tests [188]. The evening before a test, volunteers should
restrict caffeine-containing drinks, avoid vigorous physical activity and fast overnight
[195]. During the test, subjects should consume foods with 250 ml of water within 1015 min. Capillary finger-prick blood samples are collected while fasting and at 15, 30,
45, 60, 90, and 120 min after ingesting the test meal. The area under the glucoseresponse curve is calculated based on incremental AUC, by ignoring the area under
the baseline. Incremental area under the curve (IAUC) for each food is calculated as a
percent of the mean response to the IAUC of standard food taken by the same subject.
The values of all subjects are then averaged to obtain the GI value for the food [193].
According to the FAO/WHO expert report on the GI methodology, The GI is
calculated using the following equation:

𝐺𝐼 =

𝐼𝐴𝑈𝐶 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 (𝑋)𝑔 𝑜𝑓 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝐶𝐻𝑂
× 100
𝐼𝐴𝑈𝐶 𝑜𝑓 𝑎 𝑟𝑒𝑓𝑒𝑟𝑛𝑐𝑒 𝑓𝑜𝑜𝑑 𝑤𝑖𝑡ℎ 𝑎𝑛 𝑒𝑞𝑢𝑎𝑙 𝐶𝐻𝑂 𝑝𝑜𝑟𝑡𝑖𝑜𝑛
The IAUC under each blood glucose response curve (for standard food or test

food) is calculated as illustrated in Figure 2.9, by adding areas A+B+C+C+D+E+F all
together and ignoring the negative areas [188]. The individual IAUC values for each
test food in each subject are presented as a percentage of the mean IAUC value for the
repeated standard food tests taken by the same subject. The GI of each test food is
calculated as the mean of the resulting GI values from different subjects for each food
[194].
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Figure 2.9: The Incremental Area Under the Curve (IAUC) equals the sum of the
areas A, B, C, D, E and F. Negative areas are not included
Source: FAO/WHO, 1998 [188]

2.6.3 Factors influencing the Glycemic Index
The GI of foods varies significantly due to many factors such as cellular
structure (e.g. degree of ripening), gross structure (e.g. grinding and particle size),
granular starch structure (e.g. heat treatment), amount of carbohydrates, type of sugar
(i.e. glucose, sucrose, lactose, or fructose), co-existence of nutrients (i.e. dietary fiber,
fat, or protein), starch nature (amylose and amylopectin), cooking method, and food
processing [194]. Other factors could include the addition of organic acids, gelling
fibers, amylase inhibitor or sugars to the food [196]. Therefore, there is usually a
considerable variation in the GI of the same food produced by different manufacturers
or in a different country. A summary of these factors is presented in Table 2.10.
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Table 2.10: Main Factors Affecting the GI of Foods and Meals
Food Factor
Starch type

Example
Amylopectin (branched)

Effect on GI
Higher GI

Amylose (unbranched)

Lower GI

Heating
Starch granular
structure
Higher ripeness
Degree of ripeness
Grinding, milling, or rolling
Processing
Added
Acids
Added
Gelling fibers
Added
Amylase inhibitor
Fructose
Added sugars
Added
Protein
Added
Fat
Source: Arvidsson-Lenner and others, 2004 [196].

Higher GI when
gelatinized
Higher GI
Higher GI
Reduce GI
Reduce GI
Reduce GI
Reduce GI
Reduce GI
Reduce GI

2.6.4 Glycemic Index in Health and Disease
Recently, the glycemic index became not only popular as a useful tool in
planning meals for patients with diabetes, but also as an important intervention for the
prevention and management of dyslipidemia, cardiovascular disease, obesity, and
other chronic diseases in the general population [189]. The hypothesis suggests that a
higher increase in the postprandial glycaemia, is the triggering mechanism for disease
progression [19].

2.6.4.1 Glycemic Index and Obesity
Epidemiological studies show a great increase in the epidemic of obesity
worldwide. In the United States, the prevalence of overweight adults (≥ 20 years) was
33.9% in 2012 [197]. In the same report, 35.1% of the US population was found obese,
and 6.4% met the criteria of extreme obesity (BMI greater than or equal to 40) [197].
In the UAE, the prevalence of overweight and obesity among female adults increased

50
from 36% in 2000 to reach 48% in 2010 [167]. This included an increase in extreme
obesity among Emirati women from 7% in 2000 to 17% in 2010 [167]. The reason
behind this epidemic is blamed on positive energy balance, characterized by low
energy expenditure due to physical inactivity, and high energy intake due to over
consumption of calorie dense foods [198]. Yet the reality is that it is more complicated
because many genetic and environmental factors are involved. In an attempt to solve
the issue, many diets were developed over the years to promote weight loss and
maintenance, such as the low fat diet, high protein diet, low calorie diet and very low
calorie diet [104, 199]. These diets have shown poor compliance in the long run, and
were all associated with weight regain after a period of time [105]. This is probably
due to the effect of these diets on reducing basal metabolic rate, therefore,
compensating for caloric reduction [200].
The low glycemic index diet does not restrict caloric intake nor limit the intake
from any of the food groups that are essential for a balanced diet. It simply advises
increasing the consumption of foods from the low glycemic index category and avoid
those from the high glycemic index category. Moreover, recent evidence suggest that
low glycemic index diets may help prevent weight regain and promote weight
reduction maintenance after weight loss, by reducing the usual decrease in energy
expenditure and basal metabolic rate associated with weight reduction [201].
There are two suggested mechanisms by which a low GI diet is suggested to
promote weight loss. First, by reducing appetite and food intake owed to differences
in plasma glucose and insulin concentrations. The second hypothesis is that low GI
diet reduces fat storage and lessens fat oxidation due to reduced plasma insulin
responses [179].
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Many studies investigated the effect of a low glycemic index diet on body
weight. In 2014, a randomized control trail of 104 obese adolescents (15-18 years),
evaluated the effect of a low GI diet versus a conventional Chinese diet on BMI over
six months. This intervention trial reported an association between low GI diet and
decreased calorie intake, healthier dietary composition (increased fiber intake and
reduced fat intake), and reduced BMI in obese adolescents [202]. Another randomized
control trail published in 2014 included 122 individuals with overweight and obesity.
Participants were randomly assigned to a high-GI diet, a low-GI diet, or a low-fat diet.
After six months of intervention, the trail reported a significant reduction in the BMI
(Figure 2.10) and improvement in insulin sensitivity in the low GI diet group compared
to the low-fat [203].

Figure 2.10: Changes in BMI during the follow-up for each intervention group.
Source: Juanola-Falgarona and others, 2014 [203].
In contrary, another randomized clinical trial entitled “DIOGENES”
investigated the effect of a high dietary protein diet and GI diet on weight loss
maintenance in people living with overweight and obesity in two centers across
Europe. The one-year results of this intervention reported no significant difference
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between the two diets in reducing weight; however, the high protein diet was
associated with less weight regain after the year of intervention [204].
It is important to keep in mind that a high GI diet is not the only factor
contributing to the epidemic of obesity. In fact, many genetic and environmental
factors are involved in a very complex manner, not only at the individual level, but
also at the family, community, country and even global level [179]. Low GI diet has
been shown to reduce weight and help in maintaining lost weight, however,
controversy is still present because there are no long-term and big-scale studies
available on GI and body weight [100].

2.6.4.2 Glycemic Index and Diabetes
Diabetes is a chronic disease characterized by abnormalities in the metabolism
of carbohydrate, fat, and protein along with hyperglycemia. Complications of the
disease include macrovascular and microvascular damage in the eyes (retinopathy),
kidneys (nephropathy) and nerves (neuropathy). If left untreated, these complications
could progress into blindness, kidney failure, amputation and even death [205].
During the past three decades, the prevalence of diabetes mellitus in the world
has doubled, which presented a great challenge to the public health of all nations.
According to the recent regional fact sheets of the International Diabetes Federation
[2] there are 382 million people living with diabetes in the world with a prevalence of
8.3%. The IDF expected an increase by 205 million by 2035. The prevalence of
diabetes in the Middle East and North Africa (MENA) region is even higher than the
world average with 9.7%. Based on the same fact sheets, United Arab Emirates was
ranked as having the fifth highest prevalence in the MENA region (19%), coming after
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other GCC countries, Saudi Arabia, Kuwait, Bahrain and Qatar having the prevalence
of 23.9%, 23.1%, 21.9% and 19.8% respectively [2].
Diet and lifestyle modifications are considered the basis for preventing and
managing diabetes. The main aim of therapeutic lifestyle changes for people living
with diabetes are weight reduction, improving glycemic control and reducing the risk
of cardiovascular comorbidities [16]. Postprandial glycaemia could be controlled by
controlling the amount of carbohydrates in a diet (carbohydrate counting and exchange
list) or the nature of carbohydrates in food (glycemic index). The use of glycemic index
for managing diabetes is still controversial. The American Diabetes Association
(ADA) reviewed the evidence on the use of GI as an intervention for diabetes
prevention and management in the “2015-Standards of Medical Care in Diabetes”
publication [16]. They stated that the use of glycemic index and glycemic load in
individuals with diabetes is recommended as studies have demonstrated a reduction in
HbA1c by -0.2% to -0.5% when a low GI diet was followed [16]. The European
Association for the Study of Diabetes (EASD) also recommended people with diabetes
to choose low GI foods for better postprandial glycemic management [206]. However,
some researchers have criticized the use of the GI system for people with diabetes,
claiming that it is very complex and it might limit food choices if adopted as a lifestyle
[182].

2.6.4.3 Glycemic Index and Cardiovascular disease
According to the World Health Organization, cardiovascular diseases are the
leading cause of death globally. In 2012, about 17.5 million people died from
cardiovascular diseases, representing 31% of total global deaths [1]. Among these
deaths, coronary heart disease was behind 7.4 million and 6.7 million were due to
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stroke [1]. Cardiovascular diseases (CVDs) are a cluster of disorders occurring in the
heart and blood vessels, such as coronary heart disease, ischemic heart disease, stroke,
cerebrovascular disease, peripheral arterial disease, rheumatic heart disease,
congenital heart disease and others. Most of the CVDs are preventable through
improving dietary habits, cigarettes cessation, physical activity and reduction in
alcohol consumption. Diets targeting prevention of CVDs mainly focus on the type
and amount of fats present in a diet, such as the Mediterranean diet [207]. However,
epidemiological studies have reported an association between high glycemic index and
glycemic load diets and increased risk of CVDs [100, 108].
The 2011 DIOGENES trail, a controlled dietary intervention study from across
Europe that included 932 overweight adults who were randomized to one of the five
ad libitum diets for 6.5 months. The diets were either high protein, low protein, high
GI, low GI, or a control. The study resulted in a greater reduction in high-sensitivity
C-reactive protein blood levels (−0.46 mg/L; 95% CI −0.79 to −0.13) among the
groups assigned to GI diet, compared to the high GI diet group (P<0.001). This
reduction in low-grade inflammation suggests a positive effect of GI diet with
cardiovascular risk [208]. A randomized control trail among 73 people living with
obesity (18-35 years) studied the difference between low GI diet and low-fat diet for
six-months intervention and a one-year follow-up. The study indicated a beneficial
effects of the low GI on high-density lipoprotein cholesterol (HDL-C) and triglyceride
concentrations even after the intervention was over [107].
Available evidence supports the role of glycemic index and glycemic load in
cardiovascular disease risk management and prevention; however, further studies
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investigating risk of CVD in relation to GI and GL are needed to provide the required
power for future meta-analyses on this topic [209].

2.7 Summary
The epidemic of metabolic syndrome was thoroughly discussed in this
literature review. The importance of addressing this cluster of diseases in the UAE
population was highlighted, and recommendations for prevention and management
mainly through dietary practices were discussed.
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Chapter 3: Materials and Methods
3.1 Introduction
This chapter outlines and discusses the research design, methodology and
analyses followed in each of the two experiments presented in this dissertation;
therefore, it is divided into two sections:
-

Section I: prevalence of the metabolic syndrome and its component factors
among female students at United Arab Emirates University and their
association with anthropometric measurements;

-

Section II: Glycemic Index (GI) values of commonly consumed foods in
the UAE.

For both sections, the participants’ recruitment, research design schemes, data
collection and data analysis are discussed.

3.2 Prevalence of the Metabolic Syndrome and its Component Factors among
Female Students at United Arab Emirates University and their Association
with Anthropometric Measurements
3.2.1 Study Population
This study is a cross-sectional population-based epidemiological study. It was
conducted during the academic year 2013/ 2014 at United Arab Emirates University
(UAEU) in Al-Ain, United Arab Emirates. The study population included students
from all eight colleges of the university except the College of Medicine and Health
Sciences, as they are located in a different campus The sampling method was stratified
random sampling [210]. All female students were divided into strata by college, then
a random subsample consisting of 10% of the students from each college were
proportionally selected. Those were then contacted through e-mail to voluntarily
participate in the study.
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The total number of females registered in the university during that academic
year was 8846 students. 885 students received an invitation to participate. 654 students
showed interest in the study with a response rate of 74%, and out of these 99 students
were excluded from the study for the following reasons: 56 students did not show up
for the data collection appointment, 25 students refused to give blood, 7 students were
pregnant, 5 students were breastfeeding, 4 students were on long-term medication and
2 students did not have good blood flow. Therefore, the final number of participants
was 555 female students between the age of 17 and 25 years old (Figure 3.1).
n=885 Students received invitation to participate
n=654 Students responded (Response Rate=74%)
n=99 Excluded for the following reasons:
n=56 Did not show for appointment
n=25 Refused blood collection
n=7 Pregnant
n=5 Breastfeeding
n=4 On long-term Medication
n=2 Failed blood collection
n=555 Students completed the study
Figure 3.1: Study Participant’s Enrolment Process
Participants were asked to read the study information sheet carefully and were
given the chance to ask questions related to the study before taking part (Appendix 1).
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Participants were excluded if they did not meet the following inclusion criteria: had a
disease or was on medication; was pregnant or breastfeeding; older than 25 years old
or younger than 17 years old; and if she refused to provide blood sample. A written
informed consent to participate in the study has been obtained from all participants
before taking part (Appendix 2). An identification number was assigned to each
participant to maintain anonymity, which confirmed confidentiality and helped link
the participant to their clinical measurements and blood samples. Only cumulative data
was reported to protect the privacy of all participants.

3.2.2 Ethical Approval
Ethical approval for the study was obtained from the United Arab Emirates
University Scientific Research Ethics Committee (UAEU, Reference Number
DVCRGS/370/2014) and from Al Ain Medical District Human Research Ethics
Committee (Number 14/48) (Appendix 3). All participants who agreed to join the
study provided a written informed consent before taking part, as attached in Appendix
2.

3.2.3 Anthropometric Measurements
The use of anthropometric measures for the assessments of the nutritional
status of individuals and societies was first introduced by Brožek in 1956 [211]. It has
been found that anthropometric measures have a great advantage as they can be related
to past exposures, present practices or health related events in the future.
Anthropometric measurements are normally divided into two groups, the first group
contains measures for the assessment of body size, such as body weight, height and
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head circumference. The second group determines body composition, which includes
body fat and body fat-free mass [10, 212]. Both groups are highly important and their
use has been recently increased in clinical settings, assessing interventions’ outcomes
and conducting surveillance at the population level [213].
Body size and composition measures including: height, weight, body fat
composition, waist circumference (WC), hip circumference (HC]), waist-to-hip ratio
(WHR), neck circumference (NC), mid-upper arm circumference (MUAC) and skinfold thickness at four sites (biceps, triceps, subscapular and suprailiac) were all carried
out by the researcher (Mohamad, M.) in the nutrition clinic of the Nutrition and Health
Department at UAEU. All measurements were completed during a single fifty-minute
session with the participants reporting to the clinic at fasting state and have restricted
fluid (excluding water intake) for 12-14 hours prior to testing.
Results were recorded immediately after the measurements on a data sheet
(Appendix 4) and were then checked by another skilled researcher. Each measurement
was taken three times and averaged. As the participants of this study were all females,
they were asked not to visit the clinic during their menstrual cycle. Measures were
taken while the participants wore minimal clothing (as local culture permits) and no
shoes. Participants were asked to rest for 15 minutes to allow climate adjustments and
relaxation before any measurements were taken. During rest time, they were asked to
complete a brief health questionnaire (Appendix 5). It included questions about
demographic data, supplements and medications use, tobacco use, diet, physical
activity, sleeping patterns, perceptions about obesity, personal history of NCDs, and
family history (first-degree relatives) of NCDs. Participants completed the
questionnaire under the supervision of the research team to respond to any clarification
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needed on any aspects of the questionnaire or the study as a whole. All devices used
for measurements were calibrated on a daily basis though out the study.

3.2.3.1 Height
Height was measured using a portable stadiometer (Seca Stadiometer, Seca
Ltd, Birmingham, UK), and was measured to the nearest millimeter. Participants were
asked to take a deep breath and stand upright, looking straight ahead horizontal with
the Frankfurt plane, with shoulders relaxed, legs straight, and knees placed together.
They were also asked to keep their feet flat with heels close together, and their shoulder
blades, buttocks, and heels touching the measurement board [10].

3.2.3.2 Body Weight and Body Composition
Body weight and body composition were measured using the Tanita Segmental
Body Composition Analyzer (Tanita BC-418 Ltd, Tanita UK, Figure 3.2). The
analyzer was placed on a hard, flat surface, and body weight was recorded to the
nearest 0.1 kg.
The Tanita segmental body composition analyzer uses the BIA (bio-electrical
impedance analysis) method for analysis. It measures impedance by introducing a safe
known amount of constant current source with a high frequency (50 kHz, 500μA) into
the body. It then calculates body fat percentage, fat mass, fat-free mass, and predicted
muscle mass through a regression formula using height, weight, age, and impedance
between right hand and foot as variables[214].
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Figure 3.2: Tanita Segmental Body Composition Analyzer BC-418

Participants were asked to step bare foot on the weighing platform unassisted,
looking straight ahead, making sure that heels were placed on the posterior electrodes,
and the front part of the feet were in contact with the anterior electrodes. Participants
were asked to stand still for few seconds to allow weight measurement to appear on
the screen, then were asked to grasp the grips with both hand and wait for a few more
seconds to allow measurement of the impedance.

3.2.3.3 Body Mass Index
The most commonly used measure for the classification of adult population
according to their weight status is the ratio of weight to height which is known as Body
Mass Index (BMI) or (Quetelet’s Index). BMI is calculated by dividing the weight in
kilograms by the height squared in meters (kg/m2) [215]. The latest publication of the
World Health Organization (Table 3.1) was used as a guideline for the classification
of adults according to BMI [198].
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Table 3.1: WHO Classification of Overweight in Adults According to Body Mass
Index
Classification

BMI (kg/m2)

Risk of comorbidities

Underweight

< 18.50

Low

Normal range

18.50 – 24.99

Average

Overweight

≥ 25.00

Pre-obese

25.00 – 29.99

Increased

Obese class I

30.00 – 34.99

Moderate

Obese class II

35.00 – 39.99

Severe

Obese class III

≥ 40.00

Very severe

Source: WHO, 2000 [198].

3.2.3.4 Waist Circumference
Waist circumference (WC) showed high correlation with abdominal fat
content, measured by computer tomography or by dual X-ray absorptiometry (DXA),
in several studies [54, 216]. Measurement was performed using a plastic tape touching
the skin, with a width of 0.7cm, held in a horizontal plane, midway between the inferior
margin of the ribs and the superior border of the iliac crest or at umbilicus level for
obese participants [217]. The participants were asked to stand erect, relaxing the
abdomen, with arms placed on the side, and weight equally divided over both legs.
WC was recorded to the nearest millimeter. The IDF and the American Heart
Association/the National Heart, Lung, and Blood Institute (AHA/NHLBI) cut-offs [4]
(Table 3.2) were used according to ethnicity and gender to identify the increased risks
associated with excess abdominal fat like that of diabetes and metabolic syndrome.
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Table 3.2: Cut-off Values of Waist Circumference Based on Ethnicity and Gender
Country/ ethnic group

Gender

Waist circumference

Europids

Male

≥ 94 cm

Female

≥ 80 cm

Male

≥ 90 cm

Female

≥ 80 cm

Male

≥ 90 cm

Female

≥ 80 cm

Male

≥ 85 cm

Female

≥ 90 cm

South Asians

Chinese

Japanese

Ethnic South and Central
Americans

Use South Asian recommendations until more
specific data are available

Sub-Saharan Africans

Use European data until more specific data are
available

Eastern Mediterranean and
Middle East

Use European data until more specific data are
available (Arab) populations

Source: Alberti, 2009 [4].

3.2.3.5 Hip Circumference
Hip circumference (HC) is usually not used for assessing body composition
and the distribution of body fat as a single measure. It is rather used along with the
WC to calculate the waist-hip circumference ratio (WHR). HC was measured using a
plastic tape, with a width of 0.7cm, held in a horizontal plane by touching the skin
without pressing the soft tissue, at the level of maximum posterior extension of the
buttocks [218]. Participants were standing erect, relaxing the abdomen, feet together
and arms placed on the side [219], HC was recorded to the nearest millimeter.

64
3.2.3.6 Waist-Hip Circumference Ratio
Waist-Hip circumference ratio (WHR) is a simple and easy method which
allows distinguishing between fatness in hips and buttocks areas and fatness in the
abdomen and waist areas. It is calculated by dividing waist circumference by hip
circumference. Several studies reported strong association between elevated WHR and
increased risk of developing type 2 diabetes (T2D), ischemic stroke and coronary heart
disease [220, 221]. The cutoffs values used for waist–hip ratio were (0.90) and (0.80)
for men and women, respectively, as suggested for Middle Eastern populations in 2011
by the World Health Organization [222].

3.2.3.7 Neck Circumference
Neck circumference (NC) is used as an indicator for upper-body subcutaneous
adipose tissue distribution. Several population-based studies have shown an elevation
of cardiovascular and metabolic syndrome (MetS) with the increase of neck
circumference values [9, 223]. NC was measured at mid-neck height, between
midcervical spine and midanterior neck and recorded to the nearest 1 millimeter, using
plastic tape, calibrated weekly, with the tape not being too tight or too loose, and just
lying flat on the skin. Participants were asked to keep the head up, relax the shoulders
and look straight ahead [224]. The cutoffs for neck circumference are not well
established yet; however, in the Chinese population the values of ≥38 cm and ≥35 cm
for men and women respectively, were reported to be the best cutoffs to identify
overweight participants. However, the same study suggested that the values of ≥39 cm
and ≥35 cm for men and women respectively, were the best cutoffs to determine
metabolic syndrome (MetS) participants [9].
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3.2.3.8 Mid-Upper-Arm Circumference
Mid-upper-arm circumference (MUAC) is usually used for the determination
of nutritional status in population-based studies, as it is useful for the diagnosis of
protein-energy malnutrition and participants’ starvation, especially in children and
adolescents [225] . Participants were asked to remove their sleeves and stand erect,
and bend their right arm at the elbow in a perpendicular angle. The edge of the shoulder
(acromion process on shoulder blade) and elbow (olecranon process of the ulna) were
located and marked. Plastic non-stretchable tape was used to measure the distance
between the two marks and the middle point was located and marked. The MUAC was
then measured using the same measuring tape, wrapped around the mark, while the
arm is hanging down the side of the body and relaxed. MUAC was recorded to the
nearest millimeter [226]. MUAC values of 23.0 cm and 22.0 cm for men and women
respectively, were suggested to be useful cut-off points for simple screening of
nutritional state in adults of the third world [227].

3.2.3.9 Skinfold Thickness
Skinfold thickness measurements are usually used for the estimation of total
body fat; a single skinfold measure or multiple skinfolds could be used. Many studies
have suggested the use of skinfolds for assessing subcutaneous fat considering the low
cost, simplicity (when performed by trained examiner) and effectiveness in
comparison with ultrasound [228, 229].
A Lange Caliper (Cambridge Scientific Industries, Cambridge, MD, Figure
3.3) was used for the measurement of skinfold thickness at four sites: triceps, biceps,
subscapular and suprailiac sites as described by Lohman and others in 1988 [230].
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During all skinfold measures, participants were asked to stand erect, with
shoulders relaxed and arms hanging freely at their sides. The right side of the body has
been used for taking all measures, as it is the current practice by the National Health
and Nutrition Examination Survey (NHANES). The middle point in the upper right
arm was already marked for the measurement of the MUAC. This point was used for
the measurement of triceps (from the back side of the arm) and biceps (from the inner
side of the arm). The skin and underlying fat were grasped at a vertical angle, about 2
cm above the mark, using the thumb and the forefinger of the left hand of the examiner.
The caliper was then placed on the mark and the value was recorded to the nearest 0.5
millimeter. Measures were repeated three times and averaged [231]. The subscapular
skinfold was measured by grasping the skin and underlying fat at the inner border of
the scapula at an angle of 45° from horizontal. The suprailiac was taken from the
midaxilary line directly above the iliac crest by picking up the skin and underlying fat
at an angle of 45° following the natural folding of the skin [10].
The logarithmic transformation of the sum of means from all four sites of
skinfold thickness was used for the calculation of equivalent fat content as a percentage
of total body weight. Fat content was calculated using specific linear regression
equation for females between 17-29 years old, as described by Durnin and Womersley
in 1974 [232].

Figure 3.3: Lange Caliper
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3.2.4 Biochemical Measurements
Biochemical measurements are usually used to confirm a clinical diagnosis or
to detect abnormalities in the levels of lipid profile. Unlike clinical, dietary and
anthropometric measures, biochemical measures provide an objective method for the
assessment of nutritional status [10]. Static biochemical measures were used in this
study, with the biological fluid being blood, and the parameters of interest being:
fasting plasma glucose (FPG); total cholesterol (TC); high density lipoprotein (HDL);
low density lipoprotein (LDL); triglycerides (TG); high sensitivity C-reactive protein
(Hs-CRP); hemoglobin (Hb); and glycated hemoglobin (HbA1c). Wet blood chemistry
method using venous blood samples was used for the analysis of all previously
mentioned tests. Hemoglobin and glycated hemoglobin tests were completed using
whole blood, while serum was used for other tests.

3.2.4.1 Blood Collection
Blood collection was performed by a registered phlebotomist nurse. All
equipment needed for blood collection was prepared and organized at the blood
collection station ahead of time, including: gel separator in Sekurplast test tubes with
clot activator (5 ml) (VACUTEST KIMA, Arzergrande, Italy); vacutainer system with
butterfly needle attachment (Greiner Bio-One, Gmbh, Austria); alcohol swabs; cotton
swabs; tourniquet; plastic gloves; sharp container and safe-box containing dry ice to
transport blood samples into the laboratory for analysis, which was adjacent to the
nutrition clinic in our case. Labels with the identification number of each participant
were placed on the test tube by the researcher [233].
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The World Health Organization guidelines published in 2010 for drawing
blood were followed [234].The nurse identified a good size vein in the antecubital
fossa or forearm and used a vacutainer with a butterfly needle to collect blood into the
test tube. Two drops (8µL) of whole blood from the vacuum tube were utilized for the
analysis of hemoglobin and glycated hemoglobin. All used butterfly needles were
disposed in the sharp container and all other contaminated supplies were properly
disposed according to proper biohazards waste disposal. Test tubes were inverted
gently six to seven times and allowed to clot for two hours in ice. Tubes were then
centrifuged at 1500 RPM for 15 minutes. Serum was transferred (1 ml * 2 aliquots)
into 2 ml Eppendorf safe-lock tubes, properly labeled and immediately stored using
labeled Eppendorf containers at - 80°C until the time of analysis. The date of
withdrawal, centrifugation and storage were recorded. At the time of analysis, samples
were thawed on ice for 30 minutes with proper handling during thawing and storage
[235].

3.2.4.2 Analytical System
An in vitro diagnostic test for the quantitative determination of total
cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, high sensitivity CReactive protein and fasting plasma glucose concentrations in human serum was
performed using an automated biochemical analyzer (Cobas® C111, Roche
Diagnostics, Indianapolis, IN, Figure 3.4), which has been evaluated and
recommended for such use [236]. All tests were run in triplicate and averaged.
The researcher (Mohamad. M) attended the training held by the Roche
Company on the proper operation methods of the Cobas® c111 analyzer and was
certified to run the device. The Cobas® C111 reagents, calibrators, and controls were
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used according to the manufacturers’ recommendations. The reagents needed to
perform lipid, glucose and hs-CRP tests were loaded into the reagent disk and
calibrated using appropriate calibrators provided by the company. Calibrator f.a.s®
was used for the calibration of glucose, triglyceride and total cholesterol. Calibrator
f.a.s Lipids® was used for the calibration of LDL and HDL cholesterol, and Calibrator
f.a.s.Proteins® was used for the calibration of high sensitivity C-reactive protein. The
daily operation included routine tasks that are needed to prepare and monitor the
system and to analyze samples. When the system is switched on it performs several
checks to make sure that all preconditions are met, and the screen displays the current
status of the system. The system asks for daily maintenance orders that include:
checking external fluid containers; loading the reagent disk; checking the cuvettes;
performing calibration and performing quality control using PreciControl ClinChem
Multi 1® and PreciControl ClinChem Multi 2®, as required. Once preparation was
done, the samples were identified, required tests were selected and samples were
placed.

Figure 3.4: Cobas® c111 Analyzer
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3.2.4.3 Lipid Assessment
Cobas® C111 uses the homogeneous enzymatic colorimetric principle for
testing a lipid profile. A lipid profile is a group of blood tests used as a screening tool
to identify abnormalities in cholesterol, HDL, LDL and triglyceride blood levels. This
could help in the diagnosis of a certain disease, such as a genetic disorder, a
cardiovascular disease or any other diseases. It is also important for monitoring the
efficiency of certain drugs.
Dyslipidemia is one of the risk factors for many diseases like diabetes,
ischemic heart disease and hypertension [237-239]. The clinical interpretation of lipid
values in this study was according to the Integrated Guidelines for Cardiovascular
Health and Risk Reduction in Children and Adolescents (Table: 3.3) set in 2011 by the
National Heart, Lung, and Blood Institute (NIH)[240].
Table 3.3: Recommended Cut Points for Lipid and Lipoprotein Level in Young
Adults (20-24 years old)
BorderlineBorderlineAcceptable
Low,
High,
, mg/dL
mg/dL
mg/dL

Category

Low,
mg/dL

Total Cholesterol

-

-

<190

190-224

≥225

LDL-Cholesterol

-

-

<120

120-159

≥160

Non-HDL
Cholesterol

-

-

<150

150-189

≥190

Triglycerides

-

-

<115

115-149

≥150

<40

40-44

>45

-

-

HDL Cholesterol

Source: NIH, 2011[240].

High,
mg/dL
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3.2.4.4 Triglycerides
The determination of triglycerides is useful for the diagnosis and treatment of
many diseases like diabetes mellitus and nephrotic syndrome [241, 242].
Determination of triglycerides using Cobas® C111 follows the principle of enzymatic
colorimetric test, as described by Siedel and others in 1993 [243]. The triglyceride
reagent was handled as described by the manufacturer. Excessive foaming was
removed from the surface of the reagent prior to loading into the analyzer. Human
serum was collected and prepared according to Tietz, 1995 [244] as described in
section 3.2.4.1. 2µL of serum and 120µL of the reagent were required for each run of
the test. The measuring range of the test was 8.85-885 mg/dL. The expected value for
the normal range is <115 mg/dL and the cut-off value used for defining metabolic
syndrome was ≥150 mg/dL [4].

3.2.4.5 Total Cholesterol
Cholesterol analyses are used for screening against atherosclerotic risk and in
the diagnosis and treatment of disorders involving elevated cholesterol values, such as
heart diseases [245]. Cobas® C111 follows the enzymatic colorimetric method for the
analysis of cholesterol as described by Allain and others (1974) [246]. The Roche
cholesterol assay meets the National Institute of Health 1992 goals of less than or equal
to 3% for both precision and bias [247]. The Cholesterol reagent was handled as
recommended by the manufacturer. 2µL of serum and 47µL of the reagent were
required for each run of the test. The measuring range of the test was 9.7-800 mg/dL.
The acceptable value for normal range is <190 mg/dL [240].
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3.2.4.6 Low Density Lipoprotein
Low Density Lipoproteins (LDL cholesterol) play an important role in causing
and influencing the progression of atherosclerosis especially coronary sclerosis [248].
Various methods are available for the determination of LDL cholesterol such as:
ultracentrifugation as the reference method; precipitation methods; and lipoprotein
electrophoresis. Cobas® C111 follows the homogeneous enzymatic colorimetric
method for the analysis of LDL cholesterol as described by Bachorik and Ross, 1995
[249]. This direct LDL cholesterol assay meets the National Cholesterol Education
Program 1995 [249] goals of < 4% total Coefficient of Variation, bias < 4% versus
reference method, and 12% total analytical error [250].The LDL cholesterol reagent
was handled as recommended by the manufacturer. Human serum was collected,
stored and prepared as described in section 3.2.4.1. 2µL of serum and 200µL of the
reagent were required for each run of the test. The measuring range of the test was
3.86-548 mg/dL. The acceptable value for normal range is <120 mg/dL [240].

3.2.4.7 High Density Lipoprotein
Monitoring HDL cholesterol in human serum is of clinical importance, as an
inverse correlation exists between HDL cholesterol concentrations and the risk of
atherosclerotic disease. Elevated HDL cholesterol concentrations are protective
against coronary heart disease, whereas lower concentrations of HDL cholesterol
coexisting with elevated triglyceride levels, increase the risk for cardiovascular disease
[251]. A variety of methods are available to determine HDL cholesterol, including:
ultracentrifugation; electrophoresis; precipitation-based methods; high performance
liquid chromatography (HPLC); and direct methods. Cobas® C111 follows the
homogeneous enzymatic colorimetric method for the direct analysis of HDL
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cholesterol as described by Sugiuchi and others in 1995 [252]. This direct HDL
cholesterol assay meets the 1998 National Institutes of Health (NIH)/ National
Cholesterol Education Program (NCEP) goals for acceptable performance [253]. The
HDL cholesterol reagent was handled as recommended by the manufacturer. Human
serum was collected, stored and prepared as described in section 3.2.4.1. 2.5µL of
serum and 200µL of the reagent were required for each run of the test. The measuring
range of the test was 3-120 mg/dL. The normal reference range of the HDLCholesterol for females is >45 mg/dL [240]. The cut-off value used for defining
metabolic syndrome for females is HDL cholesterol of <50 mg/dL [4].

3.2.4.8 Fasting Plasma Glucose
The concentration of glucose in blood is controlled within narrow limits by
many hormones, the most important of which are produced by the pancreas. An
increase in blood glucose concentration is usually caused by a deficiency in the insulin
hormone secretion or action, which is referred to as diabetes mellitus [17]. Measuring
fasting plasma glucose has been recommended by the ADA for the diagnosis of
diabetes and screening of high risk populations [16]. It is also part of the harmonized
joint statement (IDF/AHA/NHLBI) diagnostic criteria of MetS [4]. Cobas® C111
follows the enzymatic reference method with hexokinase UV test for the analysis of
glucose as described by Tietz, 2006 [254]. The glucose reagent was handled as
recommended by the manufacturer. Human serum was collected, stored and prepared
as described in section 3.2.4.1. 2µL of serum and 180 µL of the reagent were required
for each run of the test. The measuring range of the test was 1.98-720 mg/dL. The cutoff value used for defining metabolic syndrome is FPG ≥ 100 mg/dL [4]. The cut-off
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values for fasting plasma glucose are presented in Table 3.4 according to the standards
of medical care in diabetes set by the American Diabetes Association, 2016 [255].
Table 3.4: Blood Test Levels for Diagnosis of Diabetes and Pre-diabetes
FPG mg/dL

OGTT mg/dL

HbA1c %

Normal

≤99

≤139

About 5

Pre-Diabetes

100-125

140-199

5.7–6.4

Diabetes

≥126

≥200

≥6.5

Source: American Diabetes Association, 2016 [255].

3.2.4.9 High sensitivity C-Reactive Protein
High sensitivity C-reactive protein (Hs-CRP) is an acute phase protein in
inflammatory reactions. Measurement of CRP is used for the detection of infection,
inflammatory disorders and associated diseases. Highly sensitive measurement of CRP
may also be used for the assessment of risk for future coronary heart disease [256].
Several studies have suggested the addition of Hs-CRP for metabolic syndrome
diagnostic criteria and for the assessment of global cardiovascular risk [69, 71]. A
variety of methods are available to determine Hs-CRP, including nephelometry and
turbidimetry. The Cobas® C111 Hs-CRP assay is based on the principle of particleenhanced immunological agglutination, were human CRP agglutinates with latex
particles and coated with monoclonal anti-CRP antibodies. The precipitate is then
determined turbidimetrically as described by Price and others in 1987 [257]. The HsCRP reagent was handled as recommended by the manufacturer. Human serum was
collected, stored and prepared as described in section 3.2.4.1. 6µL of serum and 110
µL of the reagent were required for each run of the test. The measuring range of the
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test as recommended by the Centers of Disease Control and Prevention (CDC) and the
American Heart Association (AHA) [63, 258] for cardiovascular disease (CVD) risk
assessment is shown in Table 3.5.
Table 3.5: High Sensitivity CRP Cut-off Points for CVD Risk Assessment
Relative risk for CVD

Hs-CRP Level mg/L

Low

<1.0

Average

1.0–3.0

High

>3.0

Source: Pearson and others, 2003 [63].

3.2.4.10 Hemoglobin and Glycated Hemoglobin
Hemoglobin (Hb) is a protein in the red blood cells responsible for carrying
oxygen from the lungs to all body tissues and returning carbon dioxide from tissues
into the lungs. Measurement of hemoglobin concentration in whole blood is the most
commonly used test for iron deficiency anemia [10]. HemoCue® Hb 201+ portable
photometer system (HemoCue® Ltd, UK, Figure: 3.5) was used for the assessment of
hemoglobin concentration using 4µL of venous whole blood according to the blood
collection method described in section 3.2.4.1. The precision and accuracy of
hemoglobin values obtained using HemoCue® Hb 201+ are comparable to those
obtained using the cyanmethmoglobin method [259]. Standardized procedures for
measuring hemoglobin concentration using HemoCue® Hb 201+ were followed to
enhance the accuracy and reliability of the test, as described by Burger and PierreLouis, 2003 [260]. The interpretive criteria used for defining anemia as recommended
by the World Health Organization [261] is presented in Table 3.6.
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Table 3.6: Hemoglobin Levels for the Diagnosis of Anemia at Sea Level
Population

NonAnemia

Mild
Anemia

Moderate Severe
Anemia
Anemia

Non-pregnant women

≥120 g/L

110-119
g/L

80-109
g/L

(15 years of age and above)

<80 g/L

Source: WHO, 2011 [261].
Glycated Hemoglobin (HbA1c) is a form of hemoglobin that was first
identified as an unusual hemoglobin found in patients with diabetes. It has been
correlated to glucose measurements and was clinically used for monitoring diabetic
patients, as it reflects average blood glucose over the previous eight to twelve weeks
[262]. HbA1c is recommended to be used as a diagnostic test for diabetes mellitus by
the World Health Organization [263].
The HemoCue® HbA1c 501 system (HemoCue® Ltd, UK, Figure: 3.6) has
been used for assessing glycated hemoglobin percentage using 4µL of venous whole
blood. Blood collection method is described in section 3.2.4.1. The HemoCue®
HbA1c 501 system uses a boronate affinity assay to separate the glycated hemoglobin
fraction from the nonglycated fraction. The setup, operating procedures and storage
instructions for the analyzer, reagent cartilage and check cartilage were performed as
described in the operating manual. Quality control of the system was performed on
daily and monthly bases using the appropriate check cartilage (HemoCue® HbA1c
501 Daily Check Cartilage and HemoCue® HbA1c 501 Monthly Check Cartilage).
Good correlation has been found when the HemoCue® HbA1c 501 system was
compared to the KESLAB laboratory method, Variant II (BioRad), using venous blood
patient samples [264]. The Cut-off values of HbA1c for the diagnosis of diabetes and
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pre-diabetes are presented in Table 3.4, which follows the 2015 recommendations of
the American Diabetes Association [16].

Figure 3.5: HemoCue® Hemoglobin 201+ Analyzer

Figure 3.6: HemoCue® HbA1c 501 System
3.2.5 Blood Pressure Measurement
Blood pressure is the pressure that blood applies on the wall of the arteries in
the circulatory system. It is measured per unit area on the walls of arteries (mm Hg).
The cardiac cycle consists of two phases, the contraction phase causing systolic blood
pressure (SBP) and the relaxation phase causing diastolic blood pressure (DBP). Blood
pressure is used for the diagnosis and monitoring of hypertension, which is
characterized by an increase of systolic or diastolic blood pressure. Hypertension is
found to be associate with increased incidence of renal disease and cardiovascular
disease (CVD) [265]. Systolic and Diastolic blood pressures were measured using a
calibrated digital automated blood pressure monitor (Omron HEM-907-E7 Digital
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Blood Pressure Monitor, Omron Healthcare Europe, Mie, Japan, Figure 3.7). Blood
pressure was measured using the participants’ right upper arm, after removing clothing
covering the cuff placement. Appropriate cuff size was determined according to the
MUAC measurements of the participant. They were seated on a comfortable chair,
asked to uncross their legs with the back of the right arm supported on a table to keep
it at the level of the right atrium. They were then instructed to relax and avoid talking
during the measurement procedure. The measurement was taken twice with 5 minutes
break between measures, and the average measurement was recorded [266].
The Omron HEM-907 device has been validated and evaluated in several
studies, having passed the two phases of the International Protocol, and therefore
becoming eligible for use in clinical measurement of blood pressure [267, 268]. The
use of such an automated device for measuring blood pressure requires no expensive
training, reduces observer errors and minimizes the white coat effect [266]. The cutoff values used for the interpretation of blood pressure measures are presented in Table
3.7, as published in the Seventh Report of the Joint National Committee (JNC7) on
prevention, detection, evaluation and treatment of high blood pressure in 2003 [269].
Table 3.7: Classification of Blood Pressure
Category

SBP mm Hg

DBP mm Hg

Normal

<120

and

<80

Prehypertension

120-139

or

80-89

Hypertension, Stage 1

140-159

or

90-99

Hypertension, Stage 2

≥160

or

≥100

Source: Chobanian and others, 2003 [269].
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Figure 3.7: Omron HEM-907-E7 Digital Blood Pressure Monitor
3.2.6 Power Analysis
A school-based study conducted by Mehairi and others in 2013 reported the
prevalence of MetS among adolescents (12-18 years old) according to the IDF criteria
to be 22% and 4% among boys and girls respectively [6]. Minitab software (version
16, Minitab Inc., PA) was used to calculate sample size. With a planned proportion
estimate of 4% at 95% confidence level, a sample size of 555 would achieve a 1.58%
margin of error for the survey of the female student population. With a planned
proportion of 50%, generally used when there is no prior information, at 95%
confidence level the sample size of 555 would achieve a 4.04% margin of error.

3.2.7 Statistical Analysis
Data analyses were carried out using Stata version 13 (Stata Corp, College
Station, TX). Descriptive statistics were computed; continuous variables were
summarized by means and standard deviations (SD) and proportions for categorical
variables. The Student’s t-test was used to compare means for continuous variables
between participants with and without MetS. Univariable and multivariable logistic
regression analysis was used to study the association between anthropometric and
chemical measures and the presence or absence of metabolic syndrome as the outcome
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variable. To account for perfect prediction of MetS by BMI categories and the small
sample size across BMI class, we applied the Firth logistic regression to obtain
reasonable and robust estimates. All statistical significance was assessed at the 5%
significance level.

3.3 Glycemic Index (GI) Value of Commonly Consumed Foods in the UAE

3.3.1 Study Population
A total of 112 healthy participants from UAEU students and staff were
recruited voluntarily to participate in this study. This was done through posters
distributed around the campus buildings, e-mail invitations and word of mouth.
Participants did not take part if they had any of the exclusion criteria, defined as: age
being less than18 or more than 55 years old; body mass index (BMI) value more than
or equal to 25 kg/m2 or less than 18.5 kg/m2; fasting plasma glucose (FPG) value of
more than 6.1 mmol/l, and having a known history of impaired glucose tolerance or
diabetes mellitus. Participants were asked to complete a health-screening
questionnaire before taking part in the study to make sure that they met the inclusion
criteria (Appendix 6). Participants who met the inclusion criteria were given complete
details about the study protocol (Information sheet, Appendix 7) and the chance to ask
questions. They were asked to fast for 12 hours the night before the test, while water
consumption was allowed in moderation. The day before the GI test, they were
requested to limit their intake of caffeine-containing drinks and to minimize their
participation in any intense physical activity, such as: long periods of swimming or
running, gym workout, lifting weights and aerobics.
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3.3.2 Ethical Approval
Ethical approval for the study was obtained from the United Arab Emirates
University Scientific Research Ethics Committee (UAEU, Reference Number
(516/09) (Appendix 8)). All participants provided written informed consent before
taking part. An example of the consent form used in this study is attached in Appendix
9.

3.3.3 Anthropometric Measurements
Anthropometric measurements were carried once for each participant, prior to
recruitment, to confirm the participant fit the inclusion criteria. All measurements were
completed in the fasting state from 7-10 a.m., while wearing minimal clothing (as local
culture permits) and no shoes, after resting for 15 minutes to allow climate adjustments
and relaxation. All devices used for measurements were calibrated on a daily basis.
Results were recorded immediately after measurement on a data sheet (Appendix 7)
and were checked by another skilled researcher. Each measurement was taken three
times and averaged.
Height, weight, body composition, waist circumference, and hip circumference
were measured as described earlier sections 3.2.2.1, 3.2.3.2, 3.2.3.4, and 3.2.3.5. Body
mass index and waist-hip ratio were calculated using equations described in sections
3.2.3.3 and 3.2.3.6, respectively.
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3.3.4 Blood Glucose
Blood samples were obtained using the OneTouch® UltraSoft™ Adjustable
Blood Sampler (Johnson and Johnson, Middle East, Inc) which uses the OneTouch®
UltraSoft™ pen and the OneTouch® FinePoint™ lancets with a thin tip for less painful
penetration. Capillary blood was obtained from the third finger on the left hand.
Several reports suggested the use of capillary blood rather than venous blood sampling
for reliable glycemic index (GI) testing [194, 270]. Before the finger-pricking process,
all the equipment and supplies that were needed were assembled and hand hygiene
was performed. Participants were asked to warm their hand to increase blood flow.
The WHO 2010 guidelines for withdrawing blood were followed [234]. The site of the
finger-pricking was selected, and 70% isopropyl alcohol was applied and allowed to
air dry. Then, the skin was punctured and the first drop of blood was wiped away using
dry tissue. Squeezing the finger was avoided to minimize plasma dilution. A 5 µL
blood sample was collected in the microcuvette by capillary action. All sharps, and
waste materials were disposed of appropriately. Blood glucose was measured using
the HemoCue Glucose 201+ portable system (HemoCue® Ltd, UK, Figure 3.8). This
machine uses the principle of modified glucose dehydrogenase in which the total
amount of glucose is measured at the end point photometrically. It is factory calibrated
and traceable to the ID GC-MS method; therefore, it needs no further calibration. It
has been previously used in a number of investigations [195, 271].

Figure 3.8: HemoCue® Glucose 201+ Analyzer
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3.3.5 Test Foods
Twenty-three different foods commonly consumed in the United Arab
Emirates were tested, including breads (n=6), entrée dishes (n=2), main dishes (n=7)
and sweet dishes (n=8) as shown in Table 3.8. The test foods were purchased from
three popular restaurants in the UAE that specialize in Emirati cuisine and have
standardized recipes (see Table 3.8 for major ingredients). These restaurants were
selected based on a questionnaire conducted on 315 participants, to investigate the
most popular Emirati cuisine restaurants in the area. Three samples from each dish
were obtained at three different occasions for the chemical analyses, and each food
sample was analyzed in triplicate. The average is reported as the mean ± SD for all
chemical tests.
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Table 3.8: Main ingredients used in the preparation of 23 traditional foods commonly
consumed in the UAE
Test Food
Breads
Arabic bread
Regag bread

Description

Major ingredients

Baked bread
Thin crispy crepe

Chebab bread

Emirati pancake

Muhalla bread

Emirati crepe

Khameer bread

Baked bread

Gurus

Fried bread

Entrée Dishes
Fendal
Chami
Main dishes

Boiled sweet potato
Cottage cheese

Sweet potato and water
Buttermilk, salt and white cumin seeds

Harees, beef

Crushed wheat with
meat

Thareed, beef

Bread with meat
stew

Thareed, chicken

Bread with chicken
stew

Biryani, chicken

Rice with chicken

Machbous, fish

Rice with fish

Arseyah

Rice with chicken

Marqoqa

Bread with chicken
stew

Crushed wheat, meat, water, ghee, salt and
cardamom
Wheat flour, meat, potatoes, onions,
tomatoes, zucchini, tomato paste, vegetable
oil, spices and water
Wheat flour, chicken, potatoes, onions,
tomatoes, zucchini, tomato paste, vegetable
oil, spices and water
Rice, salt, Ghee, spices, chicken, garlic and
onion
Rice, tomato, onion, water, salt, spices and
fish
Rice, salt, chicken, water, cardamom and
cinnamon
Wheat flour, chicken, potatoes, onions,
tomatoes, carrots, tomato paste, vegetable oil,
garlic, spices and water

Wheat flour, salt, yeast and water
Wheat flour, salt and water
Wheat flour, egg, yeast, salt, sugar, milk
powder, saffron and water
Wheat flour, egg, sugar, milk powder,
saffron, cardamom and water.
Wheat flour, egg ,yeast, salt, sugar, milk
powder, saffron and water
Wheat flour, vegetable oil, egg, sugar, salt
and water

Dessert Dishes
Khabisa

Cardamom pudding

Leqemat

Doughnut cake

Batheetha

Date paste

Kanfaroosh

Doughnut cake

Sago
Asida

Sago seed with sugar
Flour with sugar

Habba Hamra

Red seed drink

Balalet

Sweet vermicelli

Wheat flour, Water, Ghee, sugar and
cardamom
White flour, vegetable oil, salt, sugar, egg and
yeast
Date fruit, wheat flour, Ghee, sugar,
cardamom and cinnamon
Wheat flour, yeast, sugar, egg, vegetable oil,
saffron, cardamom and backing powder
Sago seeds, sugar, saffron and water
Wheat flour, sugar, salt and water
Evaporated milk, red seed, cardamom,
saffron, black pepper and sugar
Vermicelli, water, sugar, ghee and cardamom
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3.3.5.1 Chemical Analyses
Food composition databases offer comprehensive information on the
concentrations of nutrients in foods, this information is considered the base of any
quantitative study of nutrition. It is also useful in clinical practice, food manufacturing,
designing health promotions,

regulation of nutrition

and

health claims,

epidemiological studies and policy decision making [174]. Awareness about the
importance of establishing food composition tables in the UAE and other Gulf
Cooperation Council (GCC) countries has increased during the last twenty to thirty
years. In Saudi Arabia, twenty Saudi dishes were analyzed for their cholesterol and
fatty acid contents [272], and six dishes were investigated by Al-Jebrin and others in
1985 for chemical composition and nutritional quality [170]. In Qatar, seventeen
traditional Qatari dishes were chemically analyzed in the year 1994 [273]. In a 1998
study, conducted by Musaiger and others, where they studied the physical, proximate
and mineral composition of four types of fermented dairy products in Bahrain [171].
In Oman, the proximate, mineral, fatty acid and cholesterol compositions of twenty
dishes were analyzed [172]. In Kuwait, thirty-two Kuwaiti composite dishes were
analyzed for their proximate composition and phytate content [274]. Recently, ten
traditional dishes commonly consumed in the United Arab Emirates (UAE) were
chemically analyzed for proximate composition and mineral content [175]. Although
nutritional-composition data of traditional dishes in the U.A.E. and other Arab Gulf
countries exist, it does not cover all test foods selected in this study. Also, available
carbohydrate content should be known to perform glycemic index testing for any food.
It was not calculated in other studies, and one could not even calculate it by subtracting
fiber content from total carbohydrates content, because fiber content was not even
reported [275].
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Proximate composition, mineral content, vitamin content, lipids and sugars
analyses for test foods were carried out in the Nutrition and Health Department
laboratory at UAEU. The standard procedures of the Association of Official Analytical
Chemists (AOAC) 2003 were followed [276]. Mineral content was determined by
Inductively Coupled Plasma Optical Emission Spectroscopy ICP-OES [277]. Sugar,
vitamin, caffeine, and cholesterol analysis were conducted using the HPLC technique.
Total carbohydrate and available carbohydrate content were estimated by difference
[274]. The energy content was calculated by multiplying the protein, carbohydrate,
and fat by factors of 4, 4, and 9 respectively [273]. Each test was done in triplicate and
averaged to minimize possible errors, and to increase reliability and accuracy.

3.3.5.2 Sample Preparation
Each test food was purchased and analyzed on three different occasions
(beginning, middle and end of the month) to ensure consistency of restaurants in
preparing and standardizing the recipe. Upon purchase, each food was transported into
the laboratory in a cool‐box. Extraneous matter such as bones from chicken and meat,
was removed. The main components of each meal were then individually weighed.
Test foods were thoroughly homogenized using a mechanical high-speed blender and
then sampled for moisture analysis. The residual homogenized samples were dried in
the oven at 65°C for 16 hours, ground into fine powder and stored in air-tight
containers at -80°C for further analysis.
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3.3.5.3 Proximate Analysis
a) Determination of Moisture
Moisture analysis follows the simple principle of evaporation of water from the
sample through oven drying. Dry matter is then determined as the residual after drying
[278]. Aluminum dishes were dried at 105°C for two hours and then allowed to cool
down to room temperature in the desiccator. Dishes were then weighed using Scaltec®
SBA 31 analytical electronic balance sensitive to 0.01 mg (Scaltec® Instruments,
Heiligenstadt, Germany, Figure 3.9). Approximately 1 gram of sample food was
weighed and spread uniformly across the aluminum dish. Mommert® forced-air
drying oven (Schutzart DIN 400-50-IP20, Figure: 2.10) was used to dry the samples
for 16 hours at 105°C ± 3°C. Samples were placed uniformly in the oven to allow air
circulation, then moved to the desiccator to cool down to room temperature and
weighed to the nearest 0.01 mg. The percentage of total dry matter and total moisture
were calculated using the following equations [276]:

% 𝑇𝑜𝑡𝑎𝑙 𝐷𝑟𝑦 𝑚𝑎𝑡𝑡𝑒𝑟 =

(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑦 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑛𝑑 𝑑𝑖𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠 − 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑖𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)
× 100
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠

% 𝑇𝑜𝑡𝑎𝑙 𝑀𝑜𝑖𝑠𝑡𝑢𝑟𝑒 = 100 − % 𝑇𝑜𝑡𝑎𝑙 𝐷𝑀

Figure 3.9: Scaltec® SBA 31Analytical Electronic Balance
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Figure 3.10: Mommert® Forced-Air Drying Oven
b) Determination of Ash Content
Crucibles were dried in the drying oven for at least two hours at 105 °C, and moved
into a desiccator using tongs. They were allowed to cool down to room temperature,
weighed, and recorded to the nearest 0.01 mg. Approximately one gram of the sample
was weighed and ashed in a muffle furnace oven (Carbolite EML 11/6, Figure 3.11)
at 500 °C for four hours. Crucibles were then allowed to cool in the furnace to less
than 200°C, and then weighed with the ash to the nearest 0.01 mg. The percentage of
ash was calculated using the following equation [279]:

% 𝐴𝑠ℎ =

(𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑢𝑐𝑖𝑏𝑙𝑒 𝑎𝑛𝑑 𝑎𝑠ℎ 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠 − 𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑢𝑐𝑖𝑏𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)
× 100
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠

Figure 3.11: Muffle Furnace Oven and Crucibles
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c) Determination of Protein Content
The Kjeldahl method was used for nitrogen determination in food samples and a
factor of 6.25 was adopted for protein-content estimation [280].The first step in the
Kjeldahl method is the digestion of samples. Around 0.5 gram of sample was weighed
into the digestion tube and was digested by sulfuric acid (96%) and a catalyst (Kjeldahl
catalyst selenium tablets) using Foss Tecator 2020 digester (Foss Tecator, Höganäs,
Sweden, Figure 3.12) at 410°C for about 45 minutes. This process resulted in the
conversion of nitrogen to ammonia. A Foss 2300 Kjeltec Analyzer Unit (Foss
Technologies Co., Ltd., Höganaös, Sweden, Figures 3.13) was then used to determine
ammonia and protein content [276].

Figure 3.12: Foss 2300 Kjeltec Analyzer Unit

Figure 3.13: Foss Tecator 2020 Digester
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d) Determination of Fat Content
The fat content was determined by Soxhlet extraction according to the AOAC and
Horwitz, 2003 [276]. The extraction cups were dried at 105°C, for 2 hours then
weighed to the nearest 0.1 mg. 2 grams of sample were placed in a 33 mm × 80 mm
extraction thimble (supplied by the manufacture), and extracted with 50 ml nhexane/acetone (1:1, v/v) in boiling solvent for 60 minutes using the Soxhlet extraction
in a Sotex system 2050 (Foss, Hillerød, Denmark, Figure: 2.14). Thimbles were then
raised to the rinse position for another 60 minutes to allow evaporation of as much
solvent as possible. The extraction cups were removed from the extractor and placed
in an operating fume hood to finish evaporating the solvent at low temperature, then
dried at 105°C for 30 minutes, allowed to cool down in the desiccator and weighed to
the nearest 0.1 mg [281]. The percentage of fat content was then calculated using the
following equation [276]:

% 𝐶𝑟𝑢𝑑𝑒 𝐹𝑎𝑡 =

(𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑢𝑝 + 𝑓𝑎𝑡 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠) − (𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑒𝑚𝑝𝑡𝑦 𝑐𝑢𝑝 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠)
× 100
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑔𝑟𝑎𝑚𝑠

Figure 3.14: Sotex System 2050
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e) Determination of Fiber Content
The Neutral Detergent Fiber (NDF) method was used to determine fiber content in
food samples, which measures fiber residue (hemicellulose, cellulose, and lignin)
remaining after digestion in a detergent solution [282]. NDF analyses was performed
using ANKOM 200 fiber analyzer (ANKOM200, 65 rpm agitation; ANKOM
Technology, Macedon, New York, USA, Figure: 3.15). The ANKOM Technology
NDF method was followed [283]. The ANKOM filter bags (F57 and F58, ANKOM
Technology) were weighed. Subsequently 0.50 grams of sample was placed in each
bag, weighed, sealed using heat sealer (1915, ANKOM Technology) and marked using
a solvent and acid-resistant marking pen (F08, ANKOM Technology). A bag was left
empty and used as a blank. Afterwards, the bags were soaked in acetone for 10
minutes, and placed on a wire screen to dry. Samples inside the bags were spread
uniformly within them by shaking and flicking the bags to eliminate clumping. The
bags were then placed in the ANKOM 200 fiber analyzer (Figure 3.15) with Neutral
Detergent Solution, alpha-amylase, and sodium sulfate. When the NDF extraction was
over, the bags were rinsed, soaked in acetone again, and allowed to dry. Then they
were placed in an oven at 105°C for 3 hours, allowed to cool in the desiccator, and
then weighed. The percentage of Neutral Detergent Fiber content was then calculated
according to the following formula [283]:

% 𝑁𝐷𝐹 =

(Dried weight of bag with fiber process − (Bag tare weight × Blank bag correction ))
× 100
Sample Weight
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Figure 3.15: ANKOM 200 Fiber Analyzer
The Total Dietary Fiber (TDF) was also analyzed in this study. According to
the FAO/WHO in 1998[188], it is defined as the edible part of plant and animal
material that is not hydrolyzed by the digestive enzymes in humans. It was determined
using the AOAC 991.43 method[276]. TDF analyses was performed using the
ANKOMTDF dietary fiber analyzer (ANKOM Technology, Macedon, New York USA,
Figure 3.16). The ANKOM filter bags (DF-S, DF-FT, ANKOM Technology) were
labeled, and weighed using the bag weighing holder (TDF52, ANKOM Technology).
The chemicals and the enzymes containers were filled before each use of the analyzer
as recommended by the manufacturer. After completing the automated processes, the
SDF bags were rinsed with acetone twice. Once the acetone has evaporated, the bags
were sealed with a heat sealer (1915, ANKOM Technology). They were then placed
in the oven to dry for 90 minutes at 105°C. Afterwards, their weight was recorded.
One bag of each sample was then sent for the determination of the protein content and
the other one is used for the determination of the ash content. The Percentage of Total
Dietary Fiber Value was then calculated using the dietary fiber data spreadsheets
available on the ANKOM Technology website [284].
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Figure 3.16: ANKOMTDF Dietary Fiber Analyzer

3.3.5.4 Exchange List Development
Exchange list was first used as a method of meal planning for patients with
diabetes and for those on weight loss regimens [285]. The food exchange list helps
people to monitor food portion sizes, and energy intake. Basically it translates
scientific nutrition knowledge into a practical tool. Foods from the same list can be
used interchangeably without changing estimated amounts of carbohydrates, fat,
protein, and total energy obtainable in a meal [286].
The rounding-off method described by wheeler and colleagues [285] was used
to fit food items into exchanges as follows:
For carbohydrate exchange: if a food portion had 1g to 5g of carbohydrates, it
was not counted as a serving. If it had 6g to 10g of carbohydrates, it was counted as a
half serving. When food had 11g to 20g of carbohydrates, it was counted as one
serving.
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For fat exchange: if a food portion had 0g to 2g of fat, it was not counted as a
serving. Yet, if it had 3 g of fat, it was counted as a half serving. Food portion was
counted as one serving if it had 4g to 7g of fat.
For protein exchange: if a food portion had 0g to 3g of protein from the meat
and meat substitutes list, it was not counted as a serving. However, if it had 4g to 10g
of protein, it was counted as one serving.

3.3.5.5 Determination of Minerals
Major minerals and trace metals (Ca, K, Na, Mg, P, S, Co, Cu, Fe, Mn and Zn)
were simultaneously determined in foods by Inductively Coupled Plasma Optical
Emission Spectrometer (ICP-OES) on a Varian ICP-OES model 710-ES (Varian, Palo
Alto, CA, USA). Simultaneous axially viewed plasma with full computer control of
instrument settings and compatible accessories was used for the analysis as outlined in
the manufacturers’ manual. Food samples were prepared for mineral determination by
CEM Mars 5 microwave digestion system (Mars 5, CEM Corporation, Matthews,
USA, Figure 3.17). The process of preparing the samples was preformed based upon
the recommendation in US EPA method 3015A guidelines [287] as described by
Heckman in 1971 [288].
Homogenized food samples were weighed into portions of 0.5 grams and
placed into the microwave digestion vessels; then 10 ml of concentrated nitric acid and
2 ml hydrochloric acid were added into the sample. The vessels were capped and
placed in the microwave digestion system [289]. After cooling, de-ionized water was
added, and the sample solution was aspirated through a nebulizer. The resulting aerosol
was transported to the plasma torch where excitation happened. Element-specific
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emission spectra were created by radio-frequency inductively coupled plasma, which
was dispersed by a grading spectrometer; concentrations of the line spectra were
observed at specific wavelengths by a charged coupled detector. A fitted background
correction was used to offset the blank signal and the matrix effect.

Figure 3.17: Varian ICP-Optical Emission Spectrometer model 710-ES
3.3.5.6 Determination of Sugars
Various types of sugars including monosaccharides (glucose, and fructose),
disaccharides (sucrose, maltose, and lactose) and trisaccharide (raffinose) were
determined in foods by the High-Performance Liquid Chromatography (HPLC)
method.
Determination of sugars was performed using a Waters HPLC system (Waters,
Milford, MA, USA, Figure 3.18). The system is composed of a Waters 717 Plus
Autosampler, a Waters 1525 Binary HPLC pump, and a Waters 2414 Refractive Index
Detector, operated with the Breeze software. Sugars were simultaneously analyzed
onto a µBondapak® NH2 10µm 125Å column, 3.9 mm inner diameter by 300 mm
(Waters Associates, Milford, MA, USA). The temperature was kept at 35 °C. The
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mobile phase consisted of acetonitrile and water (83:17, v/v), and the flow rate was
1.5 mL/minute. Sample preparation and analysis procedures were adopted with
modification from Yuan and others (1999) [290] and from Smith and others (1986)
[291].

Figure 3.18: Waters High-Performance Liquid Chromatography (HPLC) System

3.3.5.7 Determination of Lipids
The fatty acid composition of foods has recently become mandatory to be listed
on food labels, which helps the consumer make healthier choices. However, the fatty
acid composition is a complex combination of saturated, monounsaturated, and
polyunsaturated fatty acids with a diversity of carbon chain lengths.
The identification of key fatty acids requires several standards and capillary
columns. The fatty acid composition analysis was performed using a Young Lin 6500
gas chromatograph (YL-6500 GC, Gyeonggi-do, South Korea, Figure 3.19), fitted
with a SP-2380 Fused Silica Capillary Column (30 m × 0.25 mm I.D × 0.20 µm ﬁlm
(2-4110), Sigma Aldrich, St. Louis, MO).
The analytical column was heated at 50°C for 2 minutes, afterwards it was
raised to 250°C at 4°C/min, and then held for 15 min. The carrier gas used for the
analysis was helium, (20 cm/second) at 150°C. The Supelco 37 Component FAME
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Mix standard was used for the identification of key fatty acids in the tested food
samples. The Fatty Acid Methyl Esters (FAMEs) were prepared following AOAC
Method 969.33 [276]. The analysis procedure followed was as described in the
application notes of the manufacture (Sigma Aldrich) [292].
The determination of the cholesterol content in food is also very important.
However, the possible relationship between dietary cholesterol and atherosclerosis is
still debatable and lacks homogenous scientific evidence [293]. The determination of
cholesterol was performed using a Waters HPLC system (Waters, Milford, MA, USA,
Figure 3.18). The system is composed of a Waters 717 Plus Autosampler, a Waters
1525 Binary HPLC pump, and a Waters 2487 Dual λ Absorbance Detector, operated
with the Breeze software. Cholesterol was simultaneously analyzed onto a reversed
phase XTerra C18 column, 4.6 mm inner diameter by 150 mm, 5 µm (Waters
Associates, Milford, MA, USA). The oven temperature was kept at 25 °C. The mobile
phase consisted of methanol and 2-propanol (70:30, v/v), and the flow rate was 1.0
mL/minute. Cholesterol components were detected by the UV detector that was set at
the wavelength of 212 nm. Sample preparation and analysis procedures were adopted
from Indyk (1990) and Essaka (2007) with modification [294, 295].

Figure 3.19: Young Lin 6500 Gas Chromatography System
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3.3.5.8 Determination of Vitamins
Vitamins are a wide-ranging group of organic compounds that are essential for
the functioning of human bodies. They are classified in two main groups: watersoluble and fat-soluble vitamins. The determination of vitamins in the food we
consume is important when it comes to adopting good eating habits in humans,
understanding possible loss in vitamins through food storage and preparation, and
developing food labels.
Seven water-soluble and all fat-soluble vitamins (Vitamin C, Thiamin,
Riboflavin, Niacin, Vitamin B-6, Folate, Vitamin B-12, Vitamin A, Vitamin E (alphatocopherol), Vitamin D (D2+D3), and Vitamin K (phylloquinone)) were
simultaneously determined in foods by the High-Performance Liquid Chromatography
(HPLC) method.
The determination of water-soluble vitamins was performed using a Waters
HPLC system (Waters, Milford, MA, USA, Figure 3.18) [296]. The system is
composed of a Waters 717 Plus Autosampler, a Waters 1525 Binary HPLC pump and
a Waters 2487 Dual λ Absorbance Detector, operated with the Breeze software. Watersoluble vitamins were simultaneously analyzed onto a reversed-phase XTeera C18
column (4.6 mm inner diameter by 150 mm, 5 μm) from Waters (Waters Associates,
Milford, MA, USA). For water-soluble vitamins, the mobile phase consisted of 50 mM
K2HPO4 (pH7): methanol, gradient: 1% methanol for 5 minutes, 1-30 % methanol
(liner gradient) over 15 minutes, 30 % methanol for 5 minutes and the flow rate was
1.0 mL/minute. The column temperature was kept at 35 °C. The injection volume was
10 μl. The analytical column effluents were monitored at λ=220 nm for all the water-
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soluble vitamins. Supelco Application Note 148, was used as a reference for sample
preparation and analysis procedures [297].
The determination of fat-soluble vitamins was performed using Waters
ACQUITY UPLC system (Waters, Milford, MA, USA, Figure 3.20). The system is
composed of a Waters ACQUITY sample manager, a Waters ACQUITY Binary
solvent manager, and a Waters ACQUITY PDA eλ Detector, operated on an Empower
software. Fat-soluble vitamins were simultaneously analyzed onto a reversed-phase
ACQUITY BEH C18 column (2.1 mm inner diameter by 100 mm, 1.7 μm) from
Waters (Waters Associates, Milford, MA, USA). For fat-soluble vitamins, the mobile
phase consisted of Solvent A: Water: Acetonitrile (90:10), and solvent B: methanol
and Acetonitrile (50:50, v/v), and the flow rate was 0.7 mL/minute. The temperate was
kept at 35 °C. The injection volume was 5μl. The analytical column effluents were
monitored at λ=285nm for vitamin E, at λ=265nm for vitamin K1, K2, D2, D3 and at
λ= 325 for vitamin A acetate. Sample preparation and analysis procedures were
adopted from Moreno and Salvado (2000) with modification [298].

Figure 3.20: Waters ACQUITY UPLC System
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3.3.5.9 Determination of Caffeine
Caffeine content should be listed on the food label according to food labelling
legislations. Although none of the foods investigated in this study have caffeinecontaining ingredients; caffeine analysis was still required to examine the possible
addition of caffeine during preparation.
The determination of caffeine was performed using a Waters HPLC system
(Waters, Milford, MA, USA, Figure 3.18). The system is composed of a Waters 717
Plus Auto-sampler, a Waters 1525 Binary HPLC pump, and a Waters 2487 Dual λ
Absorbance Detector, operated with the Breeze software. Caffeine was
simultaneously analyzed onto a reversed-phase XTeera C18 column (4.6 mm inner
diameter by 150 mm, 5 μm) from Waters (Waters Associates, Milford, MA, USA).
The mobile phase consisted of acetonitrile and water (10:90, v/v), and the flow rate
was 1.0 mL/minute. Caffeine was detected by the UV detector that was set at the
wavelength of 265 nm. Samples preparation procedures were adopted with
modification from Srdjenovic and others (2008) [299]. Whereas the analysis
procedures were adopted from Erickson (2011) with modification [300].

3.3.6 Glycemic Index (GI) Procedure
The GI measurement procedure followed was adapted from Wolever et al.
(1991) [193] and Brouns et al. (2005) [194]. This same protocol is also recommended
by the FAO/WHO (1998) [188]. Testing was repeated in at least fifteen participants
for each test food. Prior to the test day, participants were requested to limit their intake
of caffeinated drinks and avoid involvement in intense exercise, such as: long periods
of swimming or running, gym workouts, lifting weights and aerobics. Participants
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were asked to fast for 12 hours (overnight) the night before each test, though drinking
water was allowed in moderation.
Using the randomised crossover design, participants tested the reference food
three times and each test food for one time only. Food testing was carried out on
separate occasions with at least one-day gap between measurements to minimize any
carry-over effects. The reference food provided was glucose powder (glucose dextrose
monohydrate) dissolved in 200ml of water. Test foods were tested in equivalent
available carbohydrate amounts (25 or 50 g) as per the reference food and were also
served with 200 ml water. Test foods were purchased one day before the test, then
heated in the morning of the test. Participants were encouraged to consume the
reference or test foods within 15 minutes and to minimise physical activity during the
testing time. Available carbohydrate content was used to determine the experimental
portion (g) that would provide 50g or 25g of available carbohydrates from each test
food. The amount of available carbohydrate was calculated by subtracting dietary fiber
content from total carbohydrate content [227].The majority of test foods were tested
against 50 grams of available carbohydrate. Nevertheless, if the serving size was found
too large to ingest comfortably, this test food was tested against 25 grams of available
carbohydrate [194]. In this study, only Chami (Cottage cheese) was tested against 25
grams of available carbohydrate due to its very low carbohydrates content
(5.44g/100g). The experimental portion size of each test food, shown in Table 3.9,
could vary according to the quantity of carbohydrate available in that food.
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Table 3.9: Experimental portion size of test foods
Food
Arabic bread
Regag bread
Chebab bread
Muhalla bread
Khameer bread
Gurus
Fendal
Chami
Harees (beef)
Thareed (beef)
Thareed (chicken)
Biryani (chicken)
Machbous (fish)
Arseyah
Marqoqa
Khabisah
Leqemat
Batheetha
Kanfaroosh
Saqo
Assidah
Habba Hamra
Balalet

Available
Carbohydrate in
test Food (g/100g) *
63.47 ± 0.32
44.37 ± 0.49
45.88 ± 1.17
67.66 ± 4.79
54.93 ± 3.47
54.45 ± 2.60
31.64 ± 0.24
5.31 ± 0.58
7.74 ± 1.15
10.87 ± 0.24
12.73 ± 2.65
19.69 ± 2.05
18.00 ± 0.82
9.85 ± 0.37
16.00 ± 0.52
56.13 ± 4.65
44.19 ± 1.35
38.24 ± 0.97
39.62 ± 0.92
23.43 ± 3.54
21.09 ± 1.14
15.96 ± 1.20
27.89 ± 2.19

Reference Available
Carbohydrates (g)

Experimental
portion (g)

50
50
50
50
50
50
50
25
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50

79
113
109
74
91
92
158
471
323
460
393
254
278
508
313
89
113
131
126
213
237
313
179

*Data are expressed as Mean ± SD
As recommended by the FAO/WHO in 1998 [270], each participant was tested
for the reference food twice and once for each test food. Tests were done in random
order and on separate days, with a minimum of a one-day gap between measurements,
to lessen the carry-over effect. On the day of the test, participants were asked to report
to the clinic in the morning, having fasted for 12 hours. They were served a test food
or the reference food and were asked to consume it within 15 minutes. All the test and
standard foods were served with 200 mL water.
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Capillary blood samples were obtained by finger-prick as described earlier in
section 3.3.4. Blood glucose was measured using the HemoCue Glucose 201+ portable
system (HemoCue® Ltd, UK, Figure 3.8). A fasting blood sample was obtained at 0
minutes and the reference or a test food was consumed directly afterwards. Additional
blood samples were obtained at 15, 30, 45, 60, 90 and 120 minutes after the participant
had begun to eat. During the time of the measurements, participants were asked to stay
in the testing room and reduce physical activity to the minimum [270].

3.3.6.1 Glycemic Index Calculation
Blood glucose response is usually expressed as the area under the curve (AUC).
The total AUC includes the area underneath the curve down to a blood glucose
measure of zero, and it is a measure of the average blood glucose concentration during
the testing period; However, the incremental AUC is a measure of the change of blood
glucose from the fasting plasma glucose measurement; therefore, the GI calculation is
based on the incremental area under the blood glucose response curve (IAUC), and
above the fasting level only. Thus if blood glucose level falls below the baseline, the
area beneath it was ignored. Accordingly, the IAUC cannot be less than zero [270].The
IAUC for each test food consumed by each subject was expressed as a percentage of
the mean IAUC for the reference food consumed by the same subject, as follows:

𝐺𝐼 =

𝐼𝐴𝑈𝐶 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 (𝑋)𝑔 𝑜𝑓 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝐶𝐻𝑂
× 100
𝐼𝐴𝑈𝐶 𝑜𝑓 𝑎 𝑟𝑒𝑓𝑒𝑟𝑛𝑐𝑒 𝑓𝑜𝑜𝑑 𝑤𝑖𝑡ℎ 𝑎𝑛 𝑒𝑞𝑢𝑎𝑙 𝐶𝐻𝑂 𝑝𝑜𝑟𝑡𝑖𝑜𝑛

The GI of each test food was calculated as the mean for the whole group.
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3.3.6.2 Glycemic Load Calculation
The glycemic load is a measure of the overall glycemic impact of the meal.
Studies have shown that diets with a high glycemic load increase risk of type 2 diabetes
mellitus [19, 21]. Epidemiologic studies also suggest that a high dietary GL increases
the risk of coronary heart diseases (CHD) in manner independent of known CHD risk
factors [108]. Glycemic load was calculated by the following formula [301]:

𝐺𝐿 =

𝐺𝐼 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑 × 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝐶𝐻𝑂 𝑖𝑛 𝑎 𝑠𝑒𝑟𝑣𝑖𝑛𝑔 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑓𝑜𝑜𝑑(𝑔)
100

Serving size of test foods was not available from manufacturer, therefore it
was adopted [195] from the Photographic Atlas of Food Portions for the Emirate of
Abu Dhabi [302]. The amount that provides the best fit in the exchange system was
then chosen to be a serving [286].

3.3.7 Power Analysis
The number of participants enrolled in the study will determine the width of
the confidence interval (CI) and the power of the study to detect differences in
glycemic index. It has been suggested that inclusion of 10 participants provides a
reasonable degree of power and precision for most purposes of measuring GI [194]. In
order to increase the power of the study to detect small differences in GI as well as to
increase precision, a minimum of 15 participants were enrolled for each test food.
A recent study by Al Dhaheri and colleagues [303] reported a GI difference of
1.4 for glucose response over time, and 1.6 for glucose response between the foods
tested. A difference of 1.4 was also reported by Wolever in 2003 [301]. A power
analysis was performed using Minitab software for windows version 16 (Minitab Inc.,
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PA). The power of the study was calculated to estimate the number of participants
needed to detect 1.4 unit differences in GI with an alpha of 0.05 using a paired t-test.
A sample size of 15 participants for each test food was considered sufficient to detect
difference in GI with 88% power.

3.3.8 Statistical Analysis
Data entry and analysis were carried out using Statistical Package for Social
Sciences (SPSS) for windows, version 21.0 (SPSS Inc., Chicago, Ill., USA). Data was
analyzed using Kruskal-Wallis to compare medians of measurements of nutrients for
the various foods, because these measurements did not satisfy the normality
assumption of ANOVA. The Paired t-test was used for the comparison of the mean
glucose responses of the reference food with each one of the test foods. The KruskalWallis test was used to find the significant differences between the IAUC of the 23
meals and Mann-Whitney test was used to follow these differences. Statistical
significance was set at P-value of < 0.05. Values of different parameters were
expressed as the mean ± standard deviation.
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Chapter 4: Prevalence of Metabolic Syndrome among Young Female
Emirati Adults at United Arab Emirates University
4.1 Introduction
Non-communicable diseases (NCDs) are the leading cause of deaths
worldwide, and diabetes mellitus (DM) is the fourth major cause of NCD deaths [1].
DM is a complex, chronic illness that occurs either when pancreatic cells do not
produce enough insulin or when the body is resistance to the insulin it produces [255].
The International Diabetes Federation (IDF) estimated the global prevalence for DM
to be 8.3% in 2014. However; 46% of people with diabetes remained undiagnosed.
Moreover, the IDF expects 205 million new cases of DM by the year 2035 [304]. With
a DM prevalence of 19%, the United Arab Emirates (UAE) was ranked as having the
fifth highest prevalence in the Middle East and North Africa (MENA) region, coming
after other Gulf Cooperation Council (GCC) countries, like Saudi Arabia, Kuwait,
Bahrain and Qatar [304]. In 2010, a survey conducted in the UAE reported the
prevalence of undiagnosed DM and pre-diabetes (prediabetes refers to individuals with
impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) [255]) to be
14.6% and 31% respectively [3].This indicates the great number of people living with
undiagnosed DM and pre-diabetes in the country.
The diagnosis of Metabolic Syndrome (MetS) is based on the existence of prediabetes combined with dyslipidemia (elevated levels of total or low-density
lipoprotein (LDL) cholesterol, or low high-density lipoprotein (HDL) cholesterol
levels), elevated blood pressure, and obesity [33]. A study conducted on Emirati adults
(+20 years old) by Malik and others in 2008, reported the prevalence of MetS to be
32.9% among men, 45.9% among women, and the overall prevalence of MetS was
40.5%, based on the IDF definition of MetS [5]. This alarming prevalence is thought
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to be emerging from the high incidence of MetS among younger age groups
(adolescents 12-18 years old) as suggested by Mehairi and others in 2013 [6]. The
latter study reported that 13% of adolescents suffered from MetS, and this prevalence
showed a positive correlation with higher body mass index (BMI) values, as it reached
59% in obese boys. This dramatic increase in the incidence of MetS including prediabetes, emphasizes the need to apply the current screening recommendations by the
American Diabetes Association (ADA) for type 2 diabetes; hence, this endorses the
case for testing overweight children and adolescents to detect pre-diabetes [16].
The UAE is located in the Arabian Gulf region, and has a population with a
median age of 30 years. Only 1% of the population is aged over 60 years, and about
15% of the population is aged under 15 years of old [305]. The country has undergone
numerous social and economic changes since oil was discovered forty years ago. The
lifestyle of the Emirati population has changed considerably over the past 40 years due
to the rapid improvement in socioeconomic status. This transition has led to less
physical activity and altered eating habits. These changes, in addition to the adoption
of a western lifestyle and diet, have led to the rise in the prevalence of overweight and
obesity in the UAE, particularly among females [167].
The United Arab Emirates University (UAEU) was founded in 1976, and it is
the first and oldest comprehensive national university in the UAE. It is located in Al
Ain city in the Abu Dhabi Emirate (capital of the UAE). The University admits UAE
nationals from all seven Emirates and is currently enrolling around 14,000 students.
The prevalence of MetS among Emirati females has been reported to be higher
than that for Emirati males in the adult population (32.9% among men, 45.9% among
women); however, in adolescents the prevalence among females was found to be much
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lower than it is for males (21% among boys, and 4% among girls) [5, 6]. Several
studies from the UAE have reported the sedentary lifestyle of adolescent females [135,
306]. This highlights the importance of investigating MetS among young female
adults, in order to facilitate the understanding of its prevalence and risk factors.
High prevalence of MetS is a significant contributor to the increased
cardiovascular morbidity and mortality associated with DM [74]. Primary prevention
of the syndrome should address its risk factors including obesity, prediabetes, and
prehypertension [121]. Aiming efforts toward reducing obesity and physical inactivity,
across young populations is a start, especially among those at high risk. Therefore,
identification of high risk population coupled with risk reduction strategies, could
reduce the prevalence of MetS and may prevent its development.
There is a paucity of data available about the prevalence of MetS and its
relation with overweight and obesity among young female adults in the UAE.
Furthermore, this research aimed to determine the prevalence of MetS in Emirati
females aged 17–25 years as this age range has not been studied previously, and its
relation to overweight and obesity in the UAE. Therefore, the purpose of this study
was to answer two main questions:



What is the prevalence of MetS in Emirati females aged 17–25 years?
What are the risk factors of MetS in Emirati females aged 17–25 years?
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4.2 Results
4.2.1 Characteristics of Study Population
The demographic and clinical characteristics of the study population by
metabolic syndrome status are presented as mean ± standard deviation, in Table 4.1.
The mean age of the study population was 20.4 ± 1.7 years, ranging from 17 to 25
years. The average age of participants with MetS was not significantly different from
those without MetS (20.9 vs. 20.4 years, P = 0.057). However, participants with MetS
had a significantly higher weight; height; hip circumference; neck circumference; body
mass index; body fat percentage; and high-sensitivity C-reactive protein (P< 0.001).
MetS was also associated with higher glycated hemoglobin (6.3±1.1 vs. 5.5±0.8 %;
P<0.001), and LDL-C levels (102.5±30.9 vs. 91.0±24.7, P=0.006).

Table 4.1: Demographic and Clinical characteristics of the study population by metabolic syndrome status
With Metabolic Syndrome (N=38)

Without Metabolic Syndrome (N= 517)

Mean ± SD

Mean ± SD

Age (Year)

20.9 ± 1.7

20.4 ± 1.7

0.057

Weight (kg)

82.1 ± 17.1

58.9 ± 12.2

< 0.001

Height (cm)

161.3 ± 5.2

158.9 ± 5.8

0.013

Hip Circumference (cm)

115.42 ± 12.35

98.67 ± 9.71

<0.001

Neck Circumference (cm)

33.51 ± 5.47

30.88 ± 3.62

<0.001

Body Mass Index (kg/m2)

31.5 ± 6.3

23.2 ± 4.6

<0.001

Body Fat (%)

40.3 ± 3.9

32.9 ± 5.3

<0.001

Serum Low Density Lipoprotein
(mg/dL)

102.5 ± 30.9

91.0 ± 24.7

0.006

Serum Total Cholesterol (mg/dL)

165.7 ± 37.9

155.6 ± 31.9

0.063

6.3 ± 1.1

5.5 ± 0.8

<0.001

Hemoglobin (g/dL)

12.00 ± 1.6

11.8 ± 1.5

0.482

High sensitivity C-reactive protein
(mg/L)

5.25 ± 2.21

1.06 ± 1.56

<0.001

Glycated Hemoglobin (%)

Student’s t-test P-value *

*P < 0.05.
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4.2.2 Prevalence of Metabolic Syndrome
The overall prevalence of the MetS using the IDF harmonized joint scientific
statement criteria was 6.8 % (95% CI: 5% to 9%) (N = 38). Moreover, no MetS
defining components were found in 242 (43.6%) participants. At least one MetS
component was found in 213 participants (38.4%); two MetS components were present
in 62 participants (11.2%); three MetS components were found in 27 participants
(4.9%); four components of MetS were present in 10 participants (1.8%); and all five
MetS components were found in only one participant (0.2%). (See Figure 4.1)

Percentage of Total Sample (%)

60
50

56.4

43.6

40
30
18

20

6.8

10

2

0.2

0
0

5
≥1
≥2
≥3
≥4
Number of Metabolic Syndrome Defining Components

Figure 4.1: Number of Metabolic Syndrome (MetS) defining components present
among UAEU young female adults 17-25 years (N = 555), Al Ain, UAE
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The prevalence of MetS components among the study population are presented
in Figure 4.2. The most frequent component of MetS among UAEU young female
adults was reduced HDL-C levels (48.8%); followed by central obesity (18.2%);
impaired fasting glucose (9.7%); hypertension (5.45); and hypertriglyceridemia
(1.4%).

Percent of Total Sample%

60

48.8

50
40
30
20

18.2
9.7

10

1.4

5.4

0
High Waist
Circumference

Imparied
Fasting
Glucose

Low High
Density
Lipoprotein

High
Triglyceride

Hypertention

Metabolic Syndrome Components
Figure 4.2: Prevalence of metabolic syndrome components among UAEU young
female adults 17-25 years (N = 555), Al Ain, UAE

A Chi-square test of association between MetS and BMI categories among
young female adults showed a statistically significant association (P < 0.001), and was
particularly high among participants living with obesity (34.5%) compared to 10.1%
overweight, and 1.7% normal-weight, as shown in Figure 4.3. None of the five MetS
components were observed in 69% of the normal-weight participants whereas all obese
participants had at least one MetS component. Obese participants were more likely to
have three or more MetS components (52.6%) than overweight (34.2%) and normalweight (13.2%) participants. Furthermore, none of the underweight participants had
three or more MetS components (Figure 4.4).
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Figure 4.3: Prevalence of metabolic syndrome by body mass index (BMI)
category among young female adults aged 17 to 25 years (n = 555), Al Ain,
UAE
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Figure 4.4: Percentage of participants per number of metabolic syndrome
components and BMI category among young female adults aged 17 to 25 years
(n=555), Al Ain, UAE
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4.2.3 Univariable and Multivariable Logistic Regression Analyses
Logistic regression was used to determine the association between independent
variables such as age, family history, anthropometric measures and biochemical
measures, and the presence of metabolic syndrome defined according to the IDF
harmonized criteria. Table 4.2 and Table 4.3 show the univariable and multivariable
logistic regression results for the odds of MetS by potential risk factors, respectively.
In the univariable analyses, older participants (23–25 years) were three times more
likely to have MetS (odds ratio [OR] = 2.96; 95% CI: 1.03 to 8.52) than younger
participants (17–19 years) but this effect was not significant in the multivariable
analyses (adjusted OR [aOR]= 1.14; 95% CI: 0.30 to 4.30).
Participants who reported having a family history of diabetes or hypertension
(n = 305) had a 2.8 times elevated risk of MetS (OR = 2.81; 95% CI: 1.31 to 6.06)
compared with participants without a family history of diabetes or hypertension
(n=250) in the univariable analyses but not in the adjusted analyses (aOR=1.85; 95%
CI: 0.73 to 4.65).
Participants who were overweight or obese were, respectively, 6.4 (95% CI:2.3
to 17.5) and 29 (95% C1; 29.2 to 79.3) times more likely to have MetS than those of
normal-weight in the univariable analysis (P<0.001). These findings remained
significant even after adjusting for other potential confounders (i.e. aOR = 3.8; 95%
CI: 1.15–12.52 for overweight; and aOR = 11.2; 95% CI: 3.06–40.86 for obese
participants). Participants with percentage body fat ≥35% (n = 227) showed a
significantly higher risk for the development of MetS in the univariable analyses (OR
= 14.27; 95% CI: 4.99 to 40.83; P<0.001), but the difference was not significant after
adjusting for other factors (aOR = 3.12; 95% CI: 0.91–10.68).

115
A waist-hip ratio (WHR) of more than 0.8 was significantly associated with at
least three times increased risk of MetS (P<0.001) in the adjusted analyses when
compared with those with a WHR <0.8 (aOR= 3.04; 95% CI: 1.10–8.44).
Elevated glycated hemoglobin (HbA1c) (≥6.5%) showed a high significant
association with the presence of MetS (OR=14.15; 95% CI: 4.78 to 41.86; P<0.001)
in univariable analyses and remained significant in the adjusted analyses (aOR = 22.49,
95% CI: 6.37 to 79.42; P<0.001).
Total cholesterol ≥200 mg/dL and low density lipoprotein (LDL) ≥130 mg/dL
conferred a greater likelihood for MetS: OR= 3.34 (95% CI: 1.48 to 7.49), and OR:1.86
(95% CI: 0.96 to 3.63), respectively, in the univariable analyses but not in the adjusted
analyses aOR:1.04 (95% CI: 0.46 to 2.35), and aOR:1.71 (95% CI: 0.53 to 5.55),
respectively. However, the odds of MetS were significantly higher in those with high
sensitivity C-reactive protein >3 mg/L (OR = 339.92; 95% CI: 77.6 to 1489.5), when
compared to high sensitivity C-reactive protein ≤3 mg/L in univariable analyses and
remained significant in the adjusted analyses (aOR=217.89; 95% CI: 36.87 to 1287.81;
P<0.001).
A subgroup analysis was conducted for the study population excluding all
females with HbA1c ≥ 6.5 resulting in a total sample size of 507 participants. Results
of the subgroup analysis remain largely unchanged based on the magnitude of the
effect sizes, direction of significance and overall conclusions. However, in the
multivariate analysis, only waist hip-ratio was no longer significant in the subgroup
analysis (OR = 2.12; 95% CI: 0.65–6.87; P = 0.211) (Table 4.4)
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Table 4.2: Univariable analyses - Risk factors for MetS among young female adults
aged 17 to 25 years (n=555), Al Ain, UAE
Variable

N

Age, Year (%)
17-19
20-22
23-25
Family history of diabetes or
hypertension (%)
No
Yes

n (%)

With MetS
Crude Odds Ratio
(95%CI)

Pvalue

194
299

8 (4.1)
23 (7.7)

Reference
1.94 (0.85 - 4.42)

0.116

62

7 (11.3)

2.96 (1.03 - 8.52)

0.044
0.005

250
305

9 (3.6)
29 (9.5)

Reference
2.81 (1.31 - 6.06)

62
306
129

0 (0.0)
5 (1.6)
13 (10.1)

58

20 (34.5)

0.44 (0.02 - 8.03)
Reference
6.35 (2.30 - 17.51)
29.19 (10.75 79.28)

0.008

2

Body Mass Index (kg/m )
Underweight (<18.5)
Normal weight (18.5 - <25)
Overweight (25-29.9)
Obese (≥30.0)

<0.001

328

4 (1.2)

Reference

≥35%

227

34 (14.9)

14.27 (4.99 - 40.83)

Waist-Hip Ratio**
<0.8
≥0.8

509
46

28 (5.5)
10 (21.7)

Reference
4.77 (2.15 - 10.59)

Anemia***
No

271

22 (8.1)

Reference

Yes

284

16 (5.6)

0.67 (0.35 - 1.32)

>3

0.58
<0.001
<0.001
<0.001

Body Fat (%)*
<35%

Total Cholesterol (mg/dL)
< 200
≥200
Low Density Lipoprotein
(mg/dL)
<130
≥ 130
High sensitivity C-reactive
protein (mg/L)
≤3

P-value
trend
0.103

<0.001
0.001
<0.001
0.246
0.249
0.007

502
53

29 (5.8)
9 (16.9)

Reference
3.34 (1.48 - 7.49)

0.004
0.072

380
173

21 (5.5)
17 (9.8)

Reference
1.86 (0.96 - 3.63)

0.067
<0.001

493

2 (0.4)

62

36 (58.1)

Reference
339.92 (77.6 1489.5)

<0.001
<0.001

Glycated Hemoglobin (%)
< 5.6

374

6 (1.6)

Reference

5.6 - 6.4

133

23 (17.3)

12.82 (5.09 - 32.29)

<0.001

> 6.5

48

9 (18.8)

14.15 (4.78 - 41.86)

<0.001

* Physical status: the use and interpretation of anthropometry 1995 [213]
** Waist circumference and waist-hip ratio: Report of a WHO expert consultation 2011 [222]
*** Hemoglobin concentrations for the diagnosis of Anemia according to the WHO 2011 [261]
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Table 4.3: Multivariable analyses - Risk factors for MetS among young female adults
aged 17 to 25 years (n=555), Al Ain, UAE
N

n (%)

With MetS
Adjusted Odds Ratio
(95%CI)

17-19

194

8 (4.1)

Reference

20-22
23-25
Family history of diabetes or
hypertension (%)
No
Yes

299
62

23 (7.7)
7 (11.3)

1.89 (0.72 – 4.94)
1.14 (0.30 – 4.30)

0.19
0.85

250
305

9 (3.6)
29 (9.5)

Reference
1.85 (0.73 – 4.65)

0.19

Body Mass Index (kg/m2)
Underweight (<18.5)
Normal weight (18.5 - <25)

62
306

0 (0.0)
5 (1.6)

0.85 (0.04 – 17.26)
Reference

0.92

Overweight (25-29.9)
Obese (≥30.0)

129
58

13 (10.1)
20 (34.5)

3.80 (1.15 – 12.52)
11.19 (3.06 – 40.86)

0.028
<0.001

Body Fat (%)*
<35%
≥35%

328
227

4 (1.2)
34 (14.9)

Reference
3.12 (0.91 – 10.68)

0.07

Waist-Hip Ratio**
<0.8
≥0.8

509
46

28 (5.5)
10 (21.7)

Reference
3.04 (1.10 – 8.44)

0.033

Anaemia***
No
Yes

271
284

22 (8.1)
16 (5.6)

Reference
1.04 (0.46 – 2.35)

0.92

Total Cholesterol (mg/dL)
< 200

502

29 (5.8)

Reference

≥200

53

9 (16.9)

1.71 (0.53 – 5.55)

0.37

380
173

21 (5.5)
17 (9.8)

Reference
0.92 (0.37 – 2.32)

0.86

493
62

2 (0.4)
36 (58.1)

Reference
217.89 (36.87 – 1287.81)

<0.001

Characteristics

Pvalue

Age (Year)

Low Density Lipoprotein (mg/dL)
<130
≥ 130
High sensitivity C-reactive protein
(mg/L)
≤3
>3

Glycated Haemoglobin (%)
< 5.6
374
6 (1.6)
Reference
5.6 - 6.4
133
23 (17.3)
8.92 (3.39 - 23.48)
≥ 6.5
48
9 (18.8)
22.49 (6.37 – 79.42)
* Physical status: the use and interpretation of anthropometry 1995 [213]

<0.001
<0.001

** Waist circumference and waist-hip ratio: Report of a WHO expert consultation 2011 [222]
*** Hemoglobin concentrations for the diagnosis of Anemia according to the WHO 2011 [261]
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Table 4.4: Subgroup multivariable analysis - Risk factors for MetS among young
female adults aged 17 to 25 years (n=507), Al Ain, UAE – excluding 48 participants
that had HbA1c ≥ 6.5
Characteristics

With MetS
PAdjusted Odds
value
Ratio (95%CI)

Sample

n (%)

Crude Odds Ratio
(95%CI)

17-19

175

6 (3.4)

Reference

20-22
23-25
Family history of
diabetes or
hypertension (%)
No
Yes
Body Mass Index
(kg/m2)
Underweight
(<18.5)
Normal-weight
(18.5 - <25)
Overweight (2529.9)

278
54

17 (6.1)
6 (11.1)

1.83 (0.71, 4.75
3.52 (1.09, 11.41)

0.211
0.036

1.50 (0.53 – 4.28)
1.89 (0.47 – 7.60)

0.448
0.365

223
284

7 (3.1)
22 (7.8)

Reference
2.59 (1.09, 6.18)

0.032

Reference
1.03 (0.73 – 4.65)

0.19

58

0 (0.0)

0.94 (0.044, 19.88)

0.969

277

2 (0.7)

Reference

120

11 (9.2)

11.57 (2.89, 46.26)

0.001

Obese (≥30.0)

52

16 (30.8)

49.82 (12.61, 196.88)

<0.001

Body Fat (%)*
<35%

296

2 (0.7)

Reference

≥35%

211

27 (12.8)

21.57 (5.07, 91.78)

<0.001

467
40

23 (4.9)
6 (15.0)

Reference
3.41 (1.30, 8.93)

0.013

Reference
2.12 (0.65 – 6.87)

0.211

247
260

18 (7.3)
11 (4.2)

Reference
0.56 (0.26, 1.22)

0.143

Reference
0.68 (0.28 – 1.69)

0.411

459
48

22 (4.8)
7 (14.6)

Reference
3.39 (1.37, 8.41)

0.008

Reference
1.38 (0.37 – 5.17)

0.634

348
157

16 (4.6)
13 (8.3)

Reference
1.87 (0.88, 3.99)

0.104

Reference
0.78 (0.27 – 2.26)

0.653

374

6 (1.6)

Reference

133

23 (17.3)

12.82 (5.09, 32.29)

Pvalue

Age (Year)

Waist-Hip Ratio**
<0.8
≥0.8
Anaemia***
No
Yes
Total Cholesterol
(mg/dL)
< 200
≥200
Low Density
Lipoprotein
(mg/dL)
<130
≥ 130
Glycated
Haemoglobin (%)
< 5.6
5.6 - 6.4

Reference

1.54 (0.07 –
35.79)

0.785

Reference

<0.001

5.62 (1.13 –
27.86)
15.35 (2.92 –
80.75)

0.035
0.001

Reference
2.84 (0.57 –
14.06)

Reference
8.11 (3.12 –
21.08)

0.201

<0.001

* Physical status: the use and interpretation of anthropometry 1995 [213]
** Waist circumference and waist-hip ratio: Report of a WHO expert consultation 2011 [222]
*** Hemoglobin concentrations for the diagnosis of Anemia according to the WHO 2011 [261]
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4.2.4 High Sensitivity C-Reactive Protein and Metabolic Syndrome
Logistic regression analyses showed that the odds of MetS were significantly
higher in those with high sensitivity C-reactive protein (Hs-CRP) >3 mg/L (OR =
339.92; 95% CI: 77.6 to 1489.5), when compared to high sensitivity C-reactive protein
≤3 mg/L in univariable analyses with the odds remained significant in the adjusted
analyses (aOR:217.89; 95% CI: (36.87 to 1287.81) (P<0.001). Figure 4.5 displays the
distribution of Hs-CRP levels after females were classified according to their total
number of components of the MetS. The MetS represents an inflammatory state that
could be seen by the progressive increase of Hs-CRP levels with the increased number
of MetS components according to the harmonized IDF criteria. The graph illustrates
the strong linear increase in Hs-CRP levels as the number of MetS components
increased. The median Hs-CRP levels for those with 0, 1, 2, ≥3 components of the
MetS were 0.46, 0.78, 1.405, and 5.14 mg/L, respectively (P <0.001).
14

N=38

Hs- C-reactive protein (mg/L)

12

N=62

10
8

N=213

6
4

N=242

2
0
0

1

2

≥3

Number of Metabolic Syndrome Components
Figure 4.5: Distribution of High Sensitivity C-reactive protein according to
number of metabolic syndrome components present among young female adults
aged 17 to 25 years (n=555), Al Ain, UAE. Box plots demonstrate minimum,
maximum, median, 25th, and 75th percentile values for Hs-CRP
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4.2.5 Prevalence of Overweight/Obesity
The distribution of the studied population according to their body mass index
(BMI) categories showed that 11.2% were underweight; 55.1% were normal weight;
and 33.7% were overweight or obese (23.2% and 10.5%, respectively) as indicated in
Figure 4.6.
Table 4.5 demonstrates that 7.6% of the studied population were classified at
class I obesity (BMI 30.00 – 34.9 kg/m2); 1.6% met the class II obesity classification
(BMI 35.00 – 39.9 kg/m2); and 1.3% had a BMI ≥ 40.00 kg/m2.
Central obesity was prevalent among 18.2% of the studied population based on
the waist circumference (WC) classification. Whereas, only 8.3% of the studied
population were found living with central obesity when waist-hip ratio ≥0.8 was used
as a cutoff point. In opposition, measurement of body fat percentage from skinfold
thickness at four sites (biceps, triceps, subscapular and suprailiac) via Durnin’s
regression equation [232] showed that 40.9% of the sample population had a body fat
percent >35%.

10.5

11.2

23.2

55.1

Underweight

Normal weight

Overweight

Obese

Figure 4.6: Distribution of Emirati young female adults aged 17 to 25 years (n=555)
according to body mass index categories
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Table 4.5: Distribution of the study population according to different measures of
obesity
Variable

N

%

62

11.2

Normal weight (18.50 – 24.99 kg/m )

306

55.1

Overweight (25.00 – 29.99 kg/m2)

129

23.2

Obese class I (30.00 – 34.9 kg/m2)

42

7.6

Obese class II (35.00 – 39.99 kg/m2)

9

1.6

Obese class III (≥ 40.00 kg/m2)

7

1.3

<80 cm

454

81.8

≥80 cm (central obesity)

101

18.2

<0.8

509

91.7

≥0.8

46

8.3

<35%

328

59.1

≥35%

227

40.9

Body Mass Index
Underweight (<18.50 kg/m2)
2

Waist Circumference

Waist-Hip Ratio

Body Fat
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4.2.6 Prevalence of Diabetes
According to the standards of medical care in diabetes set by the American
Diabetes Association (ADA) in 2016 [255] (previously presented in Table 3.4)
diabetes mellitus (DM) could be diagnosed based on the level of fasting plasma
glucose (FPG) or glycated hemoglobin (HbA1c). The classification of the study
population according to FPG and HbA1c for the diagnosis of diabetes and prediabetes
are presented in Table 4.6. The prevalence of diabetes mellitus and prediabetes based
on FPG was 0.5% and 9.2%, respectively. However, 8.6% of the studied population
were diagnosed with diabetes, and 24% were living with prediabetes according to the
percentage of HbA1c. Thus, the crude prevalence of diabetes mellitus and pre-diabetes
(shown in Figure 4.7) among the study population was 8.6% and 24.7%, respectively.

Table 4.6: Classification of the study population according to different standards for
the diagnosis of diabetes and prediabetes
Variable
Fasting Plasma Glucose (FPG)
Normal (≤99 mg/dL)
Prediabetes (100-125 mg/dL)
Diabetes (≥126 mg/dL)
Glycated Hemoglobin (HbA1C)
Normal (About 5 %)
Prediabetes (5.7-6.4 %)
Diabetes (≥6.5 %)
FPG or HbA1c
Normal
Prediabetes
Diabetes

N

%

501
51
3

90.3
9.2
0.5

374
133
48

67.4
24.0
8.6

370
137
48

66.7
24.7
8.6

123

8.6%
24.7%

Normal
66.7%

Prediabetes
Diabetes

Figure 4.7: Prevalence of abnormal glycemic status based on fasting plasma glucose
(FPG) and glycated hemoglobin (HbA1c) among Emirati young female adults aged
17 to 25 years (n=555), Al Ain, UAE
Logistic regression was used to determine the association between age; family
history; anthropometric measures; and biochemical measures, and the presence of
diabetes or prediabetes, as illustrated in Table 4.7. Neither age of the participant, nor
having a family history of diabetes or hypertension had a significant association with
the risk of DM (P=0.66, 0.809, respectively). Nevertheless, participants living with
obesity (n=58) were almost 2.5 times (OR: 2.407; 95% CI: 1.373 to 4.221) more likely
to have DM than those with BMI<25.0 (n=368) (P=0.002).
Percentage of body fat did not show an association with the risk of DM
(P=0.329). However, waist circumference of more than 80 cm was significantly
associated with increased risk of DM (OR: 2.561; 95% CI: 1.650, 3.975) (P<0.001).
Hip circumference was also associated with an increased odds of DM (OR: 1.028; 95%
CI: 1.011, 1.045). Elevated high sensitivity C-reactive protein ≥3 mg/L, conferred a
greater likelihood for MD (OR: 12.095; 95% CI: 6.312, 23.176).
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Table 4.7: Univariate logistic regression analysis model of the association between
abnormal glycemic status based on fasting plasma glucose (FPG) and glycated
hemoglobin (HbA1c) and selected variables among young Emirati female adults
aged 17 to 25 years (n=555), Al Ain, UAE
With abnormal glycemic status
Variable

N
n (%)

Odds Ratio (95% CI)

P-value

P-value
0.66

Age Year (%)
17-19

194

62 (32.0)

Reference

20-22

299

94 (31.4)

0.976 (0.662 - 1.439)

0.903

23-25

62

29 (46.8)

1.871 (1.044 - 3.352)

0.035
0.809

Parents Diabetic or Hypertensive (%)
No

250

82 (32.8)

Reference

Yes

305

103 (33.8)

1.045 (0.732 - 1.490)

0.809
0.119

Blood Pressure (mm Hg)
Normal

453

147 (32.5)

Reference

Prehypertension

93

37 (39.8)

1.375 (0.869 - 2.178)

0.174

9

1 (11.1)

0.260 (0.32 - 2.100)

0.206

Hypertension
2

0.013

Body Mass Index (kg/m )
Underweight (<18.5)

62

16 (25.8)

Reference

Normal weight (18.5 - <25)

306

92 (30.1)

1.236 (0.665 - 2.296)

0.502

Overweight (25-29.9)

129

48 (37.2)

1.704 (0.870 - 3.335)

0.120

Obese (≥30.0)

58

29 (50.0)

2.875 (1.335 - 6.192)

0.007
0.329

Body Fat (%)
<35

328

104 (31.7)

Reference

≥35

227

81 (35.7)

1.195 (0.836 - 1.709)

0.329
<0.001

Waist Circumference (cm)
<80

454

133 (29.3)

Reference

≥80

101

52 (51.5)

2.561 (1.650 - 3.975)

<0.001

Hip Circumference (cm)

555

185 (33.3)

1.028 (1.011 -1.045)

0.001

0.001

Neck Circumference (cm)

555

185 (33.3)

1.022 (0.975 - 1.071)

0.365

0.353
0.238

Waist-hip Ratio
<0.8

509

166 (32.6)

Reference

≥ 0.8

46

19 (41.3)

1.454 (0.786 - 2.691)

0.233
0.904

Anemia (%)
No

271

91 (33.6)

Reference

Yes

284

94 (33.1)

0.979 (0.688 - 1.393)

Total Cholesterol (mg/dL)
< 200

502

164 (32.7)

Reference

≥200

53

21 (39.6)

1.353 (0.756 -2.418)

0.904
0.313
0.309

125
0.078

Low Density Lipoprotein (mg/dL)
<130

380

118 (31.1)

Reference

≥ 130

173

67 (38.7)

1.403 (0.964 - 2.042)

0.077
<0.001

High Density Lipoprotein (mg/dL)
>45

284

70 (24.6)

Reference

≤ 45

271

115 (42.4)

2.254 (1.570 - 3.236)

<0.001
<0.001

High-sensitivity C-reactive Protein (mg/L)
Low (<1)

326

72 (22.1)

Reference

Intermediate (1-2.9)

167

65 (38.9)

2.248 (1.497 - 3.376)

<0.001

High (≥ 3)

62

48 (77.4)

12.095 (6.312- 23.176)

<0.001

Table 4.8: Adjusted analysis model of the association between abnormal glycemic
status based on fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) and
selected variables among young Emirati female adults aged 17 to 25 years (n=555),
Al Ain, UAE

Variable

Odds Ratio

95% Confidence
Interval
Lower

Upper

P-value

Body Mass Index
(kg/m2)

1.164

0.738

1.835

0.514

Waist circumference
(cm)

0.978

0.941

1.016

0.252

Hip circumference (cm)

1.007

0.969

1.046

0.737

Hs-CRP* (mg/L)

1.578

1.360

1.832

<0.001

* High sensitivity C- reactive protein.
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4.3 Discussion
In the United Arab Emirates (UAE) rapid socioeconomic growth has resulted
in profound lifestyle changes including sedentary behaviors, westernized diets and
increased energy intake [167]. The prevalence of MetS among Emirati females has
been reported to be higher than that for Emirati males in the adult population (32.9%
among men, 45.9% among women) [5]. This research highlights the importance of
investigating MetS among young female adults, to facilitate understanding of the
prevalence and risk factors of MetS. There is paucity of data on the prevalence of MetS
among Emirati females aged 17–25 years. The current study reveals a MetS prevalence
of 6.8% among young female Emirati adults aged 17–25 years, and 34.5% among
young obese female Emirati adults.
There are few data available about the prevalence of MetS among Emirati
females aged 17-25. The current study reveals a MetS prevalence of 6.8% among
young female Emirati adults aged 17-25. This percentage is much higher than the 4%
prevalence previously reported in a separate study of female Emirati adolescents (1218 years old) [6] and much lower than that among Emirati female adults (≥20 years)
45.9% reported in 2008 [5]. A recent study by Hajat and others in 2012, during the
Weqaya screening program in the Emirate of Abu Dhabi [307], found that the overall
prevalence of MetS among Emirati adults was 48.7% and 50.3% using the MetS
definition of IDF and ATPIII, respectively. These findings suggest about 8% increase
during the period of 4 years only, when compared with those described in 2008 [5]
using the same IDF criteria, where the overall prevalence of MetS was 40.5%. The
same prevalence was described in 2010 [308] among overweight and obese adults (1850 years old) in the UAE. MetS prevalence among the young obese (<12 years old) in
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the UAE was stated to be 44% in the same year [309]. In the present study, the
prevalence of MetS was 34.5% among obese students.
The results of the current study are in line with findings among college students
(18–26 years) in Saudi Arabia [310], where the overall MetS prevalence was 7.8%,
and 26.4% in obese students. In the same study, the prevalence of MetS among Saudi
female college students was 1.7% compared to 9.9% among males. However, the
prevalence of MetS among Saudi female adults was stated to be 34.1% and 36.6%
among male adults in 2010[134].
In Kuwait, the prevalence of MetS was even higher among female adolescents
(10–19 years) at 9.1% and 14.8% according to ATP III and IDF criteria, respectively
[159]. MetS among adult Kuwaitis were similar between men and women at 36.2%
and 36.1%, respectively [133]. In Oman, the overall prevalence of MetS among adults
(>20 years old) was 23.6%, it was somewhat higher in women 24.4% compared to
men 22.8% [131]. These numbers are certainly close to those described in the UAE,
which is not surprising, considering the relatively similar rapid increase in obesity and
diabetes rates throughout the Gulf region [311, 312]. These trends are as a result of a
sedentary and westernised lifestyle [313-316], and could also be partially explained by
the “thrifty genes” hypothesis [309], which suggests that the genotype of mankind
existed as hunter-gatherers can efficiently store food in the adipose tissue during
periods of food abundance, to compensate for periods of food shortage.
Worldwide, the prevalence of MetS among young female adults in the USA
(18-21 years) was 4.7% [317], in Brazilian college students it was 1.7% [318], in
Chinese female adolescents (14-16 years) it was 2.5% [319], in Spanish female
adolescents (10-15 years) it was 3.85% [320], in Tunisian female adolescents (10-19
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years) it was 2.4% [321], and 11.7% among Indian female adolescents (10-19 years)
[322]. Clearly, the prevalence of MetS could differ between countries depending on
the MetS defining criteria used, study method and target population. We have used the
IDF and AHA/NHLBI joint statement, as it was an international attempt to harmonize
the definition of MetS; central obesity is not an obligatory component of this definition
and it is ethnic specific.
The most frequent component of MetS in this study was reduced HDL-C
levels, which was also reported in the female Emirati adolescents [6], and female
Kuwaiti adolescents [159]. Reduced HDL-C accompanied by elevated triglyceride
levels indicates dyslipidemia, which is highly prevalent among the UAE population
[323]. Insufficient physical activity and poor dietary habits are associated with low
HDL-C levels [324-326]. Elmagd et. al. reported low physical activity (defined as less
than 150 minutes/week) in 60% of Emirati college students [327]. The consumption
of high caloric diet was also reported in 33.5% of female Emirati adolescents [167].
These findings could explain the high prevalence of low-HDL-C levels observed in
our study. Regular checks and screening in this age group could be helpful in
identifying participants at an increased risk of developing MetS.
The current study found strong correlations between BMI, body fat, hbA1c,
High sensitivity C-reactive protein and the prevalence of MetS in Emirati female
students. The relationship between overweight and obesity and MetS has been
supported by many other studies [134, 158, 328].
Ridker and his colleagues showed a strong evidence that the MetS represents
an inflammatory state that could be seen by the progressive increase of Hs-CRP levels
with the increased number of the MetS components according to the ATP III criteria
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[67]. Up to date, the only well-standardized marker of inflammation and a predictor of
the MetS and future cardiovascular events, is the Hs-CRP [68]. However, the
measurement of Hs-CRP is not yet included in the diagnostic criteria of the MetS,
although it has been recommended by a large number of investigators [67-71].
Inflammation is usually measured through the measurement of serum Hs-CRP, where
a level above 3 mg/L is considered high according to the recommendations of the CDC
and the AHA for cardiovascular disease (CVD) risk assessment [63]. However, HsCRP is a sensitive marker for acute phase inflammation and has a high within-subject
variability [329]. Therefore, a value above 3 mg/L might indicate an increased risk of
cardiovascular, but could also be a result of an infection or inflammation, which may
vague any projection of coronary risk that might be attributed to the elevated level
[330].
The association between HbA1c and the prevalence of MetS has not been
previously reported; nevertheless, insulin resistance is a major underlying mechanism
accountable for the prevalence of the MetS [331]. Interestingly, the prevalence of
diabetes (8.6%) was also high in the study population. Future studies need to explore
this finding more closely.
The prevalence of diabetes mellitus and prediabetes based on FPG (0.5% and
9.2%, respectively) was found much lower than that based on the percentage of HbA1c
(8.6% and 24%, respectively) However, the crude prevalence of diabetes mellitus and
pre-diabetes among Emirati young female adults was 8.6% and 24.7%, respectively.
Our present results are in disagreement with those previously reported in a
hospital-based study were the prevalence of diabetes was higher using the FPG
criterion (31.6%) compared to the HbA1c criterion (23.5%) [332]. Moreover, in a
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retrospective study in Saudi Arabia, the prevalence of impaired glucose tolerance was
54% when using HbA1c as a diagnostic test, and 60.3% when using FPG as a
diagnostic test [333]. In contrast, our results are in agreement with a population-based
study among Palestinian Arab population that showed a lower prevalence of diabetes
diagnoses using the FPG criterion (4.5%) compared to HbA1c criterion (5.3%)[334].
In study among the Korean population, the prevalence of diabetes and prediabetes
using FPG only (10.5% and 19.3%, respectively) were lower compared to the
prevalence of diabetes and prediabetes using HbA1c as a diagnostic test (12.4% and
38.3%, respectively) [335]. In Canada, using HbA1c only for the diagnoses of overall
prediabetes prevalence resulted in a three-fold increase compared to FPG and a sixfold increase among females (FPG 2.22%, HbA1c 13.31%)[336].
Although more participants were diagnosed with diabetes when HbA1c was
added as a diagnostic criterion, yet the simultaneous measurement of FPG and HbA1c
(FPG and/or HbA1C) is recommended by the American Diabetes Association [255]
and has been shown to be a more sensitive and specific screening tool for identifying
high-risk individuals with diabetes and IGT at an early stage [337, 338]. Advantages
of using HbA1C include: convenience, pre-analytical stability, and minimum day-today perturbations during periods of stress and illness. Nevertheless, this test is pricey,
and might not be available in certain regions of the developing world [255].
The strengths of this study include a trained researcher who obtained all
measurements in the study and each measurement was repeated three times and the
average used in the analyses. Anthropometric measures and blood withdrawal were
conducted during one 50-minute morning session after assurance of a 12-hour
overnight fast. Furthermore, to the best of our knowledge, no other studies exploring
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MetS prevalence in college students have been conducted in the UAE. UAEU is the
main university in the UAE and it enrolls students from all seven emirates. However,
restricting the study to college students makes it not representative of all the Emirati
females in this age group.
Moreover, the cross-sectional design is another limitation of this study, as
causal inference cannot be drawn. Participants were voluntarily enrolled in the study,
which could have caused selection bias (overweight and obese individuals might avoid
anthropometric measurements). Additionally, a study conducted by Malik and Razig
in 2008 showed that Emirati female adults who had no formal education were 1.27
(95% CI:1.03 to 1.58) times more likely to have MetS than those who had higher
education (>12 grade) (P= 0.028) according to the IDF definition of MetS [5].
Therefore, limiting participation in the current study to university students only might
have introduced underestimation of MetS prevalence among young adults, especially
that Malik reported only 25.4% of Emirati female adults (>20) had university degrees
[5].
In addition, studying female students only does not allow for examination of
gender differences or generalizability of results to all young adults. Therefore, future
prospective studies are needed to confirm the prevalence of MetS and its relation to
overweight and obesity in Emirati young adults. Additionally, it was challenging to
clearly define the “young adult” age group. Some studies reported the MetS prevalence
in adolescents and included ages 12–18 years [6] or 10–19 years old [159]. Other
studies defined young adults as 18–24 years [317], 17–37 years [339] or college
students aged 17–25 years [340]. Having one international definition for the “young
adult” age group would be helpful for future data comparisons.
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4.4 Conclusion
In summary, we have shown that the prevalence of MetS is high among UAEU
female young adults aged 17–25 years (6.8%). One third of the studied population was
overweight and obese. The prevalence of diabetes mellitus and prediabetes based on
FPG was found much lower than that based on the percentage of HbA1c (0.5% and
9.2% Vs. 8.6% and 24% respectively). However, the crude prevalence of diabetes
mellitus and pre-diabetes among Emirati young female adults was 8.6% and 24.7%,
respectively.
MetS prevalence was highest among obese participants, as compared with
normal-weight and overweight participants. In addition, reduced HDL-C levels
followed by central obesity were the most frequent components of MetS. Using
logistic regression model MetS was significantly associated with overweight, obesity,
waist-hip ratio, glycated hemoglobin (HbA1c) and high sensitivity C-reactive protein
(P < 0.01).
The high prevalence of MetS highlights the importance of regular screening
and intervention programs targeting weight reduction. It is also necessary to design
public health policy, clinical practice, and prevention programs for the screening and
treatment of Emirati females at high risk for metabolic syndrome. Such strategies
should address cultural and community life of Emiratis to ensure relevance and
commitment by the community.
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Chapter 5: Glycemic Index (GI) Value of Commonly Consumed Foods in
the UAE
5.1 Introduction
Diabetes mellitus (DM) is a chronic disease characterized by abnormalities in
the metabolism of carbohydrates, fat, and protein along with hyperglycemia.
Complications of the disease include macrovascular and microvascular damage in the
eyes (retinopathy) [341], kidneys (nephropathy) [342] and nerves (neuropathy) [343].
If left untreated, these complications could progress into blindness, kidney failure,
amputation, and even death [205].
During the past three decades, the prevalence of DM in the world has doubled,
which presents a great challenge to international public health. According to the recent
regional fact sheets of the International Diabetes Federation (IDF), there are 382
million people living with diabetes in the world, with a prevalence of 8.3% [2]. The
IDF expects an increase of 205 million patients by 2035. The 9.7% prevalence of
diabetes in the Middle East and North Africa (MENA) regions is even higher than the
world average [2]. Based on the same fact sheets, United Arab Emirates (UAE) was
ranked fifth with regards to the highest prevalence of diabetes mellitus in the region
(19%), ranked after other Gulf Cooperation Council (GCC) countries, Saudi Arabia,
Kuwait, Bahrain and Qatar which have the prevalence of 23.9%, 23.1%, 21.9% and
19.8% respectively [304].
Type 2 Diabetes Mellitus (T2DM) is the most common type of diabetes. It was
thought to occur among adults, but is increasingly reported in children and adolescents.
With this type of diabetes, the body is capable of producing insulin but it is either not
in a sufficient amount or the body is insulin resistant, leading to the accumulation of
glucose in the blood, also known as hyperglycemia [205].
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T2DM is an increasing source of concern in the UAE. The prevalence of T2DM
was 6% among adults, according to a prevalence survey performed between1989 and
1990 [344]. A later survey conducted between 1999 and 2000 reported a greater
prevalence of about 20% [23]. A recent survey reported the prevalence of diagnosed
DM at10.5%, undiagnosed DM at 6.6%, and pre-diabetes at 20.2% [345]. The latter
also reported the prevalence of retinopathy at 54.2%, neuropathy at 34.7%,
nephropathy at 40.8%, peripheral vascular disease at 11.1%, and coronary heart
disease at 10.5% among patients diagnosed with DM.
The observed increase in incidences of T2DM and pre-diabetes among
children, adolescents and younger adults increases the need for understanding the
etiology and treatment for the disease. The causes behind the epidemic of T2DM are
part of a very complex group of genetic and social systems which, in turn, control
behavioral and environmental factors [212]. Moreover, there are several risk factors
believed to be mainly contributing to the occurrence of the disease, these include:
weight gain and obesity [11]; sedentary lifestyle with low physical activity [12, 13];
ethnicity [14]; family history of diabetes [14]; poor dietary habits [346]; other factors
like cigarette smoking and alcohol consumption [255].
The focus on the prevention and treatment of T2DM are lifestyle factors,
including diet (for glycemic control), physical activity, and weight reduction [346348]. The American Diabetes Association (ADA) recommends an effective ongoing
support program targeting glycemic control (using carbohydrates counting and
selection of low glycemic index foods), weight loss of seven percent of body weight
within the first six months of intervention, and increasing physical activity to at least
150 min/week of moderate activity for pre-diabetics [255].
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Dietary management and prevention of DM was found to be dependent on the
quality and quantity of nutrient intake. Studies suggest that total amount of
carbohydrate or fat in the diet does not seem to be associated with T2DM risk but
specific forms of carbohydrate or fat were associated with the disease [18, 19]. For
example: the ability of dietary carbohydrates to increase blood glucose and insulin
levels after ingestion differs, and that is known as the glycemic index (GI) of
carbohydrate foods [20]. This concept was developed in 1981 by Jenkins et. al. as a
tool for predicting blood glucose response to various foods [20]. It is defined as the
ratio of the blood glucose response for a tested food as compared to the blood glucose
response of a standard (usually a glucose or white bread) [349]. If glucose is used as
the reference, then a GI of ≤ 55 is considered low, between 56-69 is intermediate, and
≥ 70 is high [20]. Since the amount of carbohydrate in a food varies according to the
serving size, researchers have also introduced the concept of glycemic load (GL),
which is the amount of available carbohydrates in a serving size of food item
multiplied by its glycemic index [21].
Prospective studies investigating the relations between dietary carbohydrate
intake and risk of T2DM using GI and GL supported the protective role that low GI
and low GL diets play against the development of T2DM [19, 192, 350]. Since a high
GI food would cause a higher increase in the levels of blood glucose after its ingestion,
it will, in turn, increase the demand of insulin in the body. Regular consumption of
high GI foods would therefore contribute to beta cell distraction, due to the elevated
insulin demand and/or continuously raised glucose concentration in the blood [19].
In 2010, a study was conducted in the UAE to determine the factors associated
with poor glycemic control among patients with T2DM [22]. The results showed that
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poor glycemic control among patients with T2DM was mainly because patients were
not following the dietitian’s recommended eating plan and/or had a negative attitude
towards diabetes [22]. In a different study, researchers were examining differences in
the prevalence of DM between different ethnic groups in the UAE [23]. They reported
a higher DM prevalence among UAE citizens (25%) compared to expatriates (13–
19%, depending on country of origin) [23]. These results advocate the need for better
counseling programs focusing on Emirati citizens, which, in turn, requires more
information about dietary practices of the Emiratis, food composition tables of locally
consumed foods in the UAE, an exchange list of these foods, and glycemic index
values of Emirati foods to facilitate the role of dietitians in developing better programs
targeting glycemic control in diabetics and pre-diabetics.
This study was designed to test the null hypothesis that Emirati traditional
foods are high in their GI and GL values which might be contributing to the high
prevalence of DM and CVD. Therefore, it aimed to develop a comprehensive food
composition table with GI and GL values of locally consumed foods in the UAE. These
tables would serve as a great tool for nutrition therapy planning and dietary
management for dietitians in the UAE and other GCC countries.
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5.2 Results and Discussion
5.2.1 Proximate Analysis
Proximate analyses including fat, protein, ash, fiber and moisture content were
measured according to previously described methods in Section 3.3.5.3. The
proximate analyses data were expressed as mean ± standard derivation on a fresh
weight basis of each test food (Table 5.1). There were significant differences in the
nutritional composition of the analyzed foods due to different ingredients and
preparation methods (see Table 3.8 for main ingredients).
Moisture content ranged from 15.63g/100g in Muhalla bread to 86.66g/100g
in Arseyah. Dishes containing meat (all main dishes) like Harees (beef), Thareed
(beef), Thareed (chicken), Biryani (chicken), Machbous (fish), Arseyah (chicken), and
Marqoqa (chicken) were found to have relatively high moisture content, ranging from
63.26g/100g to 86.66g/100g. Similar results of high moisture values in dishes
containing meat have been reported by many other studies investigating food
composition of traditional dishes in the Gulf Region [172, 175, 351, 352]. Musaiger
et. al. (1998) [172], Habib et. al. (2011) [175], and Musaiger (2011) [351] reported
similar moisture content for Harees: 80.2, 79.9 and 81, respectively. These values are
only slightly higher than the 77.7g/100g of moisture in Harees presented in this study.
Machbous was found to have 68.3g/100g of moisture, which is comparable to the
68.9g/100g reported by ElObeid et. al. (2015)[352], and to the 65.91g/100g described
by Habib et. al. (2011) [175]. Breads had relatively low moisture content, ranging from
15.6g/100g for Muhalla bread to 35.7g/100g for Chebab bread. Regag bread had a
moisture content of 21.9g/100g, which is lower than what ElObeid et. al. (2015)
reported while investigating Kuwaiti traditional dishes (29.1g/100g) and much higher

138
than Bahraini and Emirati Regag bread reported in 2011(6.5 and 8.6g/100g,
respectively) [175, 351]. The moisture content of Sago was 74.9g/100g. Previous
studies reported varying moisture content in Sago, ranging from 39.8g/100g in Kuwaiti
Sago [352], to 70.7g/100g in Bahraini Sago [351]. Moisture content of a dish
resembles the amount of water available in it. Factors like recipe, cooking time, and
cooking method could affect the water content of the same dish, thus explaining the
differences found between studies.
Sago and Asida had the lowest protein content (0.80 and 0.99g/100g,
respectively) since their main ingredients are sugar and water. Similarly, ElObeid et.
al. (2015) [352] and Musaiger (2011) [351] found low protein content in Sago
(1.9g/100g and 1.0g/100g, respectively) and Asida (1.7 and 3.5g/100g, respectively).
However, the protein content was the highest in Chami (15.48g/100g). Chami is the
Emirati cottage cheese; therefore, it is expected to have high protein content. Dishes
containing meat like Biryani (chicken) and Thareed (beef) were also high in protein
(11.55 and 7.04g/100g, respectively). Mugaiger (2011) [351] found 6.8g/100 of
protein in Thareed (beef), and 8.1g/100g of protein in Biryani (beef). All six varieties
of bread had relatively high protein content, because they either contain milk, egg, or
both. The protein content of Regag bread in this study was 10.5g/100g. However,
protein content in Bahraini Regag bread was reported to be 12.5g/100g [351], and
protein content in Emirati Regag bread was 10.89g/100g [175]. Differences in protein
content could result from the type of wheat flour used, as processed wheat flour
contains less protein compared to whole grain wheat flour.
Fat content was the lowest in Asida (0.04g/100g), and the highest in
Khanfaroosh (30.32g/100g). ElObeid et. al. (2015)[352] has also reported very low fat
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content in Asida (0.08g/100g), although ghee was one of the ingredients of Asida in
both studies.
The preparation of Khanfaroosh (Emirati doughnut) requires deep-frying of the
dough in vegetable oil, which accounts for its high fat content. Lower fat content in
Bahraini Khanfaroosh (10.1g/100g) was reported by Musaiger (2011)[351]. The
difference in fat content could result from differences in cooking methods (deep
frying) and recipe (addition of vegetable oil for the dough).
Fiber values varied from 12.20g/100g in Balalet to 0.12g/100g in Chami.
Sago, a sweet dish consisting of Sago seeds and ghee, had 0.3g/100g of fiber.
Similarly, Bahraini Sago was reported to have 0.5g/100g of fiber [351]. Other dessert
dishes like Leqemat, Asida and Khanfaroosh had a fiber content of 1.45, 0.67, and
1.16/100g, respectively. However, fiber content in Leqemat, Asida and Khanfaroosh
from Bahrain was 0.5, 2.0, and 0.9/100g, respectively [351]. Differences in fiber
content could result from the type of wheat flour used (processed wheat flour or whole
grain wheat flour), since whole-wheat flour is a better source of fiber.
Carbohydrate content was calculated by the difference of {𝐶𝐻𝑂 = 100 −
(𝑃𝑟𝑜𝑡𝑒𝑖𝑛 + 𝑓𝑎𝑡 + 𝑎𝑠ℎ + 𝑤𝑎𝑡𝑒𝑟)}. Breads were found to have the highest
carbohydrate values, ranging from 68.20g in Muhalla bread to 47.08g in Chebab bread.
Arabic bread and Regag bread had a carbohydrate content of 63.61 and 65.25g/100g,
respectively. However, Musaiger (2011) [351] reported a carbohydrate content of 63.1
and 79.8g/100g in Bahraini Arabic bread and Regag bread, respectively.
Dessert dishes had lower carbohydrate content as compared to breads. Leqemat
and Balalet had a carbohydrate content of 45.63 and 40.09g/100g. Slightly lower
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values for carbohydrate content of Emirati Leqemat (42.13g/100g) and Balalet (33.76
g/100g) were reported by Habib et. al. (2011)[175].
In this study, the carbohydrate content of Harees (beef) was 13.30g/100g.
Habib et. al. (2011)[175] found similar carbohydrates content in Emirati Harees (beef)
(13.71g/100g), whereas Bahraini Harees had somewhat lower carbohydrate content
(10.5g/100g) [351].
Khanfaroush provided the highest amount of energy per 100g (462.91 Kcal)
due to its high fat content. Whereas, the energy provided by Arseyah was 57.32
Kcal/100g only because of its high water content. Breads provided similar energy
values, ranging from 298.26 Kcal/100g in Chebab bread to 382.97Kcal/100g in
Khameer bread.
In this study, Regag and Arabic breads provided 307.04, and 302.56
Kcal/100g, respectively. Lower amounts of energy were found in Bahraini Regag and
Arabic breads (297 Kcal/100g) [351]. Whereas, Habib et. al. (2011)[175] reported
much higher energy value for Emirati Regag bread (361.68 Kcal/100g).
Leqemat, a sweet dish similar to doughnut cake, had 416.49 Kcal of energy per
100g. However, a lower energy content was reported in Kuwaiti [173], Emirati [175],
and Bahraini [351] Legemat (301, 339.06, and 275 Kcal/100g, respectively). The
amount of energy provided by foods differs according to varying content of
macronutrients (protein, fat, and carbohydrate).

Table 5.1: Proximate Analysis of United Arab Emirates Traditional Dishes
Test Food
Arabic bread
Regag bread
Chebab bread
Muhalla Bread
Khameer Bread
Gurus
Fendal
Chami
Harees, beef
Thareed, beef
Thareed, chicken
Biryani, chicken
Machbous, fish
Arseyah
Marqoqa
Khabisa
Leqemat
Batheetha
Khanfaroosh
Sago
Asida
Habba Hamra
Balalet
P value*

Moisture
25.12 ± 0.34
21.93 ± 0.79
35.70 ± 2.15
15.63 ± 5.91
18.43 ± 6.42
23.89 ± 1.84
62.48 ± 0.20
77.25 ± 0.23
77.70 ± 1.63
78.40 ± 0.55
78.33 ± 3.38
63.26 ± 1.34
68.26 ± 2.24
86.66 ± 0.34
74.18 ± 1.66
24.91 ± 4.01
23.26 ± 1.72
16.40 ± 0.14
21.57 ± 2.08
74.91 ± 2.69
77.17 ± 1.30
80.24 ± 1.60
55.67 ± 3.50
<0.001

Protein
9.45 ± 0.05
10.49 ± 0.07
7.08 ± 0.35
10.34 ± 0.82
10.45 ± 0.75
8.76 ± 0.16
1.86 ± 0.02
15.48 ± 0.28
5.55 ± 0.38
7.04 ± 0.23
5.37 ± 0.58
11.55 ± 0.86
6.96 ± 1.56
2.24 ± 0.04
5.89 ± 0.89
5.38 ± 0.87
7.29 ± 0.28
5.81 ± 0.04
6.72 ± 0.20
0.80 ± 1.09
0.99 ± 0.05
1.23 ± 0.97
2.40 ± 0.26
<0.001

Fat
1.15 ± 0.04
0.46 ± 0.01
9.07 ± 0.83
4.24 ± 1.00
12.69 ± 2.13
7.71 ± 0.90
0.57 ± 0.01
0.66 ± 0.17
2.43 ± 0.84
2.13 ± 0.08
1.54 ± 0.81
3.28 ± 0.42
1.98 ± 0.29
0.88 ± 0.10
2.16 ± 1.24
10.54 ± 1.60
22.80 ± 2.09
9.54 ± 0.09
30.32 ± 1.91
0.53 ± 0.17
0.04 ± 0.05
1.84 ± 1.31
1.72 ± 0.58
<0.001

Ash
0.68 ± 0.04
1.88 ± 0.02
1.07 ± 0.07
1.59 ± 0.27
1.69 ± 0.27
1.07 ± 0.21
0.55 ± 0.06
1.17 ± 0.18
1.01 ± 0.17
0.31 ± 0.01
1.01 ± 0.23
1.26 ± 0.12
1.20 ± 0.12
0.11 ± 0.01
1.20 ± 0.26
0.32 ± 0.08
1.02 ± 0.10
1.14 ± 0.07
0.60 ± 0.10
0.04 ± 0.01
0.05 ± 0.01
0.48 ± 0.05
0.12 ± 0.04
<0.001

Fiber
0.13 ± 0.01
1.23 ± 0.14
1.20 ± 0.77
0.54 ± 0.03
1.81 ± 0.31
4.11 ± 0.73
2.91 ± 0.05
0.12 ± 0.10
5.56 ± 0.86
1.26 ± 0.19
1.02 ± 0.36
0.96 ± 0.45
3.60 ± 0.56
0.26 ± 0.01
0.56 ± 0.13
2.72 ± 0.41
1.45 ± 0.34
6.12 ± 0.44
1.16 ± 0.28
0.30 ± 0.11
0.67 ± 0.34
0.25 ± 0.06
12.20 ± 1.31
<0.001

CHO
63.61 ± 0.38
65.25 ± 0.73
47.08 ± 1.51
68.20 ± 4.78
56.74 ± 3.42
58.56 ± 2.80
34.54 ± 0.24
5.44 ± 0.49
13.30 ± 0.92
12.12 ± 0.34
13.75 ± 2.50
20.65 ± 1.06
21.60 ± 0.45
10.11 ± 0.46
16.57 ± 0.47
58.85 ± 4.56
45.63 ± 1.12
67.11 ± 0.03
40.79 ± 0.77
23.73 ± 3.56
21.75 ± 1.25
16.21 ± 1.22
40.09 ± 3.19
<0.001

Energy (Kcal)
303 ± 1.14
307 ± 3.25
298 ± 11.54
352 ± 26.53
383 ± 35.07
339 ± 5.80
151 ± 0.95
90 ± 0.74
97 ± 10.83
96 ± 2.56
90 ± 16.37
158 ± 3.72
132 ± 10.11
57 ± 0.95
109 ± 12.93
352 ± 16.12
417 ± 16.87
378 ± 0.89
463 ± 18.05
103 ± 11.56
91 ± 5.27
86 ± 12.70
185 ± 15.89
<0.001

Data are expressed as g/100g on a fresh weight basis, (mean ± SD) *P < 0.05.
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5.2.2 Minerals Analysis
Major minerals and trace metals (Ca, K, Na, Mg, P, Cu, Fe, Mn, and Zn) were
simultaneously determined in locally-consumed Emirati foods by Inductively Coupled
Plasma Optical Emission Spectrometer (ICP-OES), as previously described in section
3.3.5.5. The results of major mineral content and trace metal content in the fresh weight
basis are presented in Table 5.2 and Table 5.3, respectively.
The calcium content was the highest in Chami (432.971mg/100 g) and the
lowest in Sago (18.049mg/100g). Chami is a type of cottage cheese, which explains
the high calcium content. Calcium value in Sago was also reported low by ElObeid et.
al. (2015) [352] (13.91mg/100g) and Musaiger (2011)[351] (18mg/100g). Breads had
relatively low calcium values, ranging from 26.345mg/100g in Qurus to
59.395mg/100g in Chebab bread. Chebab and Khameer breads had higher calcium
contents when compared to other breads (59.395 and 47.831 mg/100g, respectively),
due to the presence of milk powder in their ingredients list. Ali et. al.(2013) reported
that the mean calcium intakes among Emirati children (6-10 years) and adolescents
(11-18 years) were much lower than the estimated average requirement (EAR) values
[353]. Consequently, low calcium intake could decrease the level of serum calcium,
triggering the secretion of the parathyroid hormone, which partially results in bone
resorption leading to a reduction in bone mass and osteoporosis [354]. Several studies
showed the association between adequate intakes of calcium and vitamin D, and
decreased risk of osteoporosis [354, 355]. Thus, dishes high in calcium like Chami are
favorable especially for children and women.
The phosphorus content was high in all main dishes, because they all contained
beef, chicken or fish meat. Thareed (beef) had the highest phosphorus content
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(374.353mg/100g) among main dishes, followed by Harees (beef) (374.353mg/100g),
and Thareed chicken (287.484mg/100g). The phosphorus content was the highest in
Chami (761.187mg/100g) as it is a milk product. Moreover, it was very similar among
different breads, as it ranged from 120.03mg/100g in Arabic bread to 148.839mg/100g
in Khameer bread. This study found 120.03mg/100g of phosphorus in Arabic bread,
and 156.958mg/100g in Regag bread. However, Musaiger (2011) [351] reported
100mg/100g of phosphorus in Arabic bread, and 231mg/100g in Regag bread.
Conversely, Habib et. al. (2011)[175] reported 158.65mg/100g of phosphorus in
Regag bread.
Healthy individuals have tightly regulated serum phosphorus levels, however,
several studies proposed that high intakes of phosphorus could be associated with an
increased risk of cardiovascular disease [356-358]. Moreover, high phosphorus intake
with low calcium intake could have negative impact on calcium metabolism, poor bone
density and development of osteoporosis [356, 358].
The highest sodium content was found in these main dishes: Arseyah
(1569.877mg/100g),

Thareed

chicken

(1413.947mg/100g),

thareed

(beef)

(1320.167mg/100g), and Harees (beef) (1015.980mg/100g). Varied values of sodium
were observed in the breads, ranging from 12.910mg/100g in Khameer bread to
355.100mg/100g in Regag bread. ElObeid et. al. [352] reported a sodium content of
707.40mg/100g in Regag bread, whereas Habib et. al. [175] found 574.21mg/100g of
sodium in Regag bread. This variation might be due to different amounts of salt added
to the bread dough during the preparation process. The lowest content of sodium was
in Batheetha, with only 5.440mg/100g.
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Most dishes containing meat and Regag bread presented in this study had very
high sodium levels. Consuming a high-sodium diet was found associated with an
increased risk of cardiovascular disease (CVD), hypertension, stroke, chronic kidney
disease (CKD), heart failure, and stomach cancer [359]. The prevalence of CVD in the
Middle East is increasing and becoming a major health problem [360]. According to
the 2008 Emirati CVD risk assessment study, 28.4% of Emirati adults had a
Framingham risk assessment score (a risk assessment tool for estimating a person's
ten-year risk of developing CVD [361]) of more than 20%, and 20.8% of the studied
population were found to be hypertensive [362]. Therefore, it is highly important to
take serious steps nationally towards reducing the sodium intake in diets in order to
lessen the risk of developing CVD, hypertension, and other associated complications.
The potassium content was high in main dishes like Thareed (beef) (670.667
mg/100g), Marqoqa (657.492 mg/100g), and Thareed (chicken) (610.488mg/100g).
However, it was the highest in Fendal (1123.920mg/100g), which is expected as it is
boiled sweet potato. Khameer bread had the highest content of potassium
(215.488mg/100g) among breads, whereas other breads had very similar values,
ranging from 100.256mg/100g in Arabic bread to 127.629mg/100g in Muhalla bread.
Regag bread had potassium content of 128.672mg/100g. However, Habib et. al.
(2011)[175] reported a higher potassium value in Regag bread (171.53mg/100g). The
lowest potassium content was in Sago (5.816mg/100g); ElObeid et. al. (2015) [352]
found 18.03mg/100g of potassium in Sago. The use of Sago planted in potassium
depleted soil and the use of different cooking methods between countries could be the
reason behind such variations.
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Reducing sodium intake accompanied by increasing dietary potassium intake
(low-sodium/high-potassium diet) could play an essential role in preventing and
treating kidney disease, hypertension, stroke, and CVD [363, 364].
The highest magnesium content was found in Fendal (122.697mg/100g) and
the lowest was in Sago (13.697mg/100g). Arabic bread, Biryani chicken, Arseyah,
Legemat, Asida and Balaleet had similar magnesium concentrations (36.361, 32.286,
37.206, 33.608, 33.475, and 33.733 mg/100g, respectively). The results of this study
were not in agreement with ElObeid et. al. (2015)[352], who reported the magnesium
content of Asida, Thareed (beef), and Sago to be 71.67, 57.97 and 2.42mg/100g
respectively. Additionally, Habib et. al. (2011) reported lower magnesium content in
Regag bread, Qurus, Legemat, and Balalet 51.420, 34.2, 22.93, and 9.42 mg/100g,
respectively. Furthermore, Al Nagdy et. al. [273], found 44 mg/100g of magnesium in
Asida. Musaiger et. al. (1998) [172] found only 5.9 mg/100g of magnesium in the
Omani Asida. While, Musaiger (2011) [351] reported 32 mg/100g of magnesium in
the Bahraini Asida. Such differences could occur due to the use of different recipes in
different gulf countries, as well as the use of fortified wheat flour in some countries.
Low serum magnesium level (hypomagnesemia) is associated with metabolic
syndrome (MetS) [365, 366], T2DM [367, 368] and hypertension [369]. Accordingly,
increasing magnesium intake could prevent high blood pressure [370] and improves
the glycemic status of adults with prediabetes and hypomagnesaemia [371]. Moreover,
higher serum magnesium levels were found associated with lower risk of MetS [366,
372]. Thus, consuming high magnesium foods like Fendal is recommended for the
Emirati population.
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The iron content was higher among breads compared to other dishes. It ranged
from 9.61mg/100g in Regag bread to 3.11mg/100g in Qurus. ElObeid et. al. (2015)
[352] found 7.36 mg/100g of iron in Kuwaiti Regag bread. However, Musaiger (2011)
[351] found 1.8mg/100g of iron only in Bahraini Regag bread. This difference could
be a result of using fortified wheat flour, or due to the use of date paste as an ingredient
for the production of Rgag bread in some countries.
Moreover, among main dishes, Margooga and Thareed (beef) had the highest
iron content (5.673mg/100g and 5.263mg/100g), followed by Thareed chicken
(4.306mg/100g). Low iron content was found in Sago, Khabisa and Arseyah
(0.518mg/100g, 0.599 mg/100g, and 0.711 mg/100g, respectively).
Aiming for high iron food sources (like Regag, Chebab, Muhalla, and Khameer
bread) as part of the daily diet is recommended to reduce the risk of iron deficiency
(anemia). Iron deficiency is considered one of the major public health problems in the
Arab Gulf countries. Musaiger (2002) conducted a study in the Arab gulf countries
and stated that iron deficiency prevalence among preschoolers ranged from 20% to
67%, and ranged from 12.6% to 50% among school age children. Moreover, the
percentage of pregnant women with anemia ranged from 22.7% to 54%. In the UAE,
the overall prevalence of anemia (Hb <12g/dL) among female college students
attending the University of Sharjah was 26.7% [373]. Moreover, the prevalence of
anemia, iron depletion and iron deficiency among Emirati preschoolers were estimated
to be 36.1%, 26%, and 9.9%, respectively [374].
The highest zinc content was found in Thareed (beef) and Thareed (chicken)
(4.690mg/100g and 4.870mg/100g), while Sago and Khabisa (0.119mg/100g and
0.378mg/100g) had the lowest concentrations of zinc. Breads had very similar zinc
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contents, ranging from 1.033mg/100g in Arabic bread to 1.760mg/100g in Regag
bread. Lower zinc content was reported by Habib et. al. (2011) [175] in Harees, Regag,
Qurus, Legemat, and balaleet (0.630, 1.00, 0.77, 0.8, and 0.5mg/100g, respectively).
A zinc rich diet is recommended to avoid zinc deficiency and related developmental
abnormalities [375].
Lastly, the copper and manganese concentration was very low in all foods.
Batheetha had the highest copper content (2.252mg/100g) because its main ingredient
is date fruit, and Harees (beef) had the highest manganese value (1.697mg/100g) due
to its whole-wheat content.

Table 5.2: Micronutrient (Major Elements) Composition of United Arab Emirates Traditional Dishes
Test Food
Arabic Bread
Regag Bread
Chebab Bread
Muhalla Bread
Khameer Bread
Qurus
Fendal
Chami
Harees, beef
Thareed, beef
Thareed, chicken
Biryani, chicken
Machbous, fish
Arseyah
Marqoqa
Khabisa
Legemat
Batheetha
Khanfaroosh
Sago
Asida
Habba Hamra
Balaleet

Ca
23.128 ± 0.258
31.526 ± 0.296
59.395 ± 0.255
31.413 ± 0.294
47.831 ± 0.447
26.345 ± 0.335
92.019 ± 0.153
432.971 ± 3.000
307.293 ± 4.636
164.897 ± 0.714
73.908 ± 0.246
87.003 ± 0.758
94.765 ± 0.352
123.126 ± 0.422
67.646 ± 0.391
24.154 ± 0.266
37.515 ± 0.055
63.539 ± 0.346
24.135 ± 0.482
18.049 ± 0.102
37.980 ± 0.155
235.230 ± 1.256
29.176 ± 0.070

P
120.030 ± 0.878
156.958 ± 0.030
143.556 ± 0.609
125.495 ± 0.309
148.839 ± 0.571
145.118 ± 0.842
250.605 ± 0.093
761.187 ± 3.291
322.488 ± 4.038
374.353 ± 0.616
287.484 ± 0.958
241.033 ± 0.313
251.137 ± 0.330
186.523 ± 0.649
218.739 ± 0.924
56.100 ± 0.993
124.039 ± 0.937
116.993 ± 0.826
103.445 ± 0.274
2.998 ± 0.112
105.896 ± 0.474
159.128 ± 1.071
116.748 ± 0.248

Na
163.866 ± 1.190
355.100 ± 1.618
29.516 ± 0.304
258.910 ± 1.532
12.910 ± 0.147
343.263 ± 4.430
185.567 ± 1.276
661.612 ± 8.737
1015.980 ± 1.365
1320.167 ± 3.758
1413.947 ± 5.294
711.897 ± 7.661
818.807 ± 1.688
1569.877 ± 10.597
1513.897 ± 9.729
143.485 ± 2.912
26.431 ± 0.204
5.440 ± 0.035
55.498 ± 1.397
141.127 ± 1.332
161.374 ± 1.285
100.352 ± 0.693
120.472 ± 0.665

K
100.256 ± 0.831
128.672 ± 0.563
133.194 ± 0.046
127.629 ± 0.552
215.488 ± 0.531
104.193 ± 0.837
1123.920 ± 0.065
363.357 ± 3.126
229.026 ± 4.631
670.667 ± 0.770
610.488 ± 0.468
241.940 ± 0.047
338.951 ± 0.527
154.863 ± 0.741
657.492 ± 0.790
65.303 ± 0.118
113.173 ± 0.768
416.591 ± 0.625
61.774 ± 0.971
5.816 ± 0.097
99.773 ± 0.459
196.556 ± 1.186
76.901 ± 0.622

Mg
36.361 ± 0.366
54.819 ± 0.121
48.594 ± 0.483
44.236 ± 0.334
61.460 ± 0.749
50.187 ± 0.538
122.697 ± 0.265
44.450 ± 3.263
67.878 ± 4.700
91.784 ± 0.462
76.364 ± 0.219
32.286 ± 0.137
45.076 ± 0.666
37.206 ± 0.355
62.527 ± 0.274
17.403 ± 0.196
33.608 ± 0.421
65.605 ± 0.190
24.332 ± 0.003
13.697 ± 0.061
33.475 ± 0.474
66.875 ± 1.610
33.733 ± 0.129

Data are expressed as mg/100 g on a fresh weight basis, (mean ± SD)
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Table 5.3: Micronutrient (Trace Elements) Composition of United Arab Emirates
Traditional Dishes
Test Food
Arabic Bread
Regag bread
Chebab Bread
Muhalla Bread
Khameer
Qurus
Fendal
Chammi
Harees, beef
Thareed, beef
Thareed, chicken
Biryani, chicken
Machbous, fish
Arseyah
Marqooqa
Khabisa
Legemat
Batheetha
Khanfaroosh
Sago
Asida
Habba Hamra
Balaleet

Fe
4.815 ± 0.072
9.613 ± 0.041
8.479 ± 0.036
8.238 ± 0.060
8.212 ± 0.074
3.111 ± 0.026
2.399 ± 0.010
0.798 ± 0.008
2.142 ± 0.027
5.263 ± 0.021
4.306 ± 0.023
1.253 ± 0.011
1.742 ± 0.018
0.711 ± 0.009
5.673 ± 0.021
0.599 ± 0.006
3.019 ± 0.024
6.311 ± 0.083
3.138 ± 0.052
0.518 ± 0.002
3.544 ± 0.043
4.781 ± 0.027
2.651 ± 0.011

Zn
1.033 ± 0.049
1.760 ± 0.024
1.462 ± 0.041
1.343 ± 0.063
1.423 ± 0.028
1.401 ± 0.055
0.765 ± 0.037
2.184 ± 0.037
1.841 ± 0.019
4.690 ± 0.040
4.870 ± 0.067
1.920 ± 0.043
1.338 ± 0.038
1.777 ± 0.062
2.077 ± 0.038
0.378 ± 0.039
0.965 ± 0.024
1.090 ± 0.033
0.996 ± 0.013
0.119 ± 0.014
1.004 ± 0.011
1.434 ± 0.038
1.134 ± 0.020

Cu
0.206 ± 0.009
0.302 ± 0.001
0.241 ± 0.005
0.245 ± 0.010
0.306 ± 0.005
0.244 ± 0.002
0.462 ± 0.008
0.093 ± 0.009
0.279 ± 0.005
0.311 ± 0.004
0.320 ± 0.008
0.215 ± 0.006
0.211 ± 0.002
0.189 ± 0.009
0.246 ± 0.004
0.127 ± 0.004
0.161 ± 0.006
2.252 ± 0.029
0.170 ± 0.005
0.021 ± 0.009
0.180 ± 0.003
0.079 ± 0.003
0.297 ± 0.004

Data are expressed as mg/100 g on a fresh weight basis, (mean ± SD).

Mn
0.718 ± 0.003
1.581 ± 0.003
1.526 ± 0.003
1.221 ± 0.003
1.335 ± 0.003
1.133 ± 0.003
0.632 ± 0.003
0.024 ± 0.003
1.697 ± 0.003
1.558 ± 0.003
1.195 ± 0.003
0.447 ± 0.003
0.789 ± 0.003
0.489 ± 0.003
0.666 ± 0.003
0.501 ± 0.003
0.721 ± 0.003
1.029 ± 0.003
0.706 ± 0.003
0.095 ± 0.003
0.940 ± 0.003
0.307 ± 0.003
0.744 ± 0.003
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5.2.3 Vitamins Analysis
Seven water-soluble and all fat-soluble vitamins (Vitamin C, Thiamin,
Riboflavin, Niacin, Vitamin B-6, Folate, Vitamin B-12, Vitamin A, Vitamin E (alphatocopherol), Vitamin D (D2 + D3), and Vitamin K (phylloquinone)) were
simultaneously found in foods using the High-Performance Liquid Chromatography
(HPLC) method, as described earlier in section 3.3.5.8. Data on the analysis of watersoluble and fat-soluble vitamins per 100g of fresh weight is presented in Table 5.4,
and Table 5.5 respectively.
Vitamin C (total ascorbic acid) content was the highest in Biryani chicken
(631.01mg/100g) and Arseyah (624.86mg/100g). However, no vitamin C was found
in Arabic bread, Regag bread, Gurus and Asida. Musaiger (2011) [351] reported
similar results for Arabic bread (0 mg/100g), and traces of vitamin C in Asida
(0.6mg/100g). Breads usually do not contain vitamin C, yet Chebab bread, Khameer
bread and Muhallah bread were found to have 247.82mg/100g, 245.71mg/100g, and
362.51mg/100g of vitamin C respectively, due to their milk content.
The concentration of thiamin in breads ranged from 1.40mg/100g in Regag
bread to 7.83mg/100g in Gurus. This study reported 3.94 mg/100g of thiamin in Arabic
bread, whereas lower thiamin content was found in Bahraini Arabic bread
(0.1mg/100g) [351]. These differences could result from the use of fortified wheat
flour in some recipes. Moreover, thiamin was found to be the highest in Sago
(13.98mg/100g), and no thiamin was found in Fendal, Thareed (beef), Thareed
(chicken) and Marqooqa.
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As expected, dishes containing meat had relatively higher riboflavin content:
Thareed (beef) (183.14mg/100g), Biryani chicken (76.51mg/100g), Margooga
(64.20mg/100g), and Harees (beef) (56.89mg/100g). Whereas, Arabic bread, Regag
bread, Muhallah bread, Khameer bread, Gurus, Chami, Khabisa, Batheetha,
Khanfaroosh, Sago, Asida, and Balaleet did not contain riboflavin.
High niacin content was found in Thareed chicken (13.73mg/100g), Fendal
(11.89 mg/100g) and Thareed (beef) (9.86mg/100g). However, no niacin was present
in Khameer bread, Gurus, Chami, Biryani chickin, Machbous fish, Khabisa,
Batheetha, Khanfaroosh, and Sago. The results of this study were not in agreement
with Musaiger (2011) [351], who reported the niacin content of Asida, Batheetha,
Harees, Khabisah, Khanfaroosh, Marqoqa, and Sago to be 1.2, 6.5, 1.9, 1.2, 1.0, 0.3
and 0.3 mg/100g respectively. The use of different ingredients and cooking methods
could account for these differences between studies.
The highest concentration of vitamin B-6 was found in Batheetha
(8.49mg/100g), followed by Thareed (beef) (5.70mg/100g) and Biryani chicken
(4.06mg/100g). Vitamin B-6 was not present in Regag bread, Khameer bread,
Khanfaroosh, Habba Hamra and Sago.
Habba Hamra, a red seed added in milk drink had the highest folic acid content
(188.07mg/100g), followed by Thareed (beef) (13.59mg/100g) and Thareed Chicken
(9.70mg/100g). Folate content was low in all breads, ranging from zero in Arabic and
Regag bread, to 0.97mg/100g in Qurus. The results of this study were not in agreement
with Musaiger (2011) [351], who reported much higher folic acid content in Thareed
(26.7mg/100g). This could be due to the national flour fortification program adopted
by the Kingdom of Bahrain in collaboration with the World Health Organization
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(WHO) in 2001 to control and prevent anemia by fortifying flour with iron and folic
acid [376].
All foods included in this study did not contain vitamin B-12 or vitamin A
except for Habba Hamra, which had 0.64mg/100g of vitamin B-12, due to its milk
content. Likewise, in Bahrain, B-12 was not present in Sago, Kabisah, Marqoqa, or
batheetha [351]. Vitamin E concentration was the highest in Fendal (1.79mg/100g).
However,

Arabic

bread

(0.03mg/100g),

Sago

(0.05mg/100g)

and

Chami

(0.08mg/100g) had the lowest vitamin E content. On the other hand, Bahraini Sago did
not have vitamin E (0mg/100g), and Bahraini Asida, Marqoqa, and khanfaroosh had
slightly higher vitamin E content as compared to values reported in this study (0.7, 0.7,
and 1.6 mg/100g vs. 0.31, 0.51, and 0.27 mg/100g, respectively) [351].
Some traditional foods did not contain vitamin D, such as Thareed (beef),
Thareed (chicken), Gurus, Arseya, Marqoqa, Khabisa, Sago, and Asida. Similarly,
Musaiger (2011) [351] reported 0 mg/100g of vitamin D in Sago and Marqoqa.
Vitamin K was also low in all tested foods. It ranged from 0.01mg/100g in Margooga
and Habba Hamra, to 0.11mg/100g in Thareed (beef) and Biryani (chicken).
The duration, temperature of cooking, food recipe composition, and storage
conditions are all factors that substantially influence the stability and status of vitamins
in foods [377]. The major micronutrient deficiencies reported in the UAE are iron
deficiency anemia [373, 374] and vitamin D deficiency [378, 379]. Programs aiming
to prevent and control these deficiencies could include: nutrition education;
fortification of drinks with vitamin D [380]; flour fortification with iron and folic acid
[376]; vitamin D and iron supplementation [381, 382]; and sensible sun exposure.

Table 5.4:Water-Soluble Vitamin Composition of United Arab Emirates Traditional Dishes
Test Food
Arabic bread
Regag bread
Chebab bread
Muhalla Bread
Khameer Bread
Gurus
Fendal
Chami
Harees, beef
Thareed, beef
Thareed, chicken
Biryani, chicken
Machbous, fish
Arseyah
Marqoqa
Khabisa
Leqemat
Batheetha
Khanfaroosh
Sago
Asida
Habba Hamra
Balalet

Vitamin C
0.00
0.00
247.82 ± 0.06
245.71 ± 0.53
362.51 ± 6.22
0.00
351.28 ± 7.95
121.77 ± 1.68
591.50 ± 17.54
453.91 ± 9.52
636.92 ± 1.84
631.01 ± 26.81
583.00 ± 0.18
624.86 ± 11.49
581.81 ± 26.16
339.24 ± 1.95
322.43 ± 2.91
244.09 ± 6.49
200.69 ± 8.33
133.34 ± 6.27
0.00
252.23 ± 21.24
289.65 ± 3.67

Thiamin
3.94 ± 0.10
1.40 ± 0.16
3.46 ± 0.03
2.04 ± 0.24
1.50 ± 0.02
7.83 ± 0.10
0.00
0.33 ± 0.02
2.12 ± 0.42
0.00
0.00
2.07 ± 0.56
2.02 ± 0.11
2.56 ± 0.31
0.00
3.99 ± 0.08
1.80 ± 0.14
4.30 ± 0.26
1.17 ± 0.22
13.98 ± 1.21
5.10 ± 0.27
8.52 ± 0.92
1.22 ± 0.07

Riboflavin
0.00
0.00
28.21 ± 0.68
0.00
0.00
0.00
121.53 ± 0.34
0.00
56.89 ± 3.54
183.14 ± 4.55
81.77 ± 6.60
76.51 ± 1.98
30.83 ± 1.11
36.90 ± 1.15
64.20 ± 1.09
0.00
15.65 ± 0.40
0.00
0.00
0.00
0.00
28.69 ± 1.41
0.00

Niacin
0.31 ± 0.06
0.11 ± 0.05
0.35 ± 0.06
0.31 ± 0.01
0.00
0.00
11.89 ± 1.62
0.00
0.38 ± 0.04
9.86 ± 0.53
13.73 ± 1.48
0.00
0.00
3.12 ± 1.15
4.23 ± 1.89
0.00
0.71 ± 0.08
0.00
0.00
0.00
0.11 ± 0.04
0.01 ± 0.01
1.17 ± 0.15

Vitamin B-6
0.73 ± 0.05
0.00
0.46 ± 0.28
2.27 ± 0.03
0.00
0.98 ± 0.03
1.55 ± 0.16
1.01 ± 0.72
2.63 ± 0.06
5.70 ± 0.44
2.67 ± 0.47
4.06 ± 0.17
1.92 ± 1.53
2.60 ± 0.00
1.11 ± 0.19
1.28 ± 0.17
0.74 ± 0.23
8.49 ± 2.17
0.00
0.00
0.54 ± 0.11
0.00
1.79 ± 0.37

Folate
0.00
0.00
0.63 ± 0.10
0.49 ± 0.20
0.67 ± 6.02
0.97 ± 0.06
5.28 ± 7.05
0.25 ± 1.05
0.25 ± 17.03
13.59 ± 9.45
9.70 ± 1.56
2.14 ± 26.29
0.13 ± 0.01
1.07 ± 11.08
0.81 ± 26.09
2.08 ± 1.12
0.15 ± 2.02
0.58 ± 6.00
2.41 ± 8.07
0.13 ± 6.00
1.38 ± 0.00
188.07 ± 21.84
0.82 ± 3.04

Vitamin B-12
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.64 ± 0.05
0.00

Data are expressed as mg/100 g on a fresh weight basis, (mean ± SD)
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Table 5.5: Fat-Soluble Vitamin Composition of United Arab Emirates Traditional
Dishes
Food
Arabic bread
Regag bread
Chebab bread
Muhalla Bread
Khameer Bread
Gurus
Fendal
Chami
Harees, beef
Thareed, beef
Thareed, chicken
Biryani, chicken
Machbous, fish
Arseyah
Marqoqa
Khabisa
Leqemat
Batheetha
Khanfaroosh
Sago
Asida
Habba Hamra
Balalet

Vitamin A
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Vitamin E
0.03 ± 0.00
0.17 ± 0.00
0.16 ± 0.00
0.26 ± 0.00
0.67 ± 0.00
0.41 ± 0.00
1.79 ± 0.00
0.08 ± 0.00
0.09 ± 0.00
0.79 ± 0.00
0.77 ± 0.00
0.54 ± 0.12
0.44 ± 0.00
0.06 ± 0.00
0.51 ± 0.00
0.20 ± 0.00
0.11 ± 0.00
0.50 ± 0.00
0.27 ± 0.00
0.05 ± 0.00
0.31 ± 0.00
0.13 ± 0.00
0.11 ± 0.00

Vitamin D
0.04 ± 0.00
0.04 ± 0.00
0.03 ± 0.00
0.03 ± 0.00
0.01 ± 0.00
0.00
0.02 ± 0.00
0.01 ± 0.00
0.07 ± 0.01
0.00
0.00
0.04 ± 0.00
0.02 ± 0.00
0.00
0.00
0.00
0.06 ± 0.00
0.02 ± 0.00
0.02 ± 0.00
0.00
0.00
0.01 ± 0.00
0.10 ± 0.03

Data are expressed as mg/100 g on a fresh weight basis, (mean ± SD).

Vitamin K
0.04 ± 0.00
0.02 ± 0.00
0.03 ± 0.00
0.03 ± 0.00
0.08 ± 0.00
0.08 ± 0.00
0.04 ± 0.00
0.02 ± 0.00
0.04 ± 0.00
0.11 ± 0.00
0.02 ± 0.00
0.11 ± 0.12
0.01 ± 0.00
0.02 ± 0.00
0.01 ± 0.00
0.04 ± 0.00
0.04 ± 0.00
0.04 ± 0.00
0.05 ± 0.00
0.00
0.06 ± 0.00
0.01 ± 0.00
0.06 ± 0.00
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5.2.4 Lipids Analysis
Lipid analysis, including fatty acids and cholesterol, were found in Emirati
foods using the Gas Chromatograph (GC) and High-Performance Liquid
Chromatography (HPLC) respectively, as previously described in section 3.3.5.7. Data
on the analysis of fatty acids (saturated, monounsaturated, polyunsaturated, and trans
fatty acids) and cholesterol is presented in Table 5.6.
Khanfaroosh and Legemat had the highest content of saturated fatty acids
(13.520g/100g and 9.586g/100g, respectively). This could be a result of the deepfrying preparation method used in these sweet dishes. Among breads, Chebab bread
had the highest saturated fatty acids content (6.178g/100g) followed by Khameer bread
(5.633g/100g), and Gurus (4.373g/100g). Excessive dietary fat consumption,
especially saturated fat, has been linked to an increase in many health risks such as
obesity, coronary heart disease (CHD), and certain types of cancer [383]. The 2015
USDA’s dietary guidelines recommends limiting intake of saturated fats to less than
10% of energy intake, to acquire optimal cardiovascular health [384]. Moreover, the
WHO dietary guidelines for the Eastern Mediterranean Region (2012) recommends
reducing saturated fats and trans fats to <10% and < 1% of total energy intake,
respectively, and replacing both types of fat with unsaturated fats [385].
Monounsaturated fatty acid content ranged from 0g/100g in Asida and Regag
bread to 4.202g/100g in Legemat. Whereas, polyunsaturated fatty acids content ranged
from 0.018g/100g in Asida to 15.99g/100g in Khanfaroosh. The USDA and the WHO
emphasize on replacing saturated fatty acids - usually found in red meat, processed
meats, and fried foods - with healthier monounsaturated and polyunsaturated fatty
acid-rich foods, including fatty fish (salmon, tuna, and sardines) and nuts. These
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should be combined with healthy sources of carbohydrates (fiber-rich whole-grain
sources), and adequate consumption of fruits and vegetables [384, 385].
Most foods studied did not contain trans fatty acids such as Regag bread,
Chebab bread, Muhallah bread, Khameer bread, Harees (beef), and Thareed (beef).
However, Khabisa contained the highest trans fatty acids content (1.731g/100g).
Observational studies and controlled trials provide evidence that trans fatty acid intake
from partially hydrogenated oils adversely affects several cardiovascular risk factors
and contributes significantly to increased risk of CHD events [386].
Cholesterol content ranged from 1.10mg/100g in Regag bread and Legemat, to
27.25mg/100g in Thareed chicken. Among breads, Khameer had the highest
cholesterol content (9.70mg/100g), followed by Chebab bread (6.25mg/100g) and
Muhallah bread (4.60mg/100g). These breads contain eggs, and according to Schärer
and Schulthess [387], egg yolk has the highest content of cholesterol detected in
different kinds of food.

Table 5.6: Lipid profile of United Arab Emirates Traditional Dishes
Test Food
Arabic bread
Regag bread
Chebab bread
Muhalla Bread
Khameer Bread
Gurus
Fendal
Chami
Harees, beef
Thareed, beef
Thareed, chicken
Biryani, chicken
Machbous, fish
Arseyah
Marqoqa
Khabisa
Leqemat
Batheetha
Khanfaroosh
Sago
Asida
Habba Hamra
Balalet

Fatty acids, total
saturated (g)
0.574 ± 0.130
0.116 ± 0.014
6.178 ± 0.085
2.741 ± 0.264
5.633 ± 0.187
4.373 ± 0.352
0.322 ± 0.013
0.395 ± 0.013
0.856 ± 0.011
0.826 ± 0.022
0.656 ± 0.005
1.797 ± 0.326
0.861 ± 0.003
0.234 ± 0.007
0.840 ± 0.008
3.226 ± 0.178
9.586 ± 0.439
3.758 ± 0.022
13.520 ± 0.021
0.338 ± 0.036
0.020 ± 0.000
0.538 ± 0.029
0.739 ± 0.008

Fatty acids, total
monounsaturated (g)
0.027 ± 0.013
0.000 ± 0.000
0.199 ± 0.029
0.147 ± 0.074
0.401 ± 0.152
0.095 ± 0.049
0.010 ± 0.009
0.010 ± 0.002
0.066 ± 0.002
0.052 ± 0.012
0.043 ± 0.001
0.097 ± 0.029
0.062 ± 0.003
0.119 ± 0.016
0.054 ± 0.001
1.640 ± 0.049
4.202 ± 0.131
0.093 ± 0.005
0.178 ± 0.007
0.005 ± 0.003
0.000 ± 0.000
0.170 ± 0.018
0.00

Fatty acids,
polyunsaturated (g)
0.536 ± 0.143
0.316 ± 0.021
2.693 ± 0.114
1.352 ± 0.189
6.656 ± 0.035
3.197 ± 0.238
0.222 ± 0.009
0.225 ± 0.027
1.415 ± 0.019
1.169 ± 0.011
0.744 ± 0.006
1.365 ± 0.268
1.042 ± 0.016
0.365 ± 0.013
1.170 ± 0.006
3.795 ± 0.033
7.989 ± 0.154
5.052 ± 0.030
15.990 ± 0.095
0.147 ± 0.018
0.018 ± 0.001
1.127 ± 0.054
0.913 ± 0.008

Trans Fatty acids (g)

Cholesterol (mg)

0.013 ± 0.000
0.00
0.00
0.00
0.00
0.046 ± 0.065
0.016 ± 0.004
0.030 ± 0.042
0.00
0.00
0.008 ± 0.011
0.021 ± 0.029
0.015 ± 0.022
0.129 ± 0.008
0.00
1.731 ± 0.111
0.00
0.157 ± 0.047
0.725 ± 0.021
0.041 ± 0.057
0.00
0.005 ± 0.007
0.019 ± 0.001

1.40 ± 0.14
1.10 ± 0.00
6.25 ± 0.07
4.60 ± 0.00
9.70 ± 0.00
1.70 ± 0.14
1.60 ± 0.00
6.40 ± 0.00
11.60 ± 0.00
15.75 ± 0.07
27.25 ± 0.07
26.25 ± 0.07
14.15 ± 0.07
14.05 ± 0.07
22.30 ± 0.14
1.15 ± 0.07
1.10 ± 0.00
6.55 ± 0.49
3.50 ± 0.28
2.95 ± 0.07
1.30 ± 0.00
5.85 ± 0.07
1.90 ± 0.00

Data are expressed (Unit/100g) on a fresh weight basis, (mean ± SD).
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5.2.5 Sugars Analysis
Various types of sugars including monosaccharides (glucose, and fructose),
disaccharides (sucrose, maltose, and lactose), and trisaccharide (raffinose) were found
in foods using the High-Performance Liquid Chromatography (HPLC) method, as
previously described in section 3.3.5.6. Data on the analysis of sugar is presented in
Table 5.7.
Khameer and Muhalla bread had the highest content of fructose, glucose and
total sugars among breads; this might be due to sugar added during preparation or the
use of date paste. However, fructose and glucose were not present in Chami and
Marqoqa. Recent human studies suggest that high dietary fructose levels might elevate
serum triglyceride levels and cause other metabolic diseases, dyslipidemia, nonalcoholic fatty liver, obesity and weight gain [388-390].
The highest content of sucrose was found in Sago (3.046g/100g) and Gurus
(3.005g/100g), which could be explained by the high amount of sugar in the recipe.
Most foods did not contain maltose and raffinose sugars, such as Arabic bread,
Harees (beef), Marqoqa, Leqemat, Sago, and Balalet. However, Gurus contained the
highest maltose content (0.373g/100g) and Habba Hamra had the highest content of
raffinose (0.261g/100g).
Lactose content was the highest in Fendal (1.091g/100g), followed by Chami
(0.899g/100g). However, Gurus, Thareed (Chicken), Biryani (Chicken), Machbous
(Fish), Marqoqa, and Batheetha did not contain lactose.
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Total sugars ranged from 0.009g/100g in Marqoqa to 5.018g/100g in
Batheetha. Dessert dishes like Batheetha, Sago, and Habba Hamra had higher amounts
of total sugars compared to other foods.
It is important to monitor the total amount of added sugar in the diet. According
to the 2015 World Health Organization’s (WHO) guidelines on sugar intake [391],
adults and children are recommended to reduce their daily intake of added sugars to
less than 10% of their total energy intake. Welsh et al. (2011) [392] suggested that an
additional reduction to below 5% of the total energy intake might provide added health
benefits.

Table 5.7: Sugar Composition of United Arab Emirates Traditional Dishes
Test Food
Arabic bread
Regag bread
Chebab bread
Muhalla Bread
Khameer Bread
Gurus
Fendal
Chami
Harees, beef
Thareed, beef
Thareed, chicken
Biryani, chicken
Machbous, fish
Arseyah
Marqoqa
Khabisa
Leqemat
Batheetha
Khanfaroosh
Sago
Asida
Habba Hamra
Balalet

Fructose
0.387 ± 0.005
0.009 ± 0.001
1.263 ± 0.002
1.336 ± 0.001
1.685 ± 0.001
0.045 ± 0.002
0.042 ± 0.001
0.000
0.012 ± 0.002
0.017 ± 0.001
0.011 ± 0.002
0.015 ± 0.006
0.017 ± 0.002
0.000
0.000
0.094 ± 0.002
1.240 ± 0.006
1.309 ± 0.015
0.912 ± 0.007
0.294 ± 0.001
0.227 ± 0.002
0.561 ± 0.001
0.260 ± 0.004

Glucose
0.258 ± 0.008
0.017 ± 0.001
0.769 ± 0.004
1.214 ± 0.004
1.333 ± 0.006
0.040 ± 0.000
0.085 ± 0.000
0.000
0.047 ± 0.001
0.000
0.012 ± 0.001
0.007 ± 0.001
0.012 ± 0.001
0.005 ± 0.002
0.000
1.285 ± 0.005
1.168 ± 0.004
1.181 ± 0.000
0.771 ± 0.006
1.576 ± 0.004
0.847 ± 0.004
1.192 ± 0.007
1.688 ± 0.018

Sucrose
0.000
0.039 ± 0.007
0.000
0.009 ± 0.002
0.000
3.005 ± 0.003
0.139 ± 0.003
0.000
0.10 ± 0.001
0.012 ± 0.001
0.024 ± 0.001
0.024 ± 0.002
0.028 ± 0.005
0.011 ± 0.001
0.009 ± 0.000
0.086 ± 0.000
0.053 ± 0.002
2.468 ± 0.002
0.000
3.046 ± 0.015
2.621 ± 0.020
1.808 ± 0.026
0.276 ± 0.001

Maltose
0.000
0.030 ± 0.001
0.021 ± 0.008
0.014 ± 0.005
0.010 ± 0.010
0.373 ± 0.009
0.080 ± 0.008
0.010 ± 0.010
0.000
0.015 ± 0.001
0.018 ± 0.003
0.004 ± 0.004
0.005 ± 0.002
0.006 ± 0.007
0.000
0.001 ± 0.000
0.000
0.000
0.019 ± 0.001
0.000
0.040 ± 0.000
0.018 ± 0.001
0.000

Lactose
0.257 ± 0.014
0.162 ± 0.012
0.450 ± 0.019
0.302 ± 0.012
0.264 ± 0.010
0.000
1.091 ± 0.007
0.899 ± 0.059
0.297 ± 0.019
0.059 ± 0.005
0.000
0.000
0.000
0.187 ± 0.018
0.000
0.053 ± 0.000
0.396 ± 0.005
0.000
0.299 ± 0.005
0.095 ± 0.006
0.063 ± 0.011
0.397 ± 0.006
0.154 ± 0.006

Raffinose
0.000
0.000
0.000
0.022 ± 0.002
0.000
0.050 ± 0.070
0.126 ± 0.009
0.000
0.000
0.022 ± 0.014
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.060 ± 1.001
0.000
0.000
0.045 ± 0.064
0.261 ± 0.005
0.000

Total, Sugars
0.902 ± 0.027
0.257 ± 0.018
2.503 ± 0.005
2.897 ± 0.007
3.291 ± 1.006
3.512 ± 0.068
1.562 ± 0.009
0.909 ± 0.069
0.366 ± 0.022
0.124 ± 0.019
0.064 ± 0.000
0.050 ± 0.001
0.062 ± 0.006
0.208 ± 0.029
0.009 ± 0.000
1.518 ± 0.002
2.856 ± 0.000
5.018 ± 0.016
2.001 ± 0.010
5.010 ± 0.015
3.842 ± 0.027
4.237 ± 0.046
2.377 ± 0.017

Data are expressed as g/100g on a fresh weight basis, (mean ± SD).
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5.2.6 Characteristics of Study Population
One hundred and twelve normal weight, healthy female students and staff
participants were recruited from United Arab Emirates University (UAEU) to
voluntarily participate in this study, as described earlier in section 3.3.1. The physical
characteristics of the population of this study are presented as mean ± standard
deviation, in Table 5.8. The mean age of the study population was 22.8 ± 5.01 years
old, the mean weight was 58.26 ± 8.25 kg, and the mean body mass index (BMI) was
22.86 ± 3.57 kg/m2. Other physical characteristics such as waist circumference, fat
mass and fat-free mass are also reported in Table 5.8.

Table 5.8: Physical Characteristics of the Study Population
Characteristics

Mean ± SD, (n=112)

Age (years)

22.8 ± 5.01

Height (m)

1.60 ± 0.06

Weight (kg)

58.26 ± 8.25

Body Mass Index (kg/m²)

22.86 ± 3.57

Waist Circumference (cm)

74.12 ± 14.31

Fat Mass (%)

29.00 ± 5.60

Fat Mass (kg)

17.57 ± 6.27

Fat-Free Mass (%)

65.54 ± 13.47

Fat-Free Mass (kg)

44.27 ± 12.11

Fasting Plasma Glucose (mg/dL)

88.32 ± 7.82
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5.2.7 Glycemic Response
Twenty-three traditional foods commonly consumed in the United Arab
Emirates (UAE) were chosen to investigate their glycemic index and glycemic load,
according to the previously described methodology in section 3.3.6. The mean
incremental area under the glycemic response curves of the standard food and each
test food are presented in Figures A to W of Appendix 11.
The mean incremental areas under the glycemic response curves (IAUCs) for
low glycemic index traditional meals (Chebab bread, Khameer bread, Harees (beef),
Biryani (chicken), Leqemat, Khanfaroosh, and Habba Hamra) are presented in Figure
5.1. Biryani (chicken) showed the highest increase in glycemic response compared
with other low GI foods, whereas, Harees and Khanfashoosh produced a slower and
lower raise in the glycemic response over 120 minutes. Differences in glucose
response between the meals were calculated using the Kruskal-Wallis test. The
incremental increase in blood glucose at 15 min was significantly different between
Chebab bread, Khanfaroosh, and Habba Hamra (P = 0.009, median = 0.90, 0.20, and
0.80 respectively). At 30 min the incremental increase in blood glucose was
significantly different between Chebab bread, Khameer bread, Harees (beef), Biryani
(chicken), Leqemat, Khanfaroosh, and Habba Hamra (P = 0.008, median = 1.60, 0.90,
1.10, 2.00, 1.10, 0.50, and 2.10 respectively). At 45 min the significant differences in
incremental blood glucose were between Chebab bread, Harees (beef), Biryani
(chicken), Leqemat, Khanfaroosh, and Habba Hamra (P = 0.006, median = 1.10, 1.40,
2.40, 1.10, 1.20, and 1.50 respectively). At 60 min the significant differences in
incremental blood glucose were between Harees (beef), Biryani (chicken), Leqemat,
Khanfaroosh, and Habba Hamra (P = 0.02, median = 1.00, 1.50, 1.30, 0.90 and 0.50
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respectively). At 90 min the significant differences in incremental blood glucose were
between Chebab bread, Leqemat, and Habba Hamra (P = 0.015, median = 1.10, 1.10,
and 0.40 respectively).
Several factors may alter the GI of food (Section 2.5.3), including the presence
of macronutrients such as fat and protein, the type of starch, processing, and the
addition of acids, sugars, gelling fibers, or amylase inhibitors [196].
The high protein content in Biryani (11.55g/100g) along with added vegetables
(onion, garlic and pepper) could explain its low GI [393]. Likewise, the addition of
vegetable mixed curry showed considerable reduction of GI and GL of traditional Sri
Lankan breakfast foods [394]. The high amount of dietary fibers present in Harees
(5.56g/100g) may cause its low GI, because the presence of dietary fibers in test foods
may delay its glycemic response, as it contributes to slower nutrient absorption and a
delayed transit time in the small intestines [193, 395].
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Figure 5.1: The incremental area under the blood glucose curves (IAUC) for low
glycemic index traditional meals. Standard errors of the mean values are represented by
vertical bars
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The IAUCs value for low GI test foods is presented in Table 5.9 as mean ±
standard error. The table illustrates that the IAUC for all seven low GI test foods are
significantly different from the IAUCs of the reference food (P ≤ 0.002). Among low
GI test foods, Harees and Khanfarosh had the smallest IAUC (88.08 and 93.39,
respectively). However, Biryani (chicken) had the highest IAUC (138.13 ± 10.64).

Table 5.9: Incremental Area Under the Curve (IAUC) for low GI test foods
Test Foods
Reference Food
Chebab Bread
Reference Food
Khameer Bread
Reference Food
Harees
Reference Food
Biryani, chicken
Reference Food
Leqemat
Reference Food
Khanfarosh
Reference Food
Habba Hamra

IAUC ± SE
267.96 ± 32.86
134.83 ± 18.08
215.56 ± 16.19
93.51 ± 5.65
215.61 ± 14.55
88.08 ± 4.67
285.57 ± 26.68
138.13 ± 10.64
285.67 ± 26.68
117.38 ± 8.85
215.56 ± 16.19
93.39 ± 7.34
215.56 ± 16.19
97.61 ± 5.94

P-Value
0.002
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

The mean IAUCs of medium glycemic index traditional meals (Arabic bread,
Chami, Machbous (Fish), Khabisah, Batheetha, and Balalet) are shown in Figure 5.2.
Differences in glucose response between the meals were calculated using the KruskalWallis test. The incremental increase in blood glucose at 30 min was significantly
different between Arabic bread, Chami, Machbous (Fish), Khabisah, Batheetha, and
Balalet (P = 0.029, median = 1.00, 0.16, 1.50, 1.60, 1.75, and 1.70 respectively). At 45
min the incremental increase in blood glucose was significantly different between
Arabic bread, Chami, Machbous (Fish), Khabisah, Batheetha, and Balalet (P = 0.039,
median = 1.40, 0.16, 1.75, 2.10, 1.60, and 1.80 respectively). At 60 min the significant
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differences in incremental blood glucose were between Arabic bread, Chami,
Machbous (Fish), Khabisah, Batheetha, and Balalet (P = 0.034, median = 1.70, 0.13,
1.00, 1.90, 1.10, and 1.60 respectively). At 90 min the significant differences in
incremental blood glucose were between Arabic bread, Chami, Machbous (Fish),
Khabisah, Batheetha, and Balalet (P = 0.016, median = 1.40, 0.19, 0.45, 1.20, 0.70,
and 0.80 respectively). At 120 min the significant differences in incremental blood
glucose were between Arabic bread, Chami, Machbous (Fish), Khabisah, Batheetha,
and Balalet (P = 0.006, median = 1.00, 0.80, 0.20, 0.90, 0.20, and 0.10 respectively).
Chami created a slow and low rise in the glycemic response over 120 minutes, due to
its very low carbohydrate content (5.44g/100g), which was expected as it is a dairy
product [187].
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Figure 5.2: The incremental area under the blood glucose curves (IAUC) for medium
glycemic index traditional meals. Standard errors of the mean values are represented
by vertical bars
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Table 5.10 shows the IAUC for medium GI foods. The IAUC for all medium
GI test foods showed a significant difference compared to the IAUC of the reference
food (P < 0.001), except for Chami (P=0.739). Khabisah had the highest IAUC value
(IAUC ± SE: 164.23 ± 13.58), while Chami reported the lowest IAUC value (IAUC ±
SE: 76.23 ± 8.36) among medium GI foods.

Table 5.10: Incremental Area Under the Curve (IAUC) for medium GI test foods
Test Foods
Reference Food
Arabic Bread
Reference Food *
Chami
Reference Food
Machbous, fish
Reference Food
Khabisa
Reference Food
Batheetha
Reference Food
Balalet
*(25g glucose)

IAUC ± SE
224.77 ± 11.61
145.33 ± 11.14
77.9313 ± 5.49
76.23 ± 8.36
186.37 ± 10.41
103.47 ± 7.99
250.01 ± 16.87
164.23 ± 13.58
186.3650 ± 10.41
107.93 ± 7.76
215.61 ± 14.55
132.82 ± 13.34

P-Value
<0.001
0.739
<0.001
<0.001
<0.001
<0.001

The mean IAUCs of high glycemic index traditional meals (Regag bread,
Muhalla bread, Qurus, Fendal, Thareed (beef), Thareed (chicken), Arseyah, Marqoqa,
Sago, and Asida) are presented in Figure 5.3. Muhalla bread, Asida and Sago produced
the highest increase in glycemic response, compared with other high GI foods.
Whereas, Thareed (beef) showed the highest peak (at 45 minutes) among high GI
foods. Regag bread showed a slow and low rise in glycemic response during the first
15 minutes, and then a sharp increase between 15 to 60 minutes. Differences in glucose
response between the meals were calculated using the Kruskal-Wallis test. The
incremental increase in blood glucose at 15 min was significantly different between
Regag bread, Fendal, Thareed (beef), Sago, and Asida (P = 0.025, median = 0.20, 0.65,
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0.90, 0.90, and 0.90 respectively). At 30 min the incremental increase in blood glucose
was significantly different between Regag bread, Qurus, Thareed (beef), Sago, and
Asida (P = 0.006, median = 1.10, 1.20, 2.30, 2.60, and 2.70 respectively). At 90 min
the significant differences in incremental blood glucose were between Regag bread,
Muhalla bread, Fendal, and Thareed (beef) (P = 0.01, median = 1.50, 1.30, 0.20, and
1.30 respectively).
At 120 min the significant differences in incremental blood glucose were
between Regag bread, Muhalla bread, Qurus, Fendal, Thareed (beef), Arseyah, and
Asida (P = 0.04, median = 1.10, 0.90, 1.00, 0.00, 0.90, 1.10, and 0.10 respectively).
Sago had the highest incremental blood glucose response at 15 and 30 min compared
to other high GI foods. The high moisture content (humidity) of Sago (74.91g/100g),
along with high cooking temperatures and prolonged cooking durations (time) could
have increased starch gelatinization and digestibility degree, thus, resulting in high
glycemic responses for this traditional desserts [396, 397].

The IAUC’s values for high GI test foods are presented in Table 5.11 as mean
± standard error. The table demonstrates that the IAUC for all high GI test foods are
significantly different from the IAUCs of the reference food (P ≤ 0.001), except for
Marqoqa, Sago, and Asida (P = 0.074, P =0.654, and P = 0.745, respectively). Among
high GI test foods, Fendal had the smallest IAUC (IAUC ± SE: 123.95 ± 12.02), and
Muhalla bread showed the highest IAUC (IAUC ± SE: 198.78 ± 12.39).
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Figure 5.3: The incremental area under the blood glucose curves (IAUC) for the high
glycemic index traditional meals. Standard errors of the mean values are represented by
vertical bars
Table 5.11: Incremental Area Under the Curve (IAUC) for high GI test foods
Test Foods
Reference Food
Regag Bread
Reference Food
Muhalla Bread
Reference Food
Qurus
Reference Food
Fendal
Reference Food
Thareed, beef
Reference Food
Thareed, chicken
Reference Food
Arseyah
Reference Food
Marqoqa
Reference Food
Sago
Reference Food
Asida

IAUC ± SE
224.77 ± 11.61
162.98 ± 14.88
261.9 ± 20.57
198.78 ± 12.39
202.58 ± 8.92
143.65 ± 14.5
186.37 ± 10.41
123.95 ± 12.02
250.01 ± 16.87
186 ± 55.45
202.8 ± 8.92
142.41 ± 8.36
250.01 ± 16.87
176.5 ± 10.77
202.58 ± 8.92
162.65 ± 19.17
202.58 ± 8.92
194.17 ± 14.95
202.58 ± 8.92
197.38 ± 15.02

P-Value
0.001
<0.001
0.001
0.001
<0.001
<0.001
<0.001
0.074
0.654
0.745
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5.2.8 Glycemic Index and Glycemic Load Classifications
The GI and GL values for all tested foods are presented in Table 5.12. GI values
are given as means with their standard errors. GI calculation was performed according
to the previously described procedure in Section 3.3.6.1. For practicality, GI and GL
values are usually grouped into categories of low, medium or high. If the GI of test
food was ≤ 55, then it is labeled as low GI food, between 56 and 69 (inclusive) is
medium GI food, and ≥ 70 is high GI food [398].
The four groups of food included in this study (breads, entrée, main, and
dessert) produced a wide range of GI values, with seven foods producing low GI
(Chebab bread, Khameer bread, Harees (beef), Biryani (chicken), Leqemat,
Khanfaroosh, and Habba Hamra), six foods were classified as medium GI (Arabic
bread, Chami, Machbous (fish),Khabisah, Batheetha, and Balalet), and ten foods had
high GI (Regag bread, Muhalla bread, Qurus, Fendal, Thareed (beef), Thareed
(chicken), Arseyah, Marqoqa, Sago, and Asida). Several factors may alter the GI of
food (Section 2.5.3), including the presence of macronutrients such as fat and protein,
the type of starch, processing, and the addition of acids, sugars, gelling fibers, or
amylase inhibitors [196]. Other factors may include the degree of chewing, the
concentration of amylase in the gut, the presence of other food components in the gut,
the amount of the insulin response and the rate of gastric emptying [399].
Rice is the main staple and energy source for almost half the world’s
population. Hence, it has significant nutrition and health implications. Many studies
on rice and rice products led to the conclusion that rice should generally be classified
as high GI food [349, 400-402]. However, many factors could affect the GI of rice and
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rice products, including: rice variety and starch content (Amylose and Amylopectin),
cooking, processing, cooling, soaking, fiber content, and particle size [402].
Additionally, rice is barely ever consumed on its own, it is often accompanied
with other foods such as pulses, legumes, vegetables, seafood, nuts, and meats, which
could alter the high GI of rice. In this study, Biryani, Machbous, and Arseyah - mixed
rice dishes (rice with chicken or fish) - were found to have low (52), medium (60) and
high (72) GI values, respectively. The high protein content in Biryani (11.55g/100g)
along with added vegetables (onion, garlic and pepper) could explain its low GI. In Sri
Lanka, parboiled Mottai Karupan red rice showed a mean GI value of 47 when it was
consumed with Amaranthus leaf curry, and 56 for parboiled rice with soya meat gravy
[393]. Moreover, the addition of vegetable mixed curry showed considerable reduction
of GI and GL of traditional Sri Lankan breakfast foods [394]. Many studies have also
showed a reduction in the GI of rice when consumed with legumes and pulses such as
lentils [403-405]. Furthermore, the addition of acidic condiments (vinegar or pickles),
emulsifiers, dairy products (milk, cheese, and yogurt), vegetables, pulses, and viscous
fibers seems to decrease the GI of rice [402].
Harees is a traditional dish with a porridge-like consistency; it is prepared from
crushed wheat with meat (beef or chicken) [175]. The GI value of Harees was the
lowest among the traditional dishes studied (42). The presence of dietary fibers in test
foods may delay its glycemic response, as it contributes to slower nutrient absorption
and a delayed transit time in the small intestines [193, 395]. Hence, the high amount
of dietary fibers presents in Harees (5.56g/100g) may cause its low GI.
The GI values of potatoes reported in the literature ranged from low (23) to
high (111). Similarly, the GI values for sweet potatoes ranged from 44 (low) to 78
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(high) [186]. In the current study, Fendal (boiled sweet potato) had a GI of 74 (high).
Jenkins et. al. (1981) found that sweet potato from Canada had a GI of 48 [20] while
sweet potato (Ipomoea Batatas) in Australia had a GI of 44 only [406]. However, in
New Zealand, Perry et. al. (2000) reported a GI of 77 for Kumara (sweet potato) [407].
Whereas, the GI for sweet potato that has been peeled, cubed, boiled (in salted water
for 15 minutes) was 59 [408]. Furthermore, three varieties of boiled Australian
potatoes (Sebago, Desiree, and Pontiac) showed varying high GI values (87, 101, and
88, respectively) [409].
According to the International Tables of Glycemic Index and Glycemic Load
Values (2008), boiled potato has a mean GI value of 78, whereas, the mean GI for
boiled sweet potato is 63 [187]. Thus, the consumption of sweet potatoes seems to be
a better choice for individuals wishing to reduce their dietary GI. However, studies
have shown that the GI value of potatoes could differ depending on the variety,
maturity, cooking method (baking, steaming, roasting, frying, or boiling), cutting
method (cubing, peeling, mashing, or slicing), cooling process, and storage conditions
(period and temperature) [398, 409-411].
To reduce the GI value of potatoes, researchers advise to precook potatoes and
consume them cold (potato salad, for example) or reheated [410, 412]. Moreover,
consuming potatoes with other ingredients such as acetic acid (vinegar) [413],
vinaigrette dressing (vinegar and olive oil added to potato salad) [414], or topping
baked potatoes with cheddar cheese [415] may lower the GI of potatoes but could limit
the form in which they can be consumed. Additionally, aiming to develop low GI
potato cultivars is also a valid proposition [398].
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Bread is a staple food that is prepared usually by baking a dough of flour
(wheat, rye, rice, oat, or barley) and water. In this study, six kinds of wheat bread and
three main dishes containing wheat bread were tested. Two of the breads were
classified as high GI - Regag bread (mean GI = 76) and Muhalla bread (mean GI = 77)
- and all three main dishes containing bread were also high in GI - beef Thareed (mean
GI =74), chicken thareed (mean GI = 72), and Marqoqa (mean GI = 85). Likewise, the
International Tables of Glycemic Index and Glycemic Load Values (2008) reported a
mean GI value of 75 (high) for White wheat bread and 70 (high) for unleavened wheat
bread [187].
Chebab bread and Khameer bread showed low GI values, which might be due
to their high protein (7.08g/100 and 10.45g/100g, respectively) and fat content
(9.07g/100g, and 12.69g/100g, respectively). Studies suggest that adding fat and
protein to foods containing carbohydrates could possibly reduce their glycemic
response and decrease their overall GI [416, 417]. It has been proposed that protein
stimulates greater gastric inhibitory peptide (GIP) and higher insulin responses, which,
in turn, lowers the postprandial peak of glucose and reduces the glycemic response of
high GI foods [418]. High fat content was shown to delay the rate of gastric emptying,
thus, reducing the rate of glucose digestion and absorption [415]. High fat content in
Legemat and Khanfaroosh (22.8g/100g, and 30.32g/100g, respectively) might be the
reason behind their low GI values (44 and 45, respectively). However, food choice
should not solely depend on the GI value of the food, since high fat content - especially
saturated fats as in the case of Khanfaroosh and Legemat (13.520g/100g and
9.586g/100g, respectively) - defeats the purpose of choosing low GI foods.
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White Arabic wheat bread, also referred to as “Lebanese bread” or “Pita
bread”, was also tested in the current study and showed a mean GI value of 67
(Medium). Similarly, Ali et. al. (2012) evaluated the GI of eight different types of
traditional Omani wheat breads and reported a GI value of 63 (Medium) for white
Lebanese wheat bread [419]. Moreover, Wolever et. al. (1994) found that white Pita
bread has a GI of 57 (medium) when tested on subjects with type one or type 2 diabetes
[408].
Khameer, Chebab and Arabic bread are considered leavened breads (fermented
by yeast), which could explain their lower GI values compared to other breads. The
effect of sourdough fermentation of leavened baked breads on the glycemic index has
been reported by many researchers [420-423]. Several hypotheses were proposed to
explain the reduced effect that sourdough fermentation has on the GI of bread
including the synthesis of lactic acid which in turn lowers the rate of starch digestion
[420], the synthesis of acetic and propionic acids, causing a reduction in the gastric
emptying rate [421], or the synthesis/release of amino acids and peptides, resulting in
better regulation of glucose metabolism [422].
Batheetha is a date paste made out of date fruit, wheat flour, ghee, sugar,
cardamom and cinnamon. Various studies have reported the low GI value of date fruit
[424, 425]. In 2002, Miller et. al. determined the GI of three different varieties of dates
- Khalas = 35.5, Barhi = 49.7, and Bo ma'an= 30.5. In another study, Alkaabi et. al.
(2011) reported the mean GIs of Fara'd, Lulu, Bo ma'an, Dabbas and Khalas dates
tested in thirteen healthy individuals to be 54.0, 53.5, 46.3, 49.1, and 55.1, respectively
[425]. However, in the current study, Batheetha is classified as a medium GI food (59),
possibly due to the sugar added during the preparation of Batheetha, as the sugar
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analysis showed a content of 5.02g total sugar in every 100g. The sugar analysis also
revealed that 2.468g of sugar are in the form of sucrose and 1.181g were found to be
glucose. Additionally, based on the International Tables of Glycemic Index and
Glycemic Load Values (2008), the mean GIs for sucrose and glucose are 65 (medium)
and 103 (high) respectively [187].
The low GI (47) of Habba Hamra (milk with red seed) was expected, since the
literature indicated low GI for full-fat milk, ranging from 11 to 40 [186] and the mean
GI for full-fat milk reported in the International Tables of Glycemic Index and
Glycemic Load Values (2008) was 39 [187]. Conversely, other dessert dishes tested in
the current study, like Sago and Asida, showed high GI values (mean GI = 99 for both
dishes). The high moisture content (humidity) of Sago (74.91g/100g) and Asida
(77.17g/100g), along with high cooking temperatures and prolonged cooking durations
(time) could have increased starch gelatinization and digestibility degree, thus,
resulting in high glycemic responses for these two traditional desserts [396, 397].
The GL of a standard serving size of each test food was calculated using the
equation described in Section 3.3.6.2. A GL ≤ 10 is considered low, between 11 and
19 is medium, and ≥ 20 is high. The results of the study demonstrated that the majority
of test foods were classified as high GL, which is expected as most of the test foods
had high GI, and they remained high when calculating their GL value.

Table 5.12: Glycemic Index (GI) and Glycemic Load (GL) Values of United Arab Emirates Traditional Dishes
Test Food

Available
Carbohydrate
(g/100g)*

63.47 ± 0.32
Arabic bread
44.37 ± 0.49
Regag bread
45.88 ± 1.17
Chebab bread
67.66 ± 4.79
Muhalla bread
54.93 ± 3.47
Khameer bread
54.45 ± 2.60
Gurus
31.64 ± 0.24
Fendal
5.31 ± 0.58
Chami
7.74 ± 1.15
Harees
10.87 ± 0.24
Thareed (beef)
12.73 ± 2.65
Thareed (chicken)
19.69 ± 2.05
Biryani (chicken)
18.00 ± 0.82
Machbous (fish)
9.85 ± 0.37
Arseyah
16.00 ± 0.52
Marqoqa
56.13 ± 4.65
Khabisa
44.19 ± 1.35
Leqemat
38.24 ± 0.97
Batheetha
39.62 ± 0.92
Kanfaroosh
23.43 ± 3.54
Saqo
21.09 ± 1.14
Asida
15.96 ± 1.20
Habba Hamra
27.89 ± 2.19
Balalet
*Date are expressed as Mean ± SD.

Experimental
portion (g)

78.8
112.7
109.0
73.9
91.0
91.8
158.0
470.8
323.0
460.0
392.8
253.9
277.8
507.6
312.5
89.1
113.1
130.8
126.2
213.4
237.1
313.3
179.3

Mean

SE

Standard
serving size
(g)

67
76
54
77
47
72
74
60
42
74
72
52
60
72
85
67
44
59
45
99
99
47
63

5
7
8
2
3
8
7
9
2
3
4
4
3
4
9
4
4
4
3
8
5
3
5

90
21
77
47
76
91
150
170
212
245
393
261
250
261
313
86
90
100
100
214
237
98
144

GI

Carbohydrate
(g/ serving)

GL
(per serving)

Subjects
(n)

GI
classification

GL
classification

57.1
9.3
35.3
31.8
41.7
49.5
47.5
9.0
16.4
26.6
50.0
51.4
45.0
25.7
50.1
48.3
39.8
38.2
39.6
50.1
50.0
15.6
40.2

38.3
7.1
19.2
24.5
19.5
35.5
35.3
5.4
6.9
19.7
36.0
27.0
26.8
18.5
42.4
32.1
17.6
22.7
18.0
49.8
49.6
7.4
25.4

25
25
15
15
15
15
20
16
15
15
15
15
20
15
15
15
15
20
15
15
15
15
15

Medium
High
Low
High
Low
High
High
Medium
Low
High
High
Low
Medium
High
High
Medium
Low
Medium
Low
High
High
Low
Medium

High
Low
Medium
High
Medium
High
High
Low
Low
Medium
High
High
High
Medium
High
High
Medium
High
Medium
High
High
Low
High
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5.2.9 Exchange List
The food exchange list helps in monitoring food portion sizes and energy
intake, because it translates scientific nutrition knowledge into a practical tool. Foods
from the same category can be used interchangeably without changing estimated
amounts of carbohydrates, fat, protein, and total energy obtainable in a meal [286].
The rounding-off method described by Wheeler et. al.[285] was used to fit food items
into exchanges as previously described in Section 3.3.5.4.
The exchange list for traditional dishes commonly consumed in the UAE was
established based on the proximate analysis data presented in Table 5.1. The exchanges
per serving of test foods are shown in Table 5.13. Serving sizes of test foods are
presented in standard measures (weight in grams) and equivalent cooking methods.
All test foods contained one exchange of starch, except Chami and Habba
Hamra. Habba Hamra, a red seed added to milk drink contained one exchange of low
fat milk. Whereas, Chami, a type of cottage cheese, was considered an exchange of
very lean meat, as it belongs to the low-fat meat substitute food group.
Khanfarosh, a fried dessert dish, contained the highest number of fat exchanges
(2 exchanges). All main dishes contained 1 exchange of starch and 1 exchange of lean
meat, which is expected as they are all composed of grain products (wheat or rice) with
a type of meat (chicken, beef, or fish).

Table 5.13: Meal Planning Exchange List of Twenty-Three United Arab Emirates Traditional Dishes

Test Food
Arabic bread
Regag bread
Chebab bread
Muhalla Bread
Khameer Bread
Gurus
Fendal
Chami
Harees (beef)
Thareed (beef)
Thareed (chicken)

Description
Baked bread
Thin crispy crepe
Emirati pancake
Emirati crepe
Baked bread
Fried bread
Boiled sweet potato
Cottage cheese
Crushed wheat with
meat
Bread with meat
stew
Bread with chicken
stew

Food Group
Bread
Bread
Bread
Bread
Bread
Bread
Starchy vegetable
Low-fat meat
substitute’s
Starch/Meat
Starch/Meat
Starch/Meat

Biryani (chicken)

Rice with chicken

Starch/Meat

Machbous (fish)

Rice with fish

Starch/Meat

Rice with chicken

Starch/Meat

Arseyah

Serving Size

Portion
Size (g)

Macronutrient
(Serving)

Kcal
(serving)

Exchanges per
serving

1 oz.
1 oz.
1 oz.
1 oz.
1 oz.
1 oz.
1 small potato

30
30
30
30
30
30
60

CHO
19.1
13.7
14.1
20.5
17.0
17.6
20.7

1 oz.

30

1.6

4.6

0.2

26.9

75

10.0

4.2

1.8

73.0

75

9.1

5.3

1.6

71.9

75

10.3

4.0

1.2

67.8

75

15.5

8.7

2.5

118.8

75

16.2

5.2

1.5

99.0

180

18.2

4.0

1.6

103.2

1/2 cup
composite dish
1/2 cup
composite dish
1/2 cup
composite dish
1/2 cup
composite dish
1/2 cup
composite dish
1/2 cup
composite dish

Protein
2.8
3.1
2.1
3.1
3.1
2.6
1.1

Fat
0.3
0.1
2.7
1.3
3.8
2.3
0.3

90.7
68.5
89.5
105.7
114.9
101.6
90.4

1 Starch
1 Starch
1 Starch
1 Starch
1 Starch, 1/2 Fat
1 Starch
1 Starch
1 Very Lean Meat
1 Starch, 1 Lean
Meat
1 Starch, 1 Lean
Meat
1 Starch, 1 Lean
Meat
1 Starch, 1 Lean
Meat
1 Starch, 1 Lean
Meat
1 Starch, 1 Lean
Meat
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Margoga
Khabisa

Bread with chicken
stew
Cardamom
Pudding

Leqemat

Doughnut cake

Batheetha

Date paste

Khanfaroosh
Sago
Asida
Habba Hamra
Balalet

Doughnut cake
Sago seed with
sugar
Flour with Sugar
Red seed Milk
drink
Sweet vermicelli

1/2 cup
composite dish

75

12.4

4.4

1.6

82.0

1 Starch, 1 Lean
Meat

1/2 cup Pudding

25

14.7

1.3

2.6

87.9

1 Starch

1 oz.

30

13.7

2.2

6.8

125.1

1 Starch, 1 Fat

1 oz.

30

13.3

1.7

2.9

86.0

1 Starch, 1/2 Fat

1 oz.

30

12.2

2.0

9.1

138.9

1 Starch, 2 Fat

Starch

2 oz.

60

14.2

0.5

0.3

61.7

1 Starch

Starch

2 oz.

60

13.1

0.6

0.0

54.8

1 Starch

Evaporated Milk

1/2 cup

126

20.4

1.6

2.3

108.8

1 ½ Low Fat Milk

Starch

1 oz.

30

12.0

0.7

0.5

55.7

Starch/Meat
Starchy food
Prepared with fat
Starchy food
Prepared with fat
Starchy food
Prepared with fat
Starchy food
Prepared with fat

1

Starch
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5.3 Conclusion
In conclusion, this study provides a comprehensive food composition table
including proximate data, minerals, vitamins, lipids, and sugars contents, along with
GI and GL values of twenty-three locally consumed foods in the UAE including
breads, entrées, mains and desserts. Determining the nutritional composition and the
glycemic response of Emirati traditional foods is needed to assess the dietary intake of
the population and identifying their effects on health promotion and disease
prevention. Additionally, these tables will serve as a great tool of nutrition therapy
planning and dietary management for dietitians in the UAE and other GCC countries.
Furthermore, the availability of this data should be useful for assembling national and
international food composition tables. Moreover, the knowledge of the GI and GL
values of traditional Emirati foods helps in developing better dietary guidelines for
individuals living with diabetes and/or obesity, and could be utilized by further
research studies interested in the application of GL and GI.
Most dishes containing meat presented in this study had very high sodium
levels. Therefore, it is highly important to take serious national steps towards reducing
the sodium intake in diets in order to lessen the risk of developing CVD, hypertension,
and other associated complications. Aiming for high iron food sources (like Regag,
Chebab, Muhalla, and Khameer bread) as part of the daily diet is recommended to
reduce the risk of iron deficiency (anemia).
The findings of this study advocate attention to the nutritive value and health
aspects of traditional desserts when establishing dietary guidelines for UAE.
Traditional desserts should be consumed in moderation due to their high content of
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saturated fat (Khanfaroosh and Legemat), cholesterol (batheetha), and sugar (Sago,
Asida, and Batheetha), in addition to their medium to high glycemic response.
Using whole-grain wheat flour instead of refined wheat flour for the
preparation of breads is recommended in order to reduce their high GI values. The
presence of dietary fibers in foods could also delay its glycemic response, as it
contributes to slower nutrient absorption and delayed transit time in the small intestines
[193, 395]. Furthermore, the addition of acidic condiments (vinegar or pickles),
emulsifiers, dairy products (milk, cheese, and yogurt), vegetables, pulses, or viscous
fiber to rice is recommended, since they appear to decrease its high GI value [402]. It
is also recommended that foods containing carbohydrate should be consumed with
protein-rich foods (rice and yogurt, bread and cheese, and rice with pulses) to reduce
their glycemic response [416, 417]. Controlling the portion size of foods consumed
can contribute to lowering their GL values, thus, reducing the risk of noncommunicable diseases [107, 108, 209].
It is also advised to precook potatoes and consume them cold (potato salad, for
example) or reheated [410, 412]. Moreover, consuming potatoes with other ingredients
such as acetic acid (vinegar) [413], vinaigrette dressing (vinegar and olive oil added to
potato salad) [414], or topping baked potatoes with cheddar cheese [415] are all good
ways to lower the GI of potatoes.
Dietitians are advised to consider the macronutrient content of foods, such as
fiber, total fat, saturated fat and trans fats along with the GI value when making dietary
recommendations for patients with MetS.
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The calculated exchange lists serve as a user-friendly guide, which enable
consumers to exchange foods from the same group without changing energy or
macronutrient contents. In addition, exchange lists assist dietitians in establishing
culturally appropriate meal plans for Emiratis - mainly individuals living with diabetes
and/or obesity.
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Chapter 6: Summary and Recommendations
6.1 Overall Summary
Non-communicable diseases (NCDs) are the leading cause of deaths
worldwide, and diabetes mellitus (DM) is the fourth major cause of NCD deaths [1].
United Arab Emirates (UAE) was ranked as having the fifth highest prevalence of DM
in the Middle East and North Africa (MENA) region [304].
The transition in socioeconomic status accompanied with the adoption of a
western lifestyle and diet for Emirati citizens, have led to a rise in the prevalence of
overweight and obesity, particularly among females [167]. The existence of prediabetes, dyslipidemia, elevated blood pressure, and obesity is known as metabolic
syndrome (MetS) [33]. There is paucity of data available about the prevalence of MetS
and its relation with overweight and obesity among young female adults (17-25 years)
in the UAE; therefore, determination of the prevalence of MetS in Emirati females
aged 17–25 years and its relation to overweight and obesity in Al Ain, UAE has been
part of our study.
The American Diabetes Association (ADA) recommends the use of low GI
diets for DM management and prevention [255]. Additionally, the Food and
Agriculture Organization (FAO) of the United Nations and the World Health
Organization (WHO) have also validated the use of GI for the classification of
carbohydrate-containing foods [188]. Likewise, they recommended the use of the GI
classification system along with food composition tables to guide better food choices.
Designing public health policy, clinical practice, and prevention programs for the
screening and treatment of Emirati at high risk for metabolic syndrome is highly
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important. Unfortunately, very little information is available about the food
composition and glycemic index of Emirati traditional foods.
The current study provides a comprehensive food composition table with GI
and GL values of locally consumed foods in the UAE, which could serve as a tool for
nutrition therapy planning. In addition, the produced data will facilitate the role of
dietitians in the dietary management of disease in the UAE and other GCC countries.
Moreover, the current dataset will add on the existing international table of GI and GL
values.
The following is summary of some main findings of both studies performed in
this dissertation:
1. One third of the studied population were overweight and obese.
2. The prevalence of diabetes mellitus and prediabetes based on FPG was
found much lower than that based on the percentage of HbA1c (0.5%
and 9.2% Vs. 8.6% and 24% respectively). However, the crude
prevalence of diabetes mellitus and pre-diabetes among Emirati young
female adults was 8.6% and 24.7%, respectively.
3. Screening for pre-diabetes using IFG was independent than screening
using HbA1c.
4. The overall prevalence of MetS was 6.8% (95% CI: 5% to 9%).
5. The most frequent component of MetS was reduced HDL-C levels,
followed by central obesity and impaired fasting glucose.
6. MetS prevalence was highest among obese participants, as compared
with normal-weight and overweight participants.
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7. Using logistic regression model MetS was significantly associated with
overweight, obesity, waist-hip ratio, glycated hemoglobin (HbA1c) and
high sensitivity C-reactive protein (P < 0.01).
8. Most dishes containing meat and Regag bread presented in this study
had very high sodium levels.
9. Traditional desserts had high content of saturated fat (Khanfaroosh and
Legemat), cholesterol (batheetha), and sugar (Sago, Asida, and
Batheetha), in addition to their medium to high glycemic response.
10. The exchange list developed in this study could be used by food and
nutrition professionals to plan culturally sensitive meal plans.
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6.2 Recommendations
1. Future research needs to include both male and female genders to investigate
gender differences and generalize the results to all young adults
2. Additional prospective studies with bigger sample size and including all
segments of the society are needed to confirm the prevalence of MetS and its
most predictive risk factors among Emirati young adults.
3. Developing screening programs for early detection of metabolic syndrome
among young Emirati adults, so that lifestyle interventions and treatment may
prevent the development of diabetes and/or cardiovascular disease.
4. Developing population-based strategies that address cultural and community
life of Emiratis to ensure relevance and commitment by the community.
5. Developing food-based dietary guidelines specific for the Emirati population,
to be used for improving health policies and nutrition education programs.
6. Advising the Emirati population to consume traditional desserts in moderation
due to their high content of saturated fat, cholesterol and sugar, in addition to
their medium to high glycemic response.
7. Conducting a national flour fortification program to control and prevent anemia
by fortifying flour with iron and folic acid.
8. Future intervention studies investigating the beneficial effects of low GI diets
on the prevalence of the metabolic syndrome in the UAE.
9. Running awareness campaigns about the effect of the GI on certain noncommunicable diseases common in the UAE including diabetes and obesity.
10. Encouraging dietitians to use the exchange list of Emirati foods when
establishing culturally appropriate meal plans particularly for individuals
living with diabetes and/or obesity.
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Appendices
Appendix 1: Information Sheet
Anthropometric measures and their association with metabolic syndrome risk factors in
Emirati young female adults
You are being invited to take part in a research study. Before you decide, it is important for
you to understand why the research is being done and what it will involve. Please take time
to read the following information carefully.

What is the purpose of the study?
The objective of this research is to identify the anthropometric measures of obesity that best
identify metabolic syndrome in UAE early adulthood female students of the United Arab
Emirates University. The results obtained might show that simple measurements are useful
for predicting metabolic syndrome risk.

Why have I been chosen to take part?
The subjects chosen to take part in the study are females, aged 17-25 years.We will evaluate
the screening performance of eight anthropometric measurements, Body mass index (BMI),
waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), waist to
height ratio (WHtR), neck circumference (NC), Mid-upper-arm circumference (MUAC) and
skin-fold thickness at four sites, in identifying metabolic syndrome risk factors.

Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will be
given this information sheet to keep and be asked to sign a consent form. If you decide to
take part you are still free to withdraw at any time, without giving a reason, and to withdraw
any unprocessed data previously supplied. If you are involved in a dependent relationship
(i.e. teacher/student) with the Project Principle Investigator (PI), your involvement in the
study will not affect your grades.
What will happen to me if I do take part?
The time you will spend participating in this study will be no longer than 40 min. You will
be asked to visit the Nutrition and Health clinic, UAE University only once. Prior to you test
session you will be asked to fast overnight (12-14hr), do not come during your menstrual
cycle, and we would like you to come wearing appropriate clothing to facilitate skin-fold
measurements. When you come for your appointment the researchers will take your
anthropometric (e.g. height, weight, waist and hip circumference) and body composition
measurements, fasting venous blood (by well-trained burse) and blood pressure. You will
also be asked to fill a one-page questionnaire. All measurements will be taken by trained
personnel.
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Are there any risks involved?

All measurements taken in the study are simple, easy and painless. Trained personnel will
collect the blood samples in a designated clean and privet area. The Nutrition and Health
clinic allows privacy were only females will be involved in taking the measurements and
counselling the participants.

What are the possible benefits of taking part?
You will receive your own “health check” profile, including anthropometric and body
composition measurements. You will also be provided with a participating certificate and
complementary gift to show appreciation for your valued participation.

What will happen to the results of the study?
Confidentiality of information provided can only be protected within the limitations of the
law. All information collected will be kept strictly confidential. All samples and records
will be coded and will only be available to the researchers involved in the study; your name
will never appear in any published work. The Project PI and Project Co-PI will carry out
data analysis and dissemination of results. All data from the study will be owned by the
Department of Nutrition and Health and will be stored at the department for a minimum of 5
years.

Who can I contact if I have any questions?

If you have any questions regarding this study, you can contact the Project PI:
Ms. Maysm Nezar Mohamad
Department of Nutrition and Health, College of Food and Agriculture.
United Arab Emirates University, Maqam Campus, P. O. Box 17555
Mob: 00971 55 236 8727
Email: maysmnezar88@uaeu.ac.ae
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Appendix 7: Information Sheet
Glycaemic Index (GI) value of commonly consumed foods in UAE
You are being invited to take part in a research study. Before you decide, it is important for
you to understand why the research is being done and what it will involve. Please take time
to read the following information carefully.
What is the purpose of the study?
The glycaemic index (GI) of foods has potential implications for the prevention and treatment
of major chronic diseases. The GI concept was developed to predict post-prandial increases
in blood glucose concentration after the consumption of food. Type 2 diabetes has been seen
in various populations whose lifestyle has changed from traditional patterns to a modern
‘westernized’ model. Accordingly, dietary control could have a positive impact on the number
of people affected by diabetes. The consumption of some traditional foods in the UAE (e.g.
Camel milk, Cow milk, "Reqaq bread" and "Arabic bread"….etc) raises the question, should
the UAE population and especially the diabetic patients eat these foods?
Why have I been chosen to take part?
The subjects chosen to take part in the study are aged 18-50 years. At the beginning of the
study, your fasting plasma glucose level will be tested (this will involve taking a finger-prick
blood sample after you have fasted overnight). If you are identified as being at risk of
developing impaired glucose tolerance or diabetes you will be excluded from taking part in
this study.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will be
given this information sheet to keep and be asked to sign a consent form. If you decide to take
part you are still free to withdraw at any time, without giving a reason, and to withdraw any
unprocessed data previously supplied. If you are involved in a dependent relationship (i.e.
teacher/student) with the Project Principle Investigator (PI), your involvement in the study will
not affect your grades.
What will happen to me if I do take part?
It is anticipated that your time spent taking part in the study will be approximately 2 hours per
test session (total study duration = 6 sessions). Each test session will be conducted in the
morning at the Nutrition and Health laboratory, UAE University. Prior to each test session,
you will be asked to fast overnight before anthropometric (e.g. height, weight, waist and hip
circumference) and body composition measurements are taken. During each test session, you
will be asked to eat a portion of food (milk or bread). Finger-prick blood samples will be taken
at 0 minutes (fasting) and at 15, 30, 45, 60, 90 and 120 minutes after the start of the meal, and
your blood glucose measured. For each test session, the blood glucose measurements will
require a maximum of seven finger-pricks, however you will not experience any negative
consequences. You will be asked to rate your feelings of hunger/satiety at various intervals
during the test session. All measurements will be taken by trained personnel. Tests will be
undertaken with at least 1 day between sessions.
Are there any risks involved?
During each test session, the blood glucose measurements will require a maximum of seven
finger-pricks, however you will not experience any negative consequences. Trained personnel
will take finger-prick blood samples in a designated clean area. During the course of the study,
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if you are identified as being at risk of developing diabetes, you will be provided with
immediate information and given details to take to your physician. It must be stressed that the
diagnosis of diabetes is never made on the basis of a single abnormal blood glucose value.
What are the possible benefits of taking part?
You will receive your own “health check” profile, including anthropometric and body
composition measurements

What will happen to the results of the study?
Confidentiality of information provided can only be protected within the limitations of the law.
All information collected will be kept strictly confidential. All samples and records will be
coded and will only be available to the researchers involved in the study; your name will never
appear in any published work. The Project PI and Project Co-PI will carry out data analysis
and dissemination of results. All data from the study will be owned by the Department of
Nutrition and Health and will be stored at the department for a minimum of 5 years.

Who can I contact if I have any questions?
If you have any questions regarding this study, you can contact either the Project PI or Project
Co-PI:
Dr. Ayesha Al Dhaheri (Project PI)
Department of Nutrition and Health
College of Food and Agriculture
UAE University
Maqam Campus
P. O. Box 17555
Tel: 03 7134539
Email: ayesha_aldhaheri@uaeu.ac.ae

Ms. Maysm Mohamad (Project Co-PI)
Department of Nutrition and Health
College of Food and Agriculture
UAE University
Maqam Campus
P. O. Box 17555
Tel: 055 236 8727
Email: maysmnezar88@uaeu.ac.ae
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Appendix 8: Data Sheet
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Appendix 11: Graphs of the IAUC for all Test Foods
The mean incremental area under the glycemic response curves of the standard food
and each test food are presented in Figures A to W.
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Figure A: Incremental area under the blood glucose curves (IAUC) for the
standard food and Arabic bread. Standard errors of the mean are represented
by vertical bars.
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Figure B: Incremental area under the blood glucose curves (IAUC) for the
standard food and Regag bread. Standard errors of the mean are represented by
vertical bars.
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Figure C: Incremental area under the blood glucose curves (IAUC) for the
standard food and Muhalla bread. Standard errors of the mean are represented
by vertical bars.
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Figure D Incremental area under the blood glucose curves (IAUC) for the
standard food and Chebab bread. Standard errors of the mean are represented
by vertical bars.
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Standard Food

Qurus
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Figure E: Incremental area under the blood glucose curves (IAUC) for the
standard food and Gurus. Standard errors of the mean are represented by
vertical bars.
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Figure F: Incremental area under the blood glucose curves (IAUC) for the
standard food and Khameer bread. Standard errors of the mean are
represented by vertical bars.

120

244
Standard Food

Fendal
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Figure G: Incremental area under the blood glucose curves (IAUC) for the
standard food and Fendal. Standard errors of the mean are represented by
vertical bars.
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Figure H: Incremental area under the blood glucose curves (IAUC) for the
standard food and Harees. Standard errors of the mean are represented by
vertical bars.
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Standard Food*

Chami
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Figure I: Incremental area under the blood glucose curves (IAUC) for the
standard food and Chammi. Standard errors of the mean are represented by
vertical bars.
* 25g of Glucose.
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Figure J: Incremental area under the blood glucose curves (IAUC) for the
standard food and Thareed beef. Standard errors of the mean are represented
by vertical bars.
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Standard Food

Thareed Chicken
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Figure K: Incremental area under the blood glucose curves (IAUC) for the
standard food and Thareed chicken. Standard errors of the mean are
represented by vertical bars.
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Figure L: Incremental area under the blood glucose curves (IAUC) for the
standard food and Biryani chicken. Standard errors of the mean are
represented by vertical bars.
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Standard Food

Arseyah
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Figure M: Incremental area under the blood glucose curves (IAUC) for the
standard food and Arseyah. Standard errors of the mean are represented by
vertical bars.
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Figure N: Incremental area under the blood glucose curves (IAUC) for the
standard food and Machbous fish. Standard errors of the mean are
represented by vertical bars.
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Figure O: Incremental area under the blood glucose curves (IAUC) for the
standard food and Khabisa. Standard errors of the mean are represented by
vertical bars.
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Figure P: Incremental area under the blood glucose curves (IAUC) for the
standard food and Marqoqa. Standard errors of the mean are represented by
vertical bars.
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Figure Q: Incremental area under the blood glucose curves (IAUC) for the
standard food and Leqemat. Standard errors of the mean are represented by
vertical bars.
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Figure R: Incremental area under the blood glucose curves (IAUC) for the
standard food and Batheetha. Standard errors of the mean are represented by
vertical bars.
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Standard Food

Khanfaroosh
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Figure S: Incremental area under the blood glucose curves (IAUC) for the
standard food and Khanfaroosh. Standard errors of the mean are represented
by vertical bars.
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Figure T: Incremental area under the blood glucose curves (IAUC) for the
standard food and Sago. Standard errors of the mean are represented by
vertical bars.
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Figure U: Incremental area under the blood glucose curves (IAUC) for the
standard food and Asida. Standard errors of the mean are represented by
vertical bars.
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Figure V: Incremental area under the blood glucose curves (IAUC) for the
standard food and Habba Hamra. Standard errors of the mean are represented
by vertical bars.
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Figure W: Incremental area under the blood glucose curves (IAUC) for the
standard food and Balalet. Standard errors of the mean are represented by
vertical bars.
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Appendix 12: Abstract for the 10th International Symposium on Body
Composition.
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Appendix 13: Abstract for the 12th Asian Congress of Nutrition.
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